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Heart fat, termed epicardial adipose tissue (EAT), expands in cardio-metabolic 
disease; however, whether hypertrophy of the comprising adipocytes underlies this 
expansion is unknown. Part one of my thesis aimed to examine the relationship between 
EAT adipocyte size, macroscopic EAT thickness, and obesity level. I also investigated the 
role of EAT adipocytokine release in cardiovascular pathogenesis by determining the effect 
of the EAT-derived factor, resistin, on human myocardium function. 
EAT adipocytes were measured in histological sections of EAT procured from post-
mortem case (N=43) and surgery patient (N=49) cohorts. In each cohort, EAT adipocyte 
size did not correlate with the obesity measure, body mass index (BMI) (post-mortem 
cohort: r=0.1, P=0.4; surgery cohort: r=0.1, P=0.5), despite finding a positive correlation 
for paired subcutaneous adipocytes (r=0.6, P<0.0001). Furthermore, in the surgery cohort, 
adipocyte size did not correlate with EAT thickness (r=-0.1, P=0.6). Exploratory analysis 
of adipocyte size frequency distributions indicated that EAT from obese cases contains a 
greater proportion of ‘smaller’ adipocytes. Enzyme-linked immunosorbent assay revealed 
that human EAT (N=36) releases resistin. When applied to human atrial trabeculae (N=10), 
exogenous resistin (7, 12, 20 ng/mL) did not change the propensity for spontaneous muscle 
contractions. Resistin did, however, dose-dependently increase trabeculae contractility 
(maximal 2.9-fold increase, P<0.0001), while also reducing post-pause contraction 
potentiation (maximal 2-fold decrease, P=0.002).  
These data suggest that expansion of EAT in obesity might be associated with 
hyperplastic, and not hypertrophic, remodelling of EAT adipocytes. Additionally, the 
findings suggest that resistin released from EAT exerts a direct inotropic, but not an 
arrhythmogenic, effect on human myocardium. 
Circulating levels of the metabolites, long-chain acylcarnitines (LCACs), are 
associated with CVD risk. Part two of my thesis sought to determine if LCACs also 
directly alter cellular Ca2+ handling and human myocardial function. 
Human atrial trabeculae were stimulated at 60 contractions per minute and treated 
with LCAC species 18:1 (1-25 µM, n=8 per concentration). LCAC 18:1 dose-dependently 
increased contractility (maximal 1.5-fold increase, P<0.01) and increased arrhythmic 
contraction propensity (maximal 50% increase, P<0.05). To investigate LCAC effects on 




expression were loaded with the cytosolic Ca2+ indicator, fluo-4-AM, or the intra-
endoplasmic reticulum Ca2+ indicator, D1ER. All LCAC 18:1 concentrations tested (0.1-
25 µM) promoted spontaneous Ca2+ release events by reducing the threshold for RyR2-
mediated Ca2+ release (89% of control, P<0.0001). In addition to promoting spontaneous 
Ca2+ release, higher LCAC 18:1 concentrations also markedly increased the rates of Ca2+ 
and Zn2+ influx (maximal 3- to 7-fold increases, P<0.0001) from the extracellular 
environment. Treatment with a different LCAC, LCAC 16:0, induced analogous effects on 
Ca2+ release, Ca2+ influx, and Zn2+ influx, but to a lesser extent than that induced by LCAC 
18:1, suggesting that fatty acyl chain and likely membrane disruption underlies the effects 
of LCACs. 
Circulating LCACs directly alter human myocardium function. In vitro, this is 
linked to LCAC-induced membrane perturbation that promotes Ca2+ influx and enhances 
spontaneous RyR2 Ca2+ release. This suggests that high LCACs levels might contribute to 
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PKA  Protein kinase A 
PLB  Phospholamban 
POCA  Sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate 
PPP  Post-pause potentiation 
RAA  Right atrial appendage 
RMP  Resting membrane potential 
RyR2  Ryanodine receptor type 2 
SAT  Subcutaneous adipose tissue 
SC  Spontaneous contractions 
SD  Standard deviation 
SEM  Standard error of the mean 
SERCA2a Sarco(endo)plasmic reticulum Ca2+-ATPase 
SOICR Store overload-induced Ca2+ release 
SR  Sarcoplasmic reticulum 
UCP-1  Uncoupling protein 1 
VAT  Visceral adipose tissue 
Vmax  Rate of depolarisation 
WAT  White adipose tissue 






This thesis is an investigation of the fat surrounding the heart, termed epicardial 
adipose tissue (EAT), and the fat metabolites known as long-chain acylcarnitines 
(LCACs). EAT and LCACs are typically discussed in the heart metabolism research field. 
However, in recent times, they have either emerged as potential players in the development 
of cardiovascular disease. 
The dangers of heart fat have been long recognised by physicians. Sénac (1783) and 
Corvisart (1809) linked sudden death in a patient with excessive fat spread over the heart 
surface. Sir Richard Quain (1850) then quantified cardiac fat distributions and documented 
changes to heart fat in disease that frame the diagnosis of ‘Quain’s fatty heart’. In 
contemporary times, measurement of EAT has emerged as a tool for determining patient 
diagnosis and prognosis. By contrast, laboratory research of EAT is lagging. Like other 
types of fat, EAT is well-established to expand in obesity. However, unlike other types of 
fat, we do not know the underlying mechanisms of EAT expansion. The gaps in this 
understanding need to be addressed in order to appreciate the pathological and therapeutic 
significance of EAT. Part one of this thesis determines the associations of EAT adipocytes 
with measures of obesity and how EAT secretory functions contribute to arrhythmias. 
Part two of this thesis aims to address some of the questions about how LCACs 
directly affect heart function. LCACs are intracellular components of fat metabolism. 
Without them, long-chain fatty acids, of which the heart prefers as an energy substrate, 
could not be metabolised. LCACs are also readily shuttled into the circulation and can 
therefore be measured. Recently, high LCAC levels has been identified as a novel 
biomarker for heart failure and atrial fibrillation. Curiously, extensive research from the 
20th century shows that when applied to cardiac muscle, high levels of LCACs promote 
dysfunctional muscle contraction rhythms. This century there has been a relative dormancy 
in laboratory research of LCACs on heart function. As such, significant questions remain 
about how to translate the direct effect of LCACs on the heart to the growing body of 
clinical associations of LCACs with cardiac disease.  
Therefore, my thesis explores two research fields with contrasting depths of clinical 
and pre-clinical understanding. On the one hand, the pathophysiology of EAT is poorly 
understood despite extensive clinical association of EAT deposition, while on the other 
hand, clinical study of LCACs is nascent but the pathophysiology of LCACs in the heart 
well researched.   
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Language used in the thesis 
This thesis contains general introduction and discussion sections, as well as 
published research articles. As such, the use of possessive terms (i.e., “I”, “my”, “we”, 
“our”) varies throughout. In Chapters 2-4 and 7-8 (experimental chapters), pluralised 
pronouns (“we, our”) have been maintained from the original published articles to reflect 
the true collaborative nature of the research. This is despite the majority of each study being 
performed by myself. In contrast, Chapters 1, 5, 6, and 9 (general introductions and 
discussions), singular pronouns ("I", "my") have been used to accord to traditional thesis 





Guide to the Following Chapters 
By virtue of the two independent research topics addressed in this thesis (EAT and 
LCACs), the following chapters have been arranged to enhance story cohesion and clarity. 
Part one of the thesis will include an introduction to EAT and the relevant aims and 
hypotheses (Chapter 1), followed by 3 published experimental chapters (Chapters 2-4) and 
a general discussion of the EAT studies (Chapter 5). Similarly, Part two includes an 
introduction to LCACs (based on a published review article) and the relevant aims and 
hypotheses (Chapter 6). This is followed by 2 experimental chapters (Chapters 7 & 8, 
detailed below) and a final general discussion of the LCAC studies (Chapter 9). Note that 
all experimental chapters are presented in their published forms with minor modifications 
to the figure styling, abbreviation defining, references, and sub-heading format. 
Chapter 1 of the thesis will be an introduction to EAT, as well as the aims and 
objectives of the thesis related to EAT. 
Chapter 2 is the first experimental chapter relating to Part one of this thesis. Here, 
I investigated the association of EAT adipocyte size with the obesity measure, body mass 
index (BMI), in samples from post-mortem cases. This association was compared to 
correlations of adipocytes from other subcutaneous and visceral adipose depots, including 
paracardial fat. These results provide important clarification to the properties of EAT 
adipocyte remodelling in obesity. This chapter is published in Cardiovascular Pathology 
(Aitken-Buck et al., 2019a). 
Chapter 3 is a follow up to Chapter 2. Here, I reproduced my post-mortem findings 
of EAT adipocyte remodelling in relation to BMI in EAT samples procured from cardiac 
surgery patients. Due to the echocardiography performed on these patients pre-operatively, 
I was also able to correlate EAT adipocyte size with the thickness of EAT in the same 
patients. These findings were published in Adipocyte (Aitken-Buck et al., 2019b). 
Chapter 4 examined the effect of the EAT-derived factor, resistin, on the 
arrhythmia propensity of human atrial myocardium. I found that resistin is released by 
human EAT; however, it does not directly trigger acute arrhythmias previously linked to 
the EAT secretome. Interestingly, resistin did affect myocardial contractility, thereby 
illustrating the paracrine signalling relationship between EAT and the heart. These findings 
were published in the American Journal of Physiology-Endocrinology & Metabolism 
(Aitken-Buck et al., 2020a). 
xx 
 
Chapter 5 is a general discussion of the results presented in Chapters 2-4 relating 
to EAT adipocyte morphology and EAT-derived resistin release. This discussion is 
designed to build on those included in the preceding published chapters. 
Chapter 6 is the introduction to LCACs and presentation of the relevant aims and 
objectives. The introduction included in this chapter has been adapted from a literature 
review I have published previously in Frontiers in Physiology (Aitken-Buck et al., 2020b). 
Chapter 7 is the first experimental chapter of Part two of this thesis. This chapter 
was an investigation of the effect of exogenous LCAC 18:1 on arrhythmic human 
trabeculae contractions. Furthermore, the effect of different LCAC 18:1 concentrations on 
human myocardial contractility is presented here. Supporting these ex vivo findings are 
results from fluo-4-AM loaded HEK293 cells with stable cardiac ryanodine receptor 
(RyR2) expression. Here, I utilised equivalent concentrations of LCAC 18:1, as well as 
LCAC 16:0, to show that LCACs promote RyR2-mediated spontaneous Ca2+ release in a 
manner dependent on Ca2+ influx from the extracellular environment. These findings were 
published in the American Journal of Physiology-Heart & Circulatory Physiology (Aitken-
Buck et al., 2021). 
Chapter 8 builds on the findings of the preceding chapter by investigating the 
effects of translatable circulating LCAC concentrations on spontaneous Ca2+ release in 
recombinant HEK293 cells. I show that LCACs promote spontaneous Ca2+ release when 
superfused at physiological, feasible pathological, and supra-pathological extracellular 
concentrations. I show this effect occurs via a decrease in the threshold for RyR2-mediated 
Ca2+ release from the internal Ca2+ store. Importantly, my findings also confirm that 
membrane disruption underlies the spontaneous Ca2+ release effect of excessive LCAC 
concentrations and that the effects of translatable LCAC levels are likely also due to 
increases in cytosolic Ca2+ influx. These findings are currently unpublished. 
Chapter 9 is the final chapter of this thesis. Here, I will discuss the findings of 
experimental Chapters 7 and 8 (LCAC studies) and how they relate to the broader research 
field. Like Chapter 5, this chapter aims to avoid unnecessary repetition of discussion points 




Introduction to Epicardial Adipose Tissue 
Epicardial adipose tissue (EAT) is the visceral adipose depot located between the 
myocardium and the visceral pericardium (Iacobellis et al., 2005a; Rabkin, 2007). It is 
distinct from paracardial fat (PAT), which lies superficial to the pericardium, and from 
pericardial fat, which describes the combination of EAT and PAT (Wong et al., 2017) 
(Figure 1.1). The number of clinical associations found between macroscopic EAT 
deposition and cardio-metabolic disease risk is growing rapidly (Iacobellis et al., 2005a; 
Rabkin, 2007; Wong et al., 2017). In contrast, pre-clinical study of the microscopic 
properties of EAT and the active secretory capacity of the tissue is in its infancy. EAT has 
a unique intimacy with the myocardium and coronary circulation. Therefore, understanding 
how this relationship protects the heart in health and how it changes in disease will provide 
insight into the clinical associations of EAT with cardio-metabolic disease. 
 
Figure 1.1. Epicardial adipose tissue (EAT) definition and myocardium proximity. EAT is 
located between the myocardium and visceral serous pericardium. This contrasts with paracardial 
adipose tissue (PAT), which is external to the pericardium. EAT infiltrates the myocardium in a 
manner proposed to disrupt myocyte connectivity. The myocardium and EAT share a 
microcirculation (represented by blue and red circles). Embedded are standardised cardiac 




1.1 Anatomy of EAT 
EAT is distributed predominantly over the right ventricular free wall, within the 
atrioventricular and interatrial grooves, around the atria, and along the coronary arteries 
(Ho & Shimada, 1978). EAT comprises only ~1% of total body fat and ~15-20% of total 
heart mass in healthy adults; however, in obesity, EAT deposition can increase to cover up 
to ~80% of the heart surface (Ho & Shimada, 1978; Rabkin, 2007; Sacks & Fain, 2007). 
Both EAT and the epicardium are derived from the splanchnopleuric mesoderm in 
development (Ho & Shimada, 1978; Sacks & Fain, 2007). Consequently, no fascial 
boundary separates EAT from the myocardium and coronary adventitia, which permits a 
shared microcirculation between EAT and the myocardium (Iacobellis et al., 2005a). 
Microscopically, EAT is comprised primarily of adipocytes and pre-adipocytes, as 
well as stromal-vascular and immune cells, connective tissue, and cardiac ganglia 
(Iacobellis & Bianco, 2011; Wronska & Kmiec, 2012). EAT adipocytes defy classical 
adipose tissue morphological classification. Mature EAT adipocytes have a single fat 
lobule arrangement and a peripheral nucleus characteristic of white adipose tissue (WAT) 
(Iacobellis & Bianco, 2011; Wronska & Kmiec, 2012). However, EAT adipocytes also 
have a high expression of uncoupling protein (UCP-1), which is a characteristic of brown 
adipose tissue (BAT) (Sacks et al., 2009; Sacks et al., 2013). Due to the dual resemblance 
to white and brown adipocytes, EAT has been classified as a ‘beige’ adipose type (Sacks 
et al., 2009; Sacks et al., 2013). 
1.2 Physiology of EAT 
Several functions have been proposed for EAT. Firstly, lipogenesis and lipolysis 
rates are approximated at 2-fold higher in EAT than other adipose depots, which is 
postulated to facilitate fatty acid buffering during periods of fat excess (Marchington et al., 
1989; Marchington & Pond, 1990). Secondly, EAT adipocytes have a higher protein 
content than other adipocytes, which contributes to a greater production and release of 
adipocytokines as part of the EAT secretome (Marchington et al., 1989). Due to the 
proximity to the coronary circulation and cardiomyocytes, it is hypothesised that the EAT 
secretome factors maintain normal heart function. In disease, however, the EAT secretome 
becomes hyper-inflammatory and pro-fibrotic, leading to pathological remodelling of the 
myocardium (Mazurek et al., 2003; Venteclef et al., 2014; Abe et al., 2018; Babakr et al., 
2020). A third, but less defined, function of EAT is that it provides a mechanical buffer 
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against deformation of the coronary vessels caused by torsion of the heart contraction to 
protect against coronary artery damage (Rabkin, 2017). A final hypothesised function of 
EAT is that the high UCP-1 expression contributes to heart thermoregulation as EAT 
adipocytes can transdifferentiate from a WAT to beige phenotype to generate heat (Sacks 
et al., 2009; Sacks et al., 2013). Limited evidence exists to support these putative functions; 
although new research is beginning to address this issue. 
1.3 EAT deposition in cardio-metabolic disease 
Non-invasive measures of EAT deposition have been strongly associated with both 
cardiovascular and metabolic diseases (Rabkin, 2017), which intersect to known 
collectively as cardio-metabolic disease (Merriman & Wilcox, 2018). In Aotearoa New 
Zealand, the prevalence and impact of cardio-metabolic disease is greater than any other 
non-communicable disease. This is especially true for Māori and Pasifika communities, 
where the prevalence is typically 2-3 higher than that of New Zealand European 
communities matched for age and other confounding variables (Merriman & Wilcox, 
2018). Since EAT is strongly and independently associated with CVD, assessment of the 
cardiac fat depot has emerged as an important tool for cardio-metabolic disease risk 
stratification in Aotearoa New Zealand. 
1.3.1 EAT measurement 
EAT deposition is measured as a thickness using echocardiography (Iacobellis et 
al., 2003a; Willens et al., 2007) or as a volume using either cardiac magnetic resonance 
imaging (cMRI) (Flüchter et al., 2007; Sironi et al., 2008) or computed tomography (CT) 
(Gorter et al., 2008; Wang et al., 2009). All methods provide accurate measurements of 
EAT; however, measures of EAT volume are the gold-standard due to enhanced spatial 
resolution (Wong et al., 2016).  
1.3.2 Potential confounding variables 
Several patient characteristics are independently associated with the extent of EAT 
deposition and thus need to be controlled for when assessing EAT in different patient 
groups (Table 1.1). EAT deposition is marginally greater in men in metabolically healthy 
populations and in patients with obesity (Flüchter et al., 2007; Iacobellis et al., 2008). 
Differences in EAT volume have been reported between self-reported American ethnic 




(Alexopoulos et al., 2010). Our group has found that the correlation of EAT thickness and 
body mass index (BMI) commonly found in self-identified European patients is absent in 
self-identified New Zealand Māori/Pacific Island patients (Moharram et al., 2020). 
Similarly, EAT volumes measured in self-identified indigenous Australian patients have 
been found to be greater than in non-indigenous patients (Sun et al., 2020). Finally, EAT 
deposition, whether thickness or volume, has been positively associated with age in 
multiple ethnic and disease groups (Ahn et al., 2007; Jeong et al., 2007; Natale et al., 2009; 
Alexopoulos et al., 2010).  
Table 1.1. EAT deposition relationship to basic patient characteristics. 
Variable Relationship to EAT deposition References 
Age Positive correlation (R: 0.264-0.480) 
Jeong et al., 2007; Ahn 
et al., 2008; Alexopoulos 
et al., 2010. 
Gender Absolute levels greater in men 
Fluchter et al., 2007; 




1Greater in Caucasian population than Asian than 
African American than Hispanic in American cohort. 
2Greater in Indigenous Australians than non-
Indigenous. 
3May be differences in NZ European relative to NZ 
Māori and Pacific Islanders. 
1Alexopoulos et al., 
2010; 2Sun et al., 2020; 
3Moharram et al., 2020. 
 
1.3.3 Associations with metabolic parameters 
EAT deposition is associated with indices of obesity and metabolic disease (Table 
1.2). Recent meta-analysis (Rabkin, 2014) confirms that EAT thickness and volume is 
positively correlated with BMI, waist circumference (WC), and total visceral adipose tissue 
(VAT) deposition (Iacobellis et al., 2003a; Iacobellis et al., 2003b; Iacobellis & Leonetti, 
2005; Ahn et al., 2007; Cikim et al., 2007; Jeong et al., 2007; Alexopoulos et al., 2010; 
Akyol et al., 2013). Simply put, greater general obesity correlates with greater fat around 
the heart. EAT deposition also independently correlates with plasma insulin and fasting 
glucose levels and is significantly greater in patients with type-2 diabetes and patients with 
metabolic syndrome relative to matched controls (Ahn et al., 2007; Cikim et al., 2007; 
Gorter et al., 2008; Iacobellis et al., 2008; Pierdomenico et al., 2013; Rabkin, 2014). 
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1.3.4 Associations with cardiac structure and function 
In post-mortem cases and cardiac surgery patients, EAT thickness has been shown 
to correlate with left ventricle (LV) mass (Corradi et al., 2004; Iacobellis et al., 2004). This 
is confirmed by meta-analysis showing that for every 1.2 grams increase in LV mass there 
is a 10 mL increase in EAT volume – a relationship that is independent of BMI (Mancio et 
al., 2019). EAT thickness is also associated with right and left atrial diameters in subjects 
across the obesity spectrum, which is also supported by meta-analysis (Iacobellis et al., 
2007; Mancio et al., 2019). Functionally, EAT volume is negatively correlated with LV 
circumferential shortening in anthropometrically matched patients (Kankaanpää et al., 
2006; Sironi et al., 2008). Similarly, EAT thickness is inversely associated with 
echocardiographic and haemodynamic measures of systole (fractional shortening, ejection 
fraction, systolic blood pressure) and diastole (LV diastolic acceleration, E/A ratios, 
diastolic blood pressure) (Iacobellis et al., 2007; Natale et al., 2009; Akyol et al., 2013). 
Meta-analyses suggest that the association of EAT deposition with diastolic dysfunction is 
robust, while associations with systolic function are weak or inconclusive (Rabkin, 2014; 
Mancio et al., 2019). In sum, excess EAT deposition is associated with heart remodelling 
and cardiac dysfunction. 




Measurement type N studies 
Correlation 
coefficient 
95% CI P value 
BMI 
Total 26 0.47 0.41 - 0.53 < 0.0001 
Thickness 17 0.47  < 0.0001 
Volume 9 0.44^  < 0.0001 
WC Total 20 0.57* 0.50 - 0.63 < 0.0001 
VAT Total 11 0.69*# 0.55 - 0.79 < 0.0001 
Data reported by Simon Rabkin in Metab Syndr Relat D 12, 31-42 (2014). Measurement type 
encompasses EAT thickness or volume measured by echocardiogram, computed tomography 
(CT), or cardiac magnetic resonance imaging (cMRI). Thickness represents echocardiography 
results only; volume is combination of CT and cMRI studies (combined for power). N studies 
indicative of number of eligible studies included in meta-analysis for each EAT measurement 
type. Abbreviations: BMI = body mass index; WC = waist circumference; VAT = visceral 
adipose tissue volume; CI = confidence interval. Differences in strength of correlations between 
obesity indices and measurement methods assessed by Fisher z transformation; ^ = ns vs. EAT 
thickness-BMI correlation coefficient; *P < 0.0001 vs. total EAT-BMI correlation; #P < 0.0001 




1.4 Associations of EAT deposition with cardiovascular disease 
Research from large community cohort studies, including the Framingham Heart 
Study, the Heinz Nixdorf Recall Study, and the Multi-Ethnic Study of Atherosclerosis, 
suggest that pericardial fat associates with cardiovascular disease (CVD) risk (Ding et al., 
2009; Mahabadi et al., 2009; Mahabadi et al., 2013). Furthermore, these studies suggest 
that pericardial fat volume is a stronger predictor of CVD incidence than general VAT 
volume. In addition to associating with overall CVD risk, cardiac adipose deposition, 
particularly EAT deposition, is associated with specific conditions, including coronary 
artery disease (CAD) and atrial fibrillation (AF). 
1.4.1 Coronary artery disease 
The structural contiguity of EAT with the coronary vasculature led to several 
studies of EAT deposition with CAD risk. EAT deposition associates with the incidence of 
CAD/atherosclerosis and the degree of coronary artery stenosis (Ahn et al., 2007; Jeong et 
al., 2007; Djaberi et al., 2008; Eroglu et al., 2009; Alexopoulos et al., 2010). Meta-analysis 
has established an odds ratio of 1.26 of increasing EAT thickness with high-risk plaque 
presence (Nerlekar et al., 2018). Additionally, EAT deposition independently correlates 
with CAD severity (degree of artery narrowing), number of diseased vessels, artery 
calcification score, artery stiffness and tunica intima/media thickness (Ahn et al., 2007; 
Jeong et al., 2007; Djaberi et al., 2008; Eroglu et al., 2009; Alexopoulos et al., 2010).  
1.4.2 Atrial fibrillation 
AF is the most prevalent form of cardiac arrhythmia worldwide and is estimated to 
directly affect approximately 34 million people (Chugh et al., 2014). In Aotearoa New 
Zealand, 1 in 35 individuals are estimated to be diagnosed with AF (Poppe et al., 2018); 
although, this is likely a gross underestimation (Ternouth et al., 2018). Critically, 
communities affected by long-standing health inequities, especially Māori communities, 
are disproportionately diagnosed with AF and at younger ages (Poppe et al., 2018). Cardiac 
adipose strongly associates with AF. When measured independently, total and left atrial 
EAT volumes are significantly greater in AF cases relative to matched controls. 
Furthermore, the amount of EAT is proportional to AF severity (no AF < paroxysmal < 
persistent) and is predictive of AF recurrence following catheter ablation (Batal et al., 2010; 
Nagashima et al., 2011; Shin et al., 2011; Tsao et al., 2011; Nagashima et al., 2012). A 
comprehensive meta-analysis finds that a 1-SD increase in EAT volume increases AF risk 
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2.6-fold (Wong et al., 2016). When stratified, a 1-standard deviation increase in EAT 
increases paroxysmal AF by 2.1-fold and persistent AF by 5.4-fold. Importantly, although 
differences existed in AF associations between EAT imaging modalities, EAT thickness 
and volume both significantly associate with AF risk (Wong et al., 2016). 
1.5 Adipose tissue remodelling in obesity 
Adipose tissue exhibits a high degree of plasticity and is well-known to remodel in 
obesity (White & Ravussin, 2018). Since WAT depot adipocytes are the primary sites for 
lipid storage, adipocyte morphology changes during periods of lipid excess and depletion. 
Adipocytes remodel by two main methods in obesity: 1) hypertrophy – an increase in the 
size of mature adipocytes, or 2) hyperplasia – an increase in cell number via mature cell 
proliferation and/or pre-adipocyte recruitment (White & Ravussin, 2018). Accompanying 
adipocyte remodelling is expansion of the extracellular matrix to facilitate lipid droplet 
growth and transcriptome realignment to facilitate an increased metabolic demand 
(Mariman & Wang, 2010; Gealekman et al., 2011; Alligier et al., 2012). Regional 
heterogeneity exists between WAT depots in the balance of hypertrophy and hyperplasia 
in obesity-associated remodelling. In general, SAT depots contain a greater proportion of 
pre-adipocytes with faster differentiation kinetics than VAT depots (Tchkonia et al., 2002; 
Tchkonia et al., 2005). SAT also has greater vascularisation and angiogenic capacities, 
resulting in adipose that is primed to accommodate excess nutrients (Gealekman et al., 
2011; Alligier et al., 2012). Regional heterogeneity exists between different SAT depots 
that are determined by gender, genetic predisposition, and disease (White & Tchoukalova, 
2014). Similar findings have been reported between VAT depots, including between 
omental, mesenteric, and retroperitoneal adipose depots (Tchkonia et al., 2002; Tchkonia 
et al., 2005; White & Tchoukalova, 2014).  
1.5.1 Subcutaneous and visceral adipose depot associations with obesity 
Like EAT, SAT and VAT depot volume correlates with measures of obesity, 
including BMI, WC, and body fat percentage (Janssen et al., 2002; Chan et al., 2003; Lee 
et al., 2008). This includes intrathoracic and abdominal SAT depots, as well as 
intraperitoneal, retroperitoneal, and paracardial VAT depots (Wang et al., 2009). 
Adipocyte size, whether measured as cell volume, area, or diameter, also associates with 
BMI and body fat percentage (correlation coefficient range presented in Table 1.3) (Salans 




have been reported between VAT omental adipocytes and SAT abdominal, gluteal, and 
femoral adipocytes (Tchernof et al., 2006; Veilleux et al., 2011; Michaud et al., 2016). 
 
 
Figure 1.2. Schematic of adipose depots and paradigm of adipose remodelling in obesity. A, 
schematic illustration of subcutaneous and visceral adipose depots assessed and/or discussed in 
this thesis. Note the colour coding of subcutaneous vs. visceral depots and the underline 
highlighting the depots assessed in this thesis. B, expansion of adipose tissue is a fundamental 
remodelling process in obesity. C, adipose tissue expands by two pathways: adipocyte 
hypertrophy (a, increased cell size) and adipocyte hyperplasia (b, increased cell number). D, in 
general, adipocyte hypertrophy is the predominant form of remodelling in obesity. Adipocyte 
size (from all non-EAT depots) correlates with body mass index (BMI) and adipose tissue 
deposition. See main text for more details and references, and Table 1.3 for correlation 
coefficients. 
Importantly, the sizes of adipocytes within VAT and SAT depots correlate with the 
volume of the adipose depots they populate (Table 1.3). VAT omental adipocyte diameter 
has been reported to correlate with omental adipose volume in independent all-female and 
all-male cohorts, even after adjustment for BMI, body fat percentage, and age (Tchernof et 
al., 2006; Tchoukalova et al., 2010a; Veilleux et al., 2011; Michaud et al., 2016). Similarly, 
abdominal and femoral subcutaneous adipocytes also correlate in size with abdominal and 
lower body SAT volumes, respectively (Tchernof et al., 2006; Tchoukalova et al., 2008; 
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Veilleux et al., 2011; Michaud et al., 2016). The correlation of SAT adipocyte size with 
SAT volume was identified in cross-sectional study and confirmed to change 
proportionally over time in longitudinal study (Tchoukalova et al., 2010b). Together these 
findings indicate that VAT and SAT expansion in obesity occurs predominantly via 
hypertrophy of the comprising adipocytes. VAT and SAT fat cell size independently 
correlates with anthropometric indices of obesity (such as BMI) and with the deposition of 
the adipose depots they comprise. 
Table 1.3. Subcutaneous (SAT) and visceral (VAT) adipocyte size correlations to obesity 
indices. 
Adipose depot BMI Body fat % SAT volume VAT volume 
SAT 
Abdominal 0.59-0.70 0.63-0.75 0.48-0.76 - 
Femoral 0.70 0.43-0.63 0.41 - 
VAT 
Omental 0.35-0.65 0.63 - 0.47-0.80 
Selection of results from studies indicating univariate correlation coefficient values. Data are 
correlation coefficients presented as a range from > 1 study or single coefficient from 1 study. 
Note that all correlations are statistically significant (P < 0.0001). Also note that abdominal and 
femoral SAT adipocytes correlate with fat volumes from abdominal and leg SAT origins, 
respectively. VAT omental adipocyte size correlates with VAT volume measured between L2-
L5 that is differentiated from other abdominal adipose. See text for references. 
 
1.6 EAT adipocytes in obesity 
1.6.1 Smaller adipocyte size  
In general, VAT adipocytes are smaller than paired SAT adipocytes (Salans et al., 
1973; Tchernof et al., 2006; Ray et al., 2009; Fang et al., 2015). Studies in primates and 
rodents and in human cohorts have confirmed that EAT adipocytes are smaller still than 
other VAT depots (summarised in Table 1.4) (Sons & Hoffmann, 1986; Marchington et 
al., 1989; Chatterjee et al., 2009; Eiras et al., 2010; Bambace et al., 2011; Bambace et al., 
2014). This is consistent regardless of classification as myocardial EAT or perivascular 
EAT (Sons & Hoffmann, 1986; Marchington et al., 1989; Chatterjee et al., 2009; Eiras et 











Positive correlation of EAT adipocyte size with body weight and 
EAT height (i.e., thickness). Significant differences in EAT 
adipocyte size between (in descending order) morbidly obese, 




EAT adipocyte volume is ~half that of adipocytes from  




Perivascular EAT adipocyte diameters smaller than SAT 




SAT adipocyte size (area) correlates with BMI (r = 0.601; P = 
0.003); however, EAT adipocyte size does not (r = 0.339; P = 




EAT adipocytes smaller than those from SAT (manubrium) and 
VAT (peritoneal) depots. SAT adipocyte size positively correlates 





EAT adipocytes smaller than those from manubrium SAT. N =34. Not stated 
All studies are et al. (except Sons & Hoffman). See main text and reference list for full citations. 
Findings highlight the smaller size of EAT adipocytes relative to adipocytes from other SAT or 
VAT depots, and/or highlight the correlation between EAT (or SAT) adipocyte size with body 
mass index (BMI). Obesity association column summarises the relationship between EAT 
adipocyte size with obesity (BMI as index): positive indicates EAT adipocytes are bigger with 
greater BMI, NS indicates a not significant correlation, not stated indicates that a correlation to 
BMI was not performed or it was not reported in the article. 
 
1.6.2 Associations with obesity indices 
Relative to the extensive associations of EAT deposition with obesity, little is 
known about EAT adipocyte remodelling in obesity (Table 1.4). Early work by Sons & 
Hoffman found a positive correlation between EAT adipocyte size and total body weight 
in post-mortem cases. Moreover, a correlation of EAT cell size with EAT height (i.e., 
thickness) was reported, suggesting that EAT adipocyte size correlates with EAT 
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deposition (Sons & Hoffmann, 1986). In contrast, more recent studies using adipose 
samples from cardiac surgery patients found that EAT adipocyte size does not correlate 
with BMI (or was not reported) despite a positive correlation existing between thoracic 
SAT adipocyte size and BMI (Eiras et al., 2010; Bambace et al., 2011). Together, these 
limited investigations provide conflicting evidence about EAT adipocyte remodelling in 
obesity. Furthermore, due to small sample sizes, confounding variables of EAT adipocyte 
size have not been firmly established, thereby complicating the formulation of multivariate 
models. My thesis aims to clarify the role of EAT adipocyte remodelling in EAT expansion 
and obesity. 
1.7 EAT as a secretory tissue 
As described earlier, EAT has a significantly greater capacity for synthesis and 
release of adipocytokines than other adipose depots (Marchington et al., 1989; 
Marchington & Pond, 1990). The secretome of EAT-derived factors has a pro-
inflammatory composition relative to other VAT and SAT depots, which is augmented in 
several CVDs (Mazurek et al., 2003; Baker et al., 2006; Cheng et al., 2008; Langheim et 
al., 2010). When coupled with the intimacy of EAT with the myocardium and the coronary 
circulation, the EAT secretome has been putatively implicated as a player in disease 
pathogenesis (Yudkin et al., 2005; Sacks & Fain, 2007). However, to date the elucidation 
of the specific EAT-derived factors driving cardiac pathophysiology is limited and, when 
done, often utilises deductive methods. 
For example, the adipokine leptin has been identified via screening arrays as a factor 
upregulated in the EAT secretome from CAD and heart failure (HF) patients (Cheng et al., 
2008; Bobbert et al., 2012). Using similar concentrations as measured in the secretome, 
recombinant leptin was then found to promote oxidative stress and negative inotropy in 
isolated murine cardiomyocytes (Nickola et al., 2000; Cheng et al., 2008; Bobbert et al., 
2012). This deductive methodology establishes leptin as a differentially expressed 
component of the EAT secretome that can directly affect cardiac function. Furthermore, it 
supports the hypothesis that EAT-derived factors could contribute to disease 
pathophysiology via paracrine signalling mechanisms with the myocardium (Yudkin et al., 
2005). Another EAT-derived factor, resistin, which has also been associated with CVD risk 






1.8.1 Introduction and clinical significance of resistin 
Resistin is a pro-inflammatory adipocytokine that is synthesised and released by 
several cell types, including EAT adipocytes (Jamaluddin et al., 2012). Early studies 
implicated resistin in the pathogenesis of insulin resistance (hence, resist-insulin) (Steppan 
et al., 2001). More recent studies, however, have established associations between 
circulating resistin levels and CVD risk (Jamaluddin et al., 2012). Plasma resistin levels 
are increased in paroxysmal and persistent forms of AF and high circulating resistin is 
predictive of post-operative AF risk (Gungor et al., 2011; Özcan et al., 2014; Ermakov et 
al., 2016). In at-risk populations, circulating resistin levels are associated with incident HF 
and with progressive deterioration of LV contractility (Butler et al., 2009; Bobbert et al., 
2012). Similarly, in large-scale community cohorts, plasma resistin concentrations are 
correlated independently with increased myocardial mass and decreased fractional 
shortening (McManus et al., 2012; Norman et al., 2015; Norman et al., 2020). Circulating 
resistin levels therefore serve as a novel biomarker for arrhythmic and contractile CVDs.  
1.8.2 Basic research of resistin effects in the heart 
Previous pre-clinical research suggests a role for resistin in CVD pathogenesis. 
Chronic overexpression of resistin in rodent models has been found to recapitulate the 
myocardial hypertrophy and impaired in vivo contractility characteristics of clinical HF 
(Kim et al., 2008; Chemaly et al., 2011). Structural and biochemical analyses reveal that 
long-term resistin overexpression activates hypertrophic cellular signalling pathways, 
leading to sarcomere reorganisation and increases in cardiomyocyte size. In addition, 
chronically elevated resistin promotes oxidative stress and cellular inflammation, as well 
as myocardial fibrosis (Kim et al., 2008; Chemaly et al., 2011). Cardiomyocytes isolated 
from these overexpression models exhibit impaired contractility and contraction kinetics 
paralleled by decreased Ca2+ transient amplitudes and Ca2+ decay rates (Kim et al., 2008). 
These findings suggest that structural remodelling and functional impairment of the heart 
can be promoted by chronic resistin exposure. The acute effect of circulating resistin in the 
heart is, by contrast, less known.  
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1.8.3 Link between EAT and resistin 
Incubation of isolated rat cardiomyocytes or Langendorff-perfused rat hearts with 
human SAT secretome has been found to decrease cardiomyocyte and ventricular 
contractility (Lamounier-Zepter et al., 2006; Look et al., 2011). This negative inotropic 
effect was acute, dose-dependent, and concurrent to depressions in Ca2+ transient 
amplitudes (Lamounier-Zepter et al., 2006; Look et al., 2011). Like SAT secretome, 
Greulich et al. found that exposure to human EAT secretome acutely impairs Ca2+ handling 
kinetics and inotropy of rat cardiomyocytes, while no such effect was found with the PAT 
secretome (Greulich et al., 2012). Interestingly, the reported negative inotropic effect of 
the EAT secretome was limited to that extracted from diabetic patients (Greulich et al., 
2012). We recently found that cultured human EAT secretome stimulated with a β3-
adrenergic agonist acutely promotes pro-arrhythmic contractions in human atrial trabeculae 
(Babakr et al., 2020). However, unlike Greulich et al., we found that the EAT secretome 
has an acute positive inotropic effect and has no interaction with diabetes (Babakr et al., 
2020). In this case the EAT secretome was not profiled. Therefore, the specific 
adipocytokine(s) eliciting the pro-arrhythmic and inotropic effects need to be determined. 
Resistin expression is increased within EAT biopsies and secretomes of EAT 
isolated from CAD patients (Baker et al., 2006; Langheim et al., 2010). Additionally, 
perivascular EAT resistin levels are greater in coronary artery bypass graft surgery patients 
that develop post-operative AF (Rachwalik et al., 2019). When combined with the 
extensive clinical associations of EAT deposition with CVD and the known direct effects 
of resistin on cardiac function, EAT-derived resistin has emerged as a potential direct 






Figure 1.3. Putative paracrine and vasocrine signalling relationship between epicardial adipose 
tissue (EAT) and the myocardium. A is adapted from Babakr et al. 2020. Human EAT was 
cultured in the presence and absence of the β3-adrenergic agonist, BRL37344 (BRL), for 24 
hours. The culture media was then superfused over human atrial trabeculae stimulated to contract 
ex vivo at 1 Hz. Arrhythmia propensity was assessed by the percentage of trabeculae exhibiting 
spontaneous contractions (SCs) during 1-minute rest intervals. Superfusion with BRL-treated 
EAT culture significantly increased arrhythmia propensity (*P<0.05, Fisher’s exact test, N=13 
per condition) (Babakr et al., 2020). B, schematic interpretation of findings from Babakr et al. 
(2020). The EAT-derived secretome is hypothesised to signal to the myocardium by paracrine 
and vasocrine (via blood vessels, BV) pathways. Evidence from Babakr et al. suggests this 
relationship drives acute arrhythmias and positive inotropy. *This thesis aims to determine the 
role of EAT-derived resistin in mediating the effects of the EAT secretome in the heart. 
 
1.8.4 Questions left unanswered 
Several key limitations of the literature need to be addressed in order to determine 
the role of resistin in the arrhythmogenic and inotropic effects of the EAT secretome. 
Firstly, the acute effects of exogenous resistin on myocardial function need to be 
determined. Secondly, we previously reported that human EAT secretome requires β3-
adrenergic receptor stimulation to induce effects on human atrial trabeculae (Babakr et al., 
2020). Therefore, how this external stimulus affects resistin content within the EAT 
secretome also needs to be determined. 
  




Extensive research has examined the macroscopic and microscopic properties of 
many adipose depots. This has formed a general framework dictating that, regardless of the 
depot, adipose tissue expansion in obesity occurs predominantly via hypertrophy of the 
constituent adipocytes. Contextualising EAT expansion in obesity within this framework 
cannot be done due to the poor understanding of microscopic EAT remodelling in health 
and disease. The release of pro-inflammatory factors from EAT is also thought to contribute 
to CVD pathogenesis. The content of the adipocytokine, resistin, within the EAT secretome 
is increased in CVD and chronic overexpression of resistin within cardiomyocytes has 
significant negative structural and functional consequences. Whether EAT-derived resistin, 
and the interaction with the adjacent myocardium, has an acute effect on cardiac 
automaticity and contractility has yet to be determined. In sum, changes in EAT adipocyte 
morphology and the functional effects of EAT-derived factors in cardio-metabolic is poorly 
understood. Determining these aspects of EAT will provide pathophysiological insight into 





1.10 Aims and objectives of Part one 
The overall aim of Part one of this thesis is to determine if/how EAT adipocytes 
remodel in obesity and how the EAT-derived adipocytokine, resistin, interacts with the 
arrhythmogenic and inotropic effects associated with EAT morphology. 
Aim One 
To determine the effect of obesity on EAT adipocyte morphology. 
Objectives for Aim One 
Determine the association of EAT adipocyte: 
1. Size with BMI in histological slices from post-mortem cases. 
2. Hypertrophy and hyperplasia with BMI and EAT thickness in cardiac surgery 
patients. 
Hypothesis for Aim One 
Like adipocytes from other adipose depots, EAT adipocyte size will correlate with BMI to 
suggest hypertrophic remodelling. Furthermore, EAT adipocyte size will correlate with 
EAT thickness in paired patients. 
Aim Two 
To determine the interaction of resistin with the arrhythmogenic and inotropic effects of 
EAT and the EAT secretome. 
Objectives for Aim Two 
Determine the effect of: 
1. Arrhythmogenic triggers on the expression of resistin in the EAT secretome. 
2. Recombinant resistin on the arrhythmia propensity of human atrial myocardium. 
3. Recombinant resistin on the force and kinetic parameters of human myocardial 
contractility. 
Hypothesis for Aim Two 
The release of resistin from human EAT will be increased by the arrhythmogenic β3-
adrenergic triggers. Recombinant resistin will enhance the spontaneous contraction 
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EAT deposition has a strong association with aspects of metabolic dysfunction, 
including obesity. The size of the EAT adipocytes in relation to obesity, however, has rarely 
been researched. Therefore, to contextualise EAT within the broader framework of 
pathophysiological adipocyte size changes in obesity, we aimed to determine whether EAT 
adipocyte size is associated with BMI. During routine post-mortem examination, adipose 
tissue biopsies were obtained from four depots of 43 cases, including EAT, as well as PAT, 
appendix mesenteric (AAT), and clavicular subcutaneous (SAT) adipose tissues. Tissues 
were fixed, sectioned, and stained using haematoxylin and eosin. The size (measured as 
area) of each adipocyte imaged from the depots was analysed in relation to BMI. Mean size 
of EAT adipocytes was significantly smaller than that from SAT and AAT depots, while 
not differing from PAT adipocytes. BMI positively correlated with the size of adipocytes 
isolated from SAT (r = 0.5893, P < 0.0001), PAT (r = 0.5854, P < 0.0001), and AAT (r = 
0.5829, P < 0.0001) depots, but not from EAT (r = 0.1242, P = 0.4274), even after 
multivariate adjustment for age and sex. EAT adipocyte size is not associated with 
increased BMI despite significant associations within adipocytes from other adipose 
depots. 
2.1 Introduction 
EAT is the fat depot located between the surface of the myocardium and the visceral 
pericardium. Clinical interest in EAT has piqued in the past 20 years due to associations of 
macroscopic EAT deposition, whether measured as thickness or volume, with CVD and 
anthropometric indices of obesity, including BMI (Iacobellis et al., 2003b; Pierdomenico 
et al., 2013; Rabkin, 2014). Moreover, as a fat depot, EAT shares unique contiguity with 
the underlying tissue that is not constrained by a fascial boundary. Consequently, EAT and 
the myocardium share a microcirculation and, therefore, a direct paracrine and vasocrine 
signalling relationship (Iacobellis et al., 2005a; Sacks & Fain, 2007). Despite the clinical 
interest in EAT, basic research from a morphological aspect has lagged behind. In 
particular, the understanding of EAT adipocyte size, both in health and in metabolic 
dysfunction, is poor, especially when compared to other visceral and subcutaneous adipose 
depots.  
Microscopic adipose tissue morphology, which encompasses adipocyte size and 
number, has been comprehensively researched in various subcutaneous and VAT depots 
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(Tandon et al., 2018). Although distinct regionality exists between adipose depots, the 
remodelling associated with an increase in obesity-indices is conserved. Studies of human 
SAT adipocytes, most commonly from an abdominal origin, have consistently shown that 
adipocyte size (or hypertrophy) positively correlates with BMI or body fat percentage 
(Tchernof et al., 2006; Tchoukalova et al., 2008; Eiras et al., 2010; Bambace et al., 2011; 
Heinonen et al., 2014; McLaughlin et al., 2014). Moreover, a similar correlation exists with 
adipocytes isolated from other VAT depots, including from omental, retroperitoneal, and 
mesenteric origins (Marchington et al., 1989; Tchernof et al., 2006). SAT and VAT 
adipocyte hypertrophy has been established as a risk factor for metabolic derangements, 
including insulin resistance and dyslipidaemia, and with abnormalities in the circulating 
levels of adipocyte-derived inflammatory and fibrotic markers (Skurk et al., 2007; Veilleux 
et al., 2011; Yang et al., 2012; McLaughlin et al., 2014). Therefore, because macroscopic 
EAT deposition is emerging as an important clinical marker for metabolic dysfunction, it 
is pertinent to determine whether concurrent alterations occur within the microscopic 
morphology of EAT. 
Previous investigations of changes in EAT adipocyte size with obesity have yielded 
divergent results (Rabkin, 2007). Sons and Hoffmann found that with an increase in body 
weight, adipocytes derived from the EAT of post-mortem hearts were slightly larger when 
from obese cases relative to lean cases (Sons & Hoffmann, 1986), whereas others either 
found no correlation of EAT adipocyte size with BMI or the results were inconclusive 
(Eiras et al., 2010; Bambace et al., 2011). 
We aimed to clarify the discrepancy that currently exists in the understanding of the 
EAT adipocyte morphology and obesity relationship. To this end, we have measured the 
size of adipocytes isolated from the EAT of post-mortem hearts from 43 cases with a range 
of BMIs, which is the largest sample size used for such a study. Further, we have analysed 





2.2.1 Post-mortem cases 
Adipose tissue biopsies were collected from four anatomically distinct sites during 
consecutive routine coronial post-mortem examinations as part of a 6-month prospective 
study at Auckland City Hospital, Auckland, New Zealand. Cases excluded from analysis 
were all paediatrics, those with suspicious or homicidal cause of death, or those with 
potential medico-legal implications. Further exclusion was applied to cases with advanced 
decomposition or trauma that resulted in loss of suitable tissue. No cases were severely 
malnourished and/or cachectic. Tissue sampling and processing for histological analysis 
formed part of the post-mortem examination and all post-mortem examinations were 
authorised by the chief coroner. No tissue was retained following processing. Information 
available for each case was limited to the age, sex, cause of death, as well as body weight 
and height, which was used to calculate BMI (body weight (kg)/height (m)2). No other 
potentially identifying information could be deduced from the adipose images used for 
analysis. 
2.2.2 Adipose tissue procurement 
The EAT biopsy was taken as part of routine right coronary artery examination from 
the atrioventricular groove, between the right coronary artery orifice and the right lateral 
ventricular wall. For comparison to EAT, a SAT sample from the clavicular fat was 
examined as part of biopsy for skin and muscle histology. Additionally, adipose tissue 
samples were obtained from routine appendix and paracardial wall examinations. The 
appendix mesenteric (AAT) and PAT adipose tissues were utilised as VAT controls. PAT 
was defined as the adipose tissue external to the parietal pericardium. 
2.2.3 Adipose tissue processing 
Adipose biopsies were immediately transferred to a histology cassette and 
immersed in 10% formalin for fixation. The tissues were fixed for 24-48 hours and 
transferred to an accredited histology processing laboratory (Department of Anatomical 
Pathology, LabPLUS, Auckland City Hospital). The biopsies were processed using the 
Leica Peloris Tissue Processor (Leica, Germany). This involves a stepwise infusion of 
formalin, alcohol, xylene and finally paraffin wax.  After tissue processing, the biopsies 
were embedded into paraffin wax and sectioned at 4 µm using a Thermo scientific HM325 
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microtome (ThermoFisher Scientific, USA). Sectioned tissues were then stained using 
Haematoxylin and Eosin using an automated Leica Multistainer model ST5020 (Leica 
Biosystems, Germany). The histological slides were viewed using an Olympus BX53 
microscope (Olympus, Japan) using an UPlanFL N 20x objective. One digital image was 
taken using an Olympus UC50 digital camera (Olympus, Japan) and analysed for each 
adipose depot from each case. 
2.2.4 Measuring adipocyte area 
The measurement of adipocyte area was performed using Aperio ImageScope 
software (Leica Biosystems Pathology Imaging, Germany). The researcher was blinded to 
the origin of the adipose tissue image as well as the BMI of the case. To measure the 
adipocyte area, the Positive Pen tool of the ImageScope software was used to trace the 
border of every adipocyte within the field of view. Adipocytes with ambiguous or broken 
cell membranes, as well as adipocytes cut-off by the image edge, were not traced for 
analysis. The adipocyte area (contained within each adipocyte tracing) was calculated 
based on the pixel size per µm2, which at the 20x objective used for imaging equated to 
0.289 µm2 per pixel. 
2.2.5 Data analysis 
Researcher blinding was maintained during data analysis. Results are presented as 
mean ± standard deviation (SD) or standard error (SEM) as appropriate. Case BMI was 
categorised into the standardised ranges, with <25 kg/m2 allocated into the lean group, ≥ 
25 < 30 kg/m2 into the overweight group, and ≥ 30 kg/m2 into the obese group (WHO, 
2019). Adipocyte size frequency distributions were plotted from every adipocyte measured 
from each adipose depot. Differences of mean adipocyte size between adipose depots were 
determined using one-way ANOVA followed by post hoc Tukey’s multiple comparisons 
test. Univariate (Pearson) correlations were used to assess the correlation between 
adipocyte size and BMI. Follow-up multiple linear regressions were used to adjust for age 
and sex in relation to each adipocyte depot. Scatter plots present the average adipocyte size 
from each fat depot of one case. Differences determined from all analyses were considered 
statistically significant if P < 0.05. All statistical analysis was performed using GraphPad 





Table 2.1. Post-mortem case characteristics (N = 43). 
Variable Mean ± SD Range 
Age (years) 53 ± 16 22-77 
Sex (Male/Female) 27/16  
BMI (kg/m
2
) 26.8 ± 4.3 19.0-35.5 
BMI = body mass index; SD = standard deviation. 
 
2.3 Results 
Post-mortem adipose tissue biopsies (SAT, AAT, PAT, EAT) were procured from 
43 post-mortem cases. As shown in Table 2.1, these post-mortem cases included males 
(N=27) and females (N=16), with a mean age of 53 ± 16 years (range 22-77 years), and a 
mean BMI of 26.8 ± 4.3 kg/m2 (range 19.0-35.5 kg/m2) for both sexes. In 17 of the cases, 
the cause of death was of a cardiovascular disease (sudden cardiac death, ischaemic heart 
disease, valvular heart disease, hypertensive heart disease), while the remaining 26 were of 
a non-cardiovascular cause (drowning, SUDEP, mixed drug toxicity, hanging, carbon 
monoxide toxicity). 
2.3.1 Mean adipocyte sizes from different adipose depots 
Frequency distributions of size revealed that adipocytes from each depot have a 
unimodal distribution profile (Figure 2.1A). Adipocytes from different fat origins have 
different sizes (Tchernof et al., 2006). As shown in Figure 2.1B, adipocytes isolated from 
SAT (4088.9 ± 209.1 µm2) and AAT depots (4443.6 ± 266.6 µm2) were significantly larger 
in mean when area when compared to adipocytes from PAT (2431.0 ± 131.3 µm2; P < 
0.0001 vs SAT or AAT) and EAT (2487.3 ± 83 µm2, P < 0.0001 vs SAT or AAT). Mean 
adipocyte area was not significantly different between cells from SAT and AAT depots (P 
= 0.55). Interestingly, relative to PAT mean adipocyte area, EAT adipocyte area was not 
different (P = 1.0).  




Figure 2.1. Adipocyte size frequency distributions and mean adipocyte sizes from subcutaneous 
(SAT), appendix (AAT), paracardial (PAT), and epicardial (EAT) adipose tissues. A, Unimodal 
frequency distribution of adipocyte size presented as % frequency. Frequencies calculated from 
every adipocyte analysed from each respective depot. SAT N = 2577, AAT N = 2522, PAT N = 
4428, EAT N = 3524. B, Mean adipocyte area SAT, AAT, PAT, and EAT depots. Values are 
unadjusted for BMI (average body mass index = 26.8 ± 4.3 kg/m2). *P < 0.0001 vs SAT, #P < 
0.0001 vs AAT. Results are presented as means ± SEM. Statistical difference determined using 
one-way ANOVA with post hoc Tukey’s multiple comparisons test. N = 43 for each depot. 
 
2.3.2 Adipocyte size relationship with body mass index 
As shown in Figure 2.2, when stratified into lean, overweight, and obese BMI 
categories, a significant greater mean adipocyte area was found between lean and 
overweight categories, and lean and obese categories in cells isolated from SAT, AAT, and 
PAT depots (Figures 2.3A-C). However, there was no difference in the size of EAT 
adipocytes measured from cases in the lean, overweight, and obese categories (Figure 
2.2D). To circumvent the arbitrary categorisation of BMI grouping, we performed 
univariate correlation analyses of adipocyte size and BMI (as a continuous variable). A 
significant positive correlation was found between BMI and adipocyte area of cells isolated 
from SAT (r = 0.5893, 95% confidence interval [CI]: 0.35, 0.76, P < 0.0001), PAT (r = 
0.5854, 95% CI: 0.35, 0.75, P <0.0001), and AAT (r = 0.5829, 95% CI: 0.34, 0.75, P < 
0.0001) depots (Figures 2.3A-C). These associations remained after adjustment for age 
and sex (not shown). No such correlation could be found between mean EAT adipocyte 
area and BMI, either with or without adjustment for age and sex (unadjusted: r = 0.1242, 





Figure 2.2. Mean adipocyte sizes in lean, overweight, and obese groups. Subcutaneous (SAT, 
A), appendix (AAT, B), paracardial (PAT, C), and epicardial (EAT, D) depots. *P < 0.05 vs lean 
group, **P < 0.01 vs lean group, ***P < 0.001 vs lean group. Data are presented as means ± SEM. 
Statistical difference determined using one-way ANOVA with post hoc Tukey multiple 
comparisons test. N = 43 for each depot. 
 
Figure 2.3. Univariate correlation analyses of mean adipocyte area vs BMI of cells from 
subcutaneous (SAT, A), appendix (AAT, B), paracardial (PAT, C), and epicardial (EAT, D) 
depots. Note that P values presented within the Figures are unadjusted. BMI = body mass index. 
N = 43. 
  




We aimed to determine the relationship between EAT adipocyte size and obesity. 
EAT adipocyte size, we expected, would be analogous to adipocytes from other well-
researched SAT and VAT depots and would correlate positively with increasing BMI, an 
anthropometric proxy for obesity. Our main findings showed that an increase in BMI was 
not associated with hypertrophy of EAT adipocytes, despite this association being observed 
for adipocytes isolated from SAT, AAT, and PAT depots. This suggests that EAT 
adipocytes do not conform to the obesity-driven morphological size changes attributable to 
subcutaneous and visceral adipose depots. 
2.4.1 Lack of epicardial adipocyte size and body mass index correlation 
Previous studies have found conflicting results when determining the relationship 
of EAT adipocyte size to BMI. Measuring EAT adipocytes from 10 sampling sites of 34 
post-mortem adult hearts, Sons and Hoffman reported a robust positive correlation between 
EAT cell size and body weight (Sons & Hoffmann, 1986). Moreover, at the sampling site 
most similar to that used in our study (beside the aortic ostium at the arteria coronaria dextra 
above the wall of the right ventricle), 21% and 47% increases in mean EAT cell size were 
reported in groups with average BMIs of 30.1 and 34.7 kg/m2, respectively, when compared 
to the group with a 22.2 kg/m2 average (Nakaya & Tohse, 1986). Conversely, and more 
recently, as part of their assessment of EAT morphology in coronary artery disease patients, 
Eiras et al. found that no correlation existed between EAT adipocyte size and BMI, despite 
finding a positive correlation with adipocytes from SAT depots (Eiras et al., 2010).  
Our study has found a similar adipocyte size to those reported by Sons and Hoffman 
and Eiras et al. (Figure 2.1B), but extended and directly clarified with a larger sample size 
that no association exists between mean EAT adipocyte size and BMI (Figure 2.3D). While 
EAT adipocyte size did not correlate with BMI, adipocytes from the SAT, AAT, and PAT 
depots did (Figures 2.3A-C). Moreover, this adipocyte hypertrophy was dependent on the 
category of BMI, with mean adipocyte size increasing significantly in the overweight and 
obese groups relative to the lean group (Figures 2.2A-C). Hypertrophic growth of 
adipocytes from various SAT and VAT depots with increasing BMI is well-established in 
the field. Whether measured as cell lipid content (Salans et al., 1973; Tchoukalova et al., 
2008), diameter (Tchernof et al., 2006; Bambace et al., 2011), or area (Eiras et al., 2010), 




with BMI. This includes adipocytes with a subcutaneous manubrium sternal origin 
(Bambace et al., 2011), which has anatomical proximity to the clavicular adipose depot 
sampled in our study, as well as cells of mesenteric or omental origin that share anatomical 
proximity to the appendix adipose used in our study (Sons & Hoffmann, 1986; Tchernof et 
al., 2006). Our study, therefore, corroborates previous reports of adipocyte-BMI 
associations from other SAT and VAT depots, while directly measuring the association of 
EAT and BMI with a greater sample size and paired comparison with 3 other adipose 
depots. 
This absence of EAT adipocyte hypertrophy, therefore, is not concordant to 
adipocytes from other depots. Increased BMI has not only been correlated with an increase 
in SAT adipocyte size, but concurrently with an increase in the expression and activity of 
key lipid-handling enzymes, including lipoprotein lipase and hormone-sensitive lipase 
(Reynisdottir et al., 1997; Tchernof et al., 2006). As an energy storage and release organ, 
increased lipoprotein lipase and hormone-sensitive lipase activity, coupled with increased 
lipolysis rates, results in enhanced lipid and fatty acid flux across the adipocyte membrane, 
thereby facilitating excess energy storage and release as required (Tandon et al., 2018). We 
were unable to assess EAT adipocyte fatty acid metabolism as part of this study because it 
is not part of routine post-mortem examination; however, previous studies using EAT 
isolated from an array of other mammalian species have found that EAT has a uniquely 
active role in fatty acid uptake, lipogenesis, and lipolysis (Marchington et al., 1989; Liu et 
al., 2009). Relative to other VAT depots, including paracardial, popliteal, and perirenal, 
maximal lipogenic and lipolytic capacities of EAT are more than 2-fold greater 
(Marchington et al., 1989). Moreover, fatty acid incorporation is approximately 1.7-fold 
greater in EAT compared to pericardial, and more than 3-fold higher than all other VAT 
depots (Marchington & Pond, 1990). Furthermore, EAT fatty acid incorporation has been 
found to significantly increase in guinea-pigs fed a high-fat diet (Marchington & Pond, 
1990).  
Collectively, this creates a curious contradiction. EAT fatty acid handling has been 
found to increase with an obesity-inducing diet, but this is not accompanied by the 
adipocyte hypertrophy that is characteristic of other adipose depots. As part of their early 
work, Sons and Hoffman also noted that in a very small number of post-mortem cases 
matched for sex and height but with different body weights, there was near-identical EAT 
cell sizes. In these particular cases, EAT deposition was found to be increased, thereby 
suggesting that an alternative, hyperplastic expansion of EAT adipocytes is a possible 
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mechanism of EAT remodelling (Sons & Hoffmann, 1986). Therefore, based on the 
hypothesis that EAT functions as a buffer against localised lipotoxicity at the myocardium, 
hyperplastic remodelling of EAT adipocytes may predominate over hypertrophy to 
maintain adequate lipid handling (Marchington et al., 1989; Sacks & Fain, 2007).  
Finally, our finding that PAT and EAT have similar mean adipocyte sizes but 
different BMI associations highlights a further difference between PAT and EAT depots. 
Although often conflated, PAT and EAT arise from differential origins and are, 
consequently, anatomically distinct and are thought to have different roles in adipose 
physiology (Iacobellis et al., 2005a; Sacks & Fain, 2007). Importantly, PAT does not have 
contiguity with the myocardium. This means that PAT and the myocardium have different 
circulations and no physical contact, thereby preventing direct paracrine and vasocrine 
signalling between the tissues (Östman et al., 1979; Rebuffé-Scrive et al., 1989; 
Reynisdottir et al., 1997; Iacobellis et al., 2005a; Tchernof et al., 2006). Therefore, not 
only is it apparent that PAT and EAT have divergent macroscopic associations with the 
underlying cardiac muscle, our results show clearly that the response of each fat depot to 
increased adiposity is also different. 
2.4.2 Smaller epicardial adipocyte size 
We also obtained adipose samples from three other fat depots, one of SAT origin, 
and two from non-EAT VAT depots. Regional distinction in adipocyte morphology has 
been well-established. With regard to adipocyte size, those from SAT depots have 
consistently been shown to be larger, whether measured as cell diameter, volume, lipid 
content, or area than those from numerous VAT depots. Studies of patient cohorts have 
found that without adjustment for BMI abdominal SAT adipocytes are 12-30% larger than 
adipocytes from omental, retroperitoneal, and mesenteric VAT depots (Östman et al., 1979; 
Rebuffé-Scrive et al., 1989; Reynisdottir et al., 1997; Tchernof et al., 2006; Liu et al., 
2009). Moreover, adipocytes isolated from abdominal, thoracic, and sternal SAT depots 
and other VAT depots, including omental, peritoneal, and paracardial fat, have consistently 
been reported as larger than EAT adipocytes, typically by ~20% and ~10%, respectively 
(Sons & Hoffmann, 1986; Marchington et al., 1989; Eiras et al., 2010; Bambace et al., 
2011). Our study has corroborated this well-established regional adipocyte size distinction; 
however, the size differences were greater than previous studies as the clavicular SAT 
adipocytes we isolated were ~40% greater than both the PAT and EAT adipocytes (Figure 




origins, which has previously been reported in other mammalian species, but not in humans 
(Marchington & Pond, 1990). As shown, PAT adipocyte size positively correlates with 
BMI while EAT adipocytes are not (Figure 2.3). Therefore, the adiposity of the 
mammalian species utilised for this previous work would influence size variation between 
the depots and could explain the discrepancy between our studies. 
2.4.3 Limitations 
Our study was limited in the information that could be obtained from each adipose 
case. Made available to us was the age, sex, and the BMI for each case; however, other 
measures such as body fat percentage, blood glucose levels and HbA1c, and macroscopic 
EAT thickness were not available. Blood glucose, and by extension insulin resistance, have 
been well documented as metabolic derangements that are correlated with altered adipocyte 
morphology (McLaughlin et al., 2014). Because these measures were not available for this 
study, we cannot exclude the possible effect these measures have on EAT adipocyte 
morphology. EAT thickness correlates strongly with BMI (Iacobellis et al., 2003b; 
Pierdomenico et al., 2013; Rabkin, 2014), therefore future work will be required to directly 
determine how macroscopic EAT thickness and EAT adipocyte size correlate. 
Additionally, the maximal case BMI used for this study was 35.5 kg/m2. Adipocyte 
hypertrophy is finite in the extent to which the remodelling can occur and it is hypothesised 
that fat cells increase in size initially, but when a critical size is reached an alternative 
hyperplastic remodelling occurs, which ultimately impacts the mean adipocyte size (Liu et 
al., 2009). Therefore, because cases with BMI > 40 kg/m2 were unavailable for our study, 
we could not assess whether EAT adipocyte morphology is altered in extreme adiposity. 
Finally, the method of cell size analysis used for this study generated a mean adipocyte size 
distribution with a unimodal profile (Figure 2.1A). Other methods, such as particle 
counters, generate bimodal distributions (McLaughlin et al., 2007; Liu et al., 2009). This 
bimodality, in turn, allows the determination of a ‘nadir’ in the distribution and the 
categorisation of ‘small’ and ‘large’ adipocytes. These categories can be used as proxy 
markers for pre-adipocytes and mature adipocytes, respectively (McLaughlin et al., 2007). 
Without a bimodal size distribution, we could not differentiate small adipocytes from large 
and, therefore, we could not determine whether hyperplastic EAT adipocyte remodelling 
could account for the results of the study. 
  




We have shown that the size of EAT adipocytes isolated from routine post-mortem 
cases does not correlate with BMI. Further, we found this lack of association despite 
corroborating previous findings of adipocytes from SAT and other VAT depots having a 
positive correlation with BMI. These results extend our understanding of EAT as a fat 
depot, and begin to contextualise EAT adipocytes within the framework of well-established 
adipocyte morphology. Finally, they provide the rationale for future investigations of the 
pathophysiological consequences of EAT adipocyte remodelling on the function of EAT, 
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Macroscopic deposition of EAT has been strongly associated with numerous 
indices of obesity and cardiovascular disease risk. In contrast, the morphology of the 
adipocytes comprising EAT has rarely been investigated. We aimed to determine whether 
analogous obesity-driven adipocyte hypertrophy, which is characteristic of other visceral 
fat depots, is found within EAT adipocytes. EAT samples were collected from cardiac 
surgery patients (N = 49), stained with haematoxylin & eosin, and analysed by 
determination of mean adipocyte size and relative non-adipocyte area. Additionally, EAT 
thickness was measured using two-dimensional transthoracic echocardiography. A 
significant positive relationship was found between EAT thickness and BMI. When 
stratified into standardised BMI categories, EAT thickness was 58.7% greater (P = 0.003) 
in patients from the obese category (7.3 ± 1.8 mm) relative those classified as normal (4.6 
± 0.9 mm). Moreover, BMI as a continuous variable significantly correlated with EAT 
thickness (r = 0.56, P < 0.0001), even after adjustment for established modulators of fat 
deposition. Conversely, no correlation was observed between adipocyte size and either 
BMI or EAT thickness. No difference in the non-adipocyte area was found between BMI 
groups; however, the unimodal EAT adipocyte size frequency distribution revealed a 
discernible increase in proportion of smaller adipocytes in obese patients relative to normal 
and overweight patients. Our results suggest that the increased macroscopic EAT 
deposition associated with obesity is not caused by adipocyte hypertrophy. Rather, 
alternative remodelling via adipocyte proliferation might be responsible for the observed 
EAT expansion. 
3.1 Introduction 
EAT deposition has emerged as a novel clinical marker for systemic metabolic 
dysfunction and cardiovascular disease. When measured as either thickness or volume, 
macroscopic EAT deposition has been found to be strongly associated with measures of 
obesity and insulin resistance (Iacobellis et al., 2003b; Pierdomenico et al., 2013; Rabkin, 
2014), as well as CAD (Jeong et al., 2007; Xu et al., 2012; Mahabadi et al., 2013) and AF 
(Wong et al., 2016). With regard to CVD, EAT deposition often associates with greater 
strength than traditional anthropometric and biochemical risk factors, and might eventually 
serve as a predictive variable for adverse post-operative outcomes (Mahabadi et al., 2013; 




EAT dimensions for risk stratification, study of how microscopic EAT morphology relates 
to macroscopic deposition in obesity has rarely been performed. 
Adipose expansion in obesity occurs by two main morphological alterations to the 
constituent adipocytes: an increase in cell size (hypertrophy) and an increase in cell number 
(hyperplasia) (Tandon et al., 2018). The relative contributions of trophic and plastic 
remodelling vary between different SAT and VAT depots; however, hypertrophic growth 
seems to be the predominant mechanism in obesity (Tandon et al., 2018). Consistently, an 
increase in the volume of various SAT depots, including at abdominal, femoral, and gluteal 
sites has been found to not only correlate with indices of obesity, like BMI and body fat 
percentage, but also with the size of the adipocytes comprising each depot (Janssen et al., 
2002; Chan et al., 2003; Tchernof et al., 2006; Lee et al., 2008; Tchoukalova et al., 2008; 
Tchoukalova et al., 2010a; Veilleux et al., 2011; Michaud et al., 2016). Similar associations 
have been reported between adipocyte size, adipose volume, and BMI in omental, 
retroperitoneal, and intraperitoneal VATs (Tchernof et al., 2006; Veilleux et al., 2011; 
Michaud et al., 2016). No such investigations of EAT morphology have been undertaken. 
Non-invasive imaging using two-dimensional EAT thickness and three-
dimensional EAT volume has established a firm positive correlation between EAT 
deposition and BMI (Iacobellis et al., 2003b; Pierdomenico et al., 2013; Rabkin, 2014). 
Furthermore, macroscopic quantification of EAT measured from post-mortem hearts has 
revealed a similar step-wise increase in overall EAT volume or thickness with increased 
myocardial mass (Corradi et al., 2004). In contrast, EAT adipocyte morphology has a less 
defined relationship with BMI. Although early work seemed to suggest that mean EAT 
adipocyte size increased slightly with BMI in lean, overweight, and obese post-mortem 
cases (Sons & Hoffmann, 1986), recent intra-individual post-mortem analyses from our 
group found that unlike adipocytes from other SAT and VAT depots, EAT adipocyte size 
does not correlate with BMI (Aitken-Buck et al., 2019a). 
Unfortunately, quantification of EAT deposition was not accessible for our previous 
study (Aitken-Buck et al., 2019a). Therefore, for the current study we utilised 
echocardiographic EAT thickness measured in cardiac surgery patients and assessed the 
relationship between the EAT thickness and the size of the adipocytes comprising the fat 
tissue. By doing so, we aimed to clarify whether hypertrophy is the dominant form of 
adipocyte remodelling in the well-established EAT expansion in obesity (Iacobellis et al., 
2003b; Pierdomenico et al., 2013; Rabkin, 2014). Interestingly, we have found that EAT 
thickness increases linearly with BMI, but this is not concurrent with hypertrophy of the 
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paired EAT adipocytes. Additionally, the frequency distribution of adipocyte sizes revealed 
an increase in the proportion of smaller adipocytes within the EAT from obese patients 
relative to normal and overweight patients. This suggests that hyperplastic rather than 




Patients undergoing cardiac surgery (N = 49) at Dunedin Hospital, New Zealand, 
provided informed consent for the collection of a sample of their EAT and their clinical 
data to be used for this study. All use was approved by the local Human Ethics Committee 
(Approval number: LRS12-01-001) and conformed to the principles outlined in the 
Declaration of Helsinki. The surgeries included lone coronary artery bypass grafting 
surgery (CABG) (n = 27) and aortic (n = 7) or mitral (n = 4) valve replacement or a 
combination (n = 11). In addition to the patient age and sex, other relevant anthropometric, 
biochemical, and haemodynamic preoperative patient information was made available for 
this study and is presented in Table 3.1. Patients were stratified into standardised BMI 
groups as follows: BMI < 25 kg/m2 = normal, ≥ 25 and < 30 kg/m2 = overweight, ≥ 30 
kg/m2 = obese (WHO, 2019). 
3.2.2 Echocardiography 
All patients had a comprehensive echocardiogram obtained preoperatively using 
commercially available machines (Vivid E9 or E95, GE Healthcare, IL, USA). Images were 
recorded according to the recommendations of the American Society of Echocardiography 
(Mitchell et al., 2019). EAT thickness was assessed in the parasternal long axis view using 
a standardised method based on that of Iacobellis and Willens (Iacobellis & Willens, 2009). 
Intra-observer and inter-observer variability were calculated from 21 randomly selected 
subjects with excellent agreement; inter-observer and intra-observer interclass correlation 
coefficients were both over 95%. 
3.2.3 EAT procurement and processing 
During surgery, an EAT biopsy was obtained from the right atrioventricular groove. 




mM) 118.5 NaCl, 4.5 KCl, 1.0 MgCl26H2O, 0.33 NaH2PO4, 25 NaHCO3, 11 glucose, and 
0.5 CaCl2 that was previous bubbled with carbogen (95% O2 + 5% CO2). At the laboratory, 
the biopsy was fixed with formalin. The fixed tissue was then dehydrated, embedded in 
paraffin, and sectioned at 5 µm using a microtome. Each section was then stained with 
haematoxylin & eosin. Briefly, this involved deparaffinisation of each section using 
sequential xylene solution immersions (2 minutes per immersion). Rehydration of the 
sections was then achieved through sequential immersions in ethanol of decreasing 
concentrations (100%, 100%, 95% for 2 minutes each followed by 70% for 1 minute). 
Following a 1-minute wash in deionised water, the sections were immersed in Gillis 
haematoxylin for 4 minutes, water again for 2 minutes, Scott’s solution for 2 minutes, and 
finally for 30 seconds in eosin stain before a 1-minute water rinse. Finalisation of the stain 
was achieved by serial 100% ethanol immersions (30-seconds each) followed by serial 
xylene immersions (2-minutes each).  
3.2.4 Measurement of adipocyte size 
The fixed and stained EAT sections were scanned at 20x magnification using an 
Aperio Digital Slide Scanning System (Leica Biosystems Pathology Imaging, Germany) to 
generate a digital image of the section. Measurement of adipocyte size was performed using 
Aperio ImageScope software (Leica Biosystems Pathology Imaging, Germany). Briefly, 
using the Positive Pen Tool of the software, the border of every intact adipocyte contained 
within the field of view of each EAT image was traced. Then, based on the image resolution 
generated at section scanning, the area contained within each traced adipocyte was 
calculated. Adipocytes with a disrupted membrane border were not traced for analysis, nor 
were those with incomplete borders at the image frame. One section was imaged from each 
patient. 
3.2.5 Measurement of non-adipocyte area 
In the same sections used for EAT adipocyte size analysis, the relative non-
adipocyte area, which comprises the stromal vascular fraction, was determined using 
ImageJ software (National Institutes of Health, Bethesda, MD, USA). Tagged imaged files 
imported into ImageJ using the Bio-Formats importer (Open Microscopy Environment, 
Dundee, UK) were analysed by determining the area and relative colour threshold of 
adipocytes within the field of view. Once determined, image area classified within the 
 EAT Adipocyte Size Association with BMI and EAT Thickness 
35 
 
adipocyte colour threshold was deleted to render a measurable black background. The 
relative black (adipose) and non-black (non-adipose) areas were then quantified. 
3.2.6 Data analysis 
Analysis of EAT thickness and EAT adipocyte size was performed by a researcher 
blinded to the BMI of the patient and the corresponding EAT thickness/adipocyte size 
related to each patient. Data, including patient characteristics, are presented as mean values 
± standard deviation (SD) or standard error (SEM) as appropriate. Differences in BMI-
stratified data were assessed to be statistically significant by Fisher’s exact test or one-way 
ANOVA with post hoc Tukey’s multiple comparisons test as appropriate. The relationships 
between two continuous variables were determined using simple univariate Pearson 
correlation with fitted linear regression. Additional adjustment for age, sex, and HbA1c 
was performed using multiple linear regression analyses. Adipocyte size frequency 
distribution curves were fitted based on the size of every adipocyte measured in each 
section. Differences for all data were deemed significant if P < 0.05. Data were analysed 
using GraphPad Prism 8 software (GraphPad Software Inc., La Jolla, CA, USA). 
3.3 Results 
3.3.1 Patient characteristics 
In total, EAT was obtained from 49 patients undergoing cardiac surgery. When 
stratified into standardised BMI categories, 8 patients were defined as normal (average BMI 
= 23.3 ± 2.1 kg/m2), 28 as overweight (27.7 ± 1.5 kg/m2), and 13 as obese (33.2 ± 1.6 
kg/m2). Table 3.1 presents the average anthropometric, biochemical, and basic 
haemodynamic indices recorded from each patient within each BMI category. No 
differences in any patient characteristic was found between BMI groups. Additionally, no 
difference in mean adipocyte size was found between patients undergoing lone CABG 
surgery when compared to those undergoing lone aortic or mitral valves replacement 





Table 3.1. Characteristics of patients by body mass index categories. 





(n = 8) 
Overweight  
(n = 28) 
Obese  
(n = 13) 
Age (years) 72.9 ± 8.7 70.5 ± 8.2 71.3 ± 4.8 
Sex (M/F) 7/1 26/2 12/1 
BMI (kg/m
2
) 23.3 ± 2.1 27.7 ± 1.5 
a
 33.2 ± 1.6 
a,b
 
SBP (mmHg) 138.0 ± 24.1 135.8 ± 20.7 142.0 ± 21.9 
DBP (mmHg) 80.6 ± 16.2 74.4 ± 11.5 78.5 ± 16.7 
Ejection fraction (%) 58.0 ± 9.5 54.7 ± 10.3 56.5 ± 7.2 
HbA1c (mmol/mol) 36.8 ± 3.7 42.8 ± 10.1 42.1 ± 13.4 
Type 2 diabetes (%) 0.0 21.4 15.4 
EAT thickness (mm) 4.6 ± 0.9 6.0 ± 1.7 7.3 ± 1.8 
c
 
EAT adipocyte area (µm
2
) 2828 ± 693 2987 ± 734 3080 ± 881 
BMI = body mass index, normal BMI category <25 kg/m
2





. M = male, F = female. SBP = systolic blood pressure, DBP = diastolic blood pressure, 
ejection fraction = left ventricular ejection fraction measured with transthoracic echocardiography, 
EAT = epicardial adipose tissue. Values are presented as means ± SD. Differences between groups 
determined by Fisher’s exact test or one-way ANOVA followed by post hoc Tukey’s multiple 
comparisons test. 
a
P < 0.0001 vs normal group, 
b
P < 0.0001 vs overweight group, 
c
P < 0.01 vs 
normal group. 
 
3.3.2 EAT thickness and BMI relationship 
EAT thickness was measured using 2-dimensional echocardiography in the 
parasternal long axis view. The mean EAT thickness from the patient cohort was 6.1 ± 1.9 
mm. When stratified, the mean thickness from patients within the normal BMI group was 
4.6 ± 0.9 mm, whereas the EAT thickness of the overweight patients showed a non-
significant increase of 30.4% (6.0 ± 1.7 mm, P = 0.122). The EAT of the obese patients 
was significantly thicker (7.3 ± 1.8 mm, P = 0.003) than normal BMI patients (Table 3.1, 
Figure 3.1A). A trend towards an increased EAT thickness in obese compared to 
overweight patients was found (P = 0.064). To circumvent the limitations incurred by BMI 
categorisation, including discrepancy in sample sizes, we performed correlation analyses 
to utilise BMI as a continuous variable (Figure 3.1B). When correlated using univariate 
linear regression, a significant and robust positive association was found between EAT 
thickness and BMI (r = 0.56, P < 0.0001), even with adjustment for age, sex, and HbA1c 
(β = 0.29 ± 0.06 (SE), 95% confidence interval [CI]: 0.16 to 0.43, R2 (adjusted) = 0.27, P < 
0.0001).  





Figure 3.1. Relationship of epicardial adipose tissue (EAT) thickness with body mass index 
(BMI). (A) EAT thickness stratified into standardised BMI categories (normal < 25 kg/m2, 
overweight ≥ 25 and < 30 kg/m2, obese ≥ 30 kg/m2). The average BMI for each category was: 
normal patients (n = 8) = 23.3 ± 2.1 kg/m2, overweight patients (n = 28) = 27.7 ± 1.5 kg/m2, obese 
patients (n = 13) = 33.2 ± 1.6 kg/m2. Statistical differences in EAT thickness between the groups 
was determined using one-way ANOVA with post hoc Tukey’s multiple comparisons test. **P 
= 0.0028. Difference between overweight and obese patient EAT thicknesses: P = 0.06. Data are 
presented as mean ± SEM. (B) Simple univariate correlation of EAT thickness vs BMI (range 
19.0-35.5 kg/m2). A significant positive correlation was found between EAT thickness and BMI 
(r = 0.56, P < 0.0001). N = 49. 
 
3.3.3 EAT adipocyte size and BMI relationship 
We have recently reported that the size of adipocytes comprising the EAT of 43 
post-mortem cases have no association with BMI, neither when stratified into BMI 
categories nor when analysed using Pearson correlation (Aitken-Buck et al., 2019a). We 
aimed to corroborate these results in patients undergoing cardiac surgery in the current 
study. Representative images taken from the EAT sections used for adipocyte analysis are 
shown in Figure 3.2A. Quantification of the average adipocyte area, without adjustment 
for BMI, was 2991 ± 777 µm2. With BMI categorisation, no difference was found in 
average adipocyte size between the normal (2828 ± 693 µm2), overweight (2987 ± 734 
µm2), and obese (3080 ± 881 µm2) groups (Table 3.1, Figure 3.2B). Furthermore, no 
correlation was found between EAT adipocyte size and BMI using univariate correlation 
analysis (r = 0.11, P = 0.5) (Figure 3.2C), or after adjustment for age, sex, and HbA1c (β 




3.3.4 EAT thickness and EAT adipocyte relationship 
Macroscopic adipose deposition has been correlated with the constituent adipocyte 
size in many previous studies (Tchernof et al., 2006; Tchoukalova et al., 2008; 
Tchoukalova et al., 2010a; Veilleux et al., 2011; Michaud et al., 2016). This includes SAT 
and VAT depots. To determine whether an analogous relationship exists with EAT 
thickness and EAT adipocyte size, we performed simple correlation analysis and found no 
correlation between the two parameters (r = -0.07, P = 0.6) (Figure 3.2D). 
 
 
Figure 3.2. Epicardial adipose tissue (EAT) adipocyte size relationship with body mass index 
(BMI) and EAT thickness in cardiac surgery patients. (A) Top panel shows representative images 
of haematoxylin & eosin stained EAT sections. From left to right, images are representative of 
normal (n = 8), overweight (n = 28), and obese (n = 13) patients as indicated. Scale bar indicates 
100 µm. (B) Average adipocyte area is not different between any BMI category. Data are 
presented as means ± SEM. Statistical difference measured using one-way ANOVA with post 
hoc Tukey’s multiple comparisons test. (C) Adipocyte area does not correlate with BMI (range 
19.0-35.5 kg/m2) or with EAT thickness (D) as assessed by univariate Pearson correlation. For C 
and D, N = 49. 
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3.3.5 Non-adipocyte area 
To determine whether the 58.7% thicker EAT in obese patients compared to normal 
patients might relate to an increase in non-adipocyte area (stromal-vascular fraction and/or 
fibrosis), we also determined the relative non-adipocyte area within each section. The non-
adipocyte area was remarkably similar between the three groups (normal: 34 ± 4.9%, 
overweight: 34.1 ± 5.3%, obese: 30.0 ± 3.8%, P = 0.6) (Figure 3.3A). 
3.3.6 Adipocyte size frequency distribution 
By analysing the frequency distribution of EAT adipocyte size from each BMI 
group, we were able to provide a rough indication of whether an increase in adipocyte 
number (hyperplasia) could account for the increase in EAT thickness in obese patients. As 
shown in Figure 3.3B), our analysis indicates a leftward and upward shift in the curve 
derived from the frequency distribution of EAT adipocytes from obese patients relative to 
the curves from both normal and overweight patients. This suggests that EAT from obese 
patients is comprised of a relatively greater proportion of smaller adipocytes. 
 
 
Figure 3.3. Quantification of non-adipocyte area and epicardial adipocyte size frequency 
distribution in normal, overweight, and obese groups. (A) Non-adipocyte area is presented as a 
percentage relative to adipocyte area. No difference was found between the groups as assessed 
by one-way ANOVA (P = 0.55). (B) Curves fitted from the adipocyte size frequency distributions 
from normal (886 cells from 8 patients), overweight (1739 cells from 28 patients), and obese 
(1247 cells from 13 patients) BMI groups. The distribution from the obese group is relatively 
leftward and upward of the normal and overweight groups, indicating a higher proportion of 






Based on studies of other SAT and VAT depots, which show a positive correlation 
in adipocyte size with adipose deposition (Tchernof et al., 2006; Tchoukalova et al., 2008; 
Tchoukalova et al., 2010a; Veilleux et al., 2011; Michaud et al., 2016), we hypothesised 
that an analogous relationship would exist within EAT. Interestingly, our data does not 
support our hypothesis, as no correlation could be found between EAT thickness and EAT 
adipocyte size. Moreover, we found that despite EAT thickness positively correlating with 
an increase in BMI, no such relationship exists for EAT adipocyte size. Increases in stromal 
vascular fractional or fibrotic deposits do not seem to account for the increased EAT 
thickness in obese individuals, whereas adipocyte size frequency distribution analysis 
suggests an increase in the number of adipocytes. Our main finding is therefore that the 
increased thickness of EAT in obesity is not associated with adipocyte hypertrophy, while 
our exploratory findings suggest that hyperplasia might instead underlie the expansion of 
EAT.  
3.4.1 Adipose tissue and adipocyte size relationship 
Total body fat deposition has been independently, and robustly, correlated with 
BMI and increased adipocyte size for SAT and VAT (Deurenberg et al., 1998; Janssen et 
al., 2002; Tchernof et al., 2006; Arner et al., 2010). When measured specifically using CT, 
dual-energy X-ray absorptiometry, or MRI, the macroscopic deposition of numerous SAT 
and VAT depots have been shown to increase predictably with increased BMI (Janssen et 
al., 2002; Chan et al., 2003; Lee et al., 2008). The relationship between BMI and SAT 
mass, whether measured as anterior or posterior abdominal fat, has been reported with 
strong correlation coefficients ranging from 0.65 to 0.89 (Janssen et al., 2002; Chan et al., 
2003; Lee et al., 2008). Similarly, intra-abdominal, intraperitoneal, and retroperitoneal 
VAT mass has been correlated with BMI with lesser coefficients between 0.32 to 0.58 
(Janssen et al., 2002; Chan et al., 2003; Lee et al., 2008). Meta-analysis of non-invasively 
imaged EAT deposition has found a significant BMI association with average correlation 
coefficients of 0.47 and 0.43 for echocardiography and CT studies, respectively (Rabkin, 
2014). For the current study, we found that average EAT thickness measured by 
echocardiography is significantly greater in obese patients relative to patients with normal 
BMI (Figure 3.1A), with thickness measures analogous to those reported previously for 
cohorts with similar BMI (Akyol et al., 2013). Moreover, with univariate correlation we 
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found a robust correlation between EAT thickness and BMI (r = 0.56) (Figure 3.1B), which 
agrees with data recently meta-analysed (Rabkin, 2014). Therefore, our data reinforce the 
finding that EAT thickness positively, and reproducibly, correlates with BMI. 
We aimed to determine the microscopic adipocyte remodelling associated with this 
increased macroscopic EAT thickness. The sizes of adipocytes from various SAT and VAT 
depots have consistently been shown to positively correlate with BMI (Salans et al., 1973; 
Tchernof et al., 2006). Moreover, this adipocyte hypertrophy has been comprehensively 
correlated with an increased deposition of the adipose depot that the cells comprise 
(Tchernof et al., 2006; Tchoukalova et al., 2008; Tchoukalova et al., 2010a). Cross-
sectional studies found strong correlations between abdominal and femoral SAT adipocyte 
sizes and the area of the same SAT sites(coefficients typically 0.60 to 0.76) (Tchernof et 
al., 2006; Tchoukalova et al., 2008; Tchoukalova et al., 2010a). Analogous cross-sectional 
associations have also been reported for omental VAT adipocyte size and VAT area 
(Tchernof et al., 2006; Veilleux et al., 2011), while longitudinal analysis of regional 
adipose deposition and adipocyte size has revealed that overfeeding (with resultant ~4kg 
weight gain) induces abdominal SAT adipocyte size hypertrophy that is proportional with 
increased abdominal SAT area (r = 0.74) (Tchoukalova et al., 2010b). These findings 
thereby suggest that the increased deposition of an adipose tissue associated with increased 
BMI is predominantly dependent on hypertrophy of the adipocytes comprising the tissue. 
The results of our study contrast with findings from other adipose depots. Our data 
suggest that not only does EAT adipocyte size not change with BMI, but that EAT 
adipocyte size does not change in parallel with increased EAT deposition (Figure 3.2C). 
Recent work from our group, and earlier work from other labs, has found that EAT 
adipocyte size does not correlate with BMI in post-mortem cases or cardiac surgery patients 
(Eiras et al., 2010; Aitken-Buck et al., 2019a). Thus, our current study suggests that 
increased EAT thickness that is associated with increased BMI does not occur by 
hypertrophy of the constituent adipocytes, as has been reported as the predominant 





3.4.2 If not adipocyte hypertrophy, what are the alternative explanations? 
If adipocyte hypertrophy cannot explain the 58.7% increase in macroscopic EAT 
thickness that occurs from normal to obese patients (Figure 3.1A), then alternative 
remodelling mechanism(s) must occur. Adipose tissue also contains extensive stromal 
vascular components (non-adipocyte cells). As a longitudinal study, Alligier et al. found 
that subjects fed a diet supplemented with excess fat not only had an increased mean body 
weight after 56 days (~2.5 kg gain) but significant fibrotic and microvascular remodelling 
of the microscopic adipose structure had occurred (Alligier et al., 2012). Expression of pro-
fibrotic, pro-angiogenic, and pro-inflammatory genes was significantly increased relative 
to the beginning of the study, as was the histological density of capillaries and intercellular 
matrix deposits (Alligier et al., 2012). Moreover, mRNA expression and histological 
examination of SAT and omental fat (VAT) has shown that obese subjects have increased 
pro-fibrotic gene expression and increased pericellular fibrosis compared to lean subjects 
(Divoux et al., 2010). Investigation of stromal vascular remodelling within EAT has only 
been performed in relation to AF. Extracellular fibrosis of EAT has been found in the fatty 
infiltrate of atrial tissue from AF patients and sheep models of AF (Haemers et al., 2015). 
Additionally, fibrosis of peri-myocardial EAT has been found to increase in severity 
concurrently with the extent of atrial fibrosis and the degree of AF (Abe et al., 2018). In 
our study the non-adipocyte area was not different between the three stratified BMI groups 
(Figure 3.3A). Although our method only provides a rough indication, the observed range 
of non-adipocyte area between normal and obese individuals makes it unlikely that the 
observed 58.7% increase in EAT thickness in obese individuals is due to an increase in 
stromal vascular or fibrotic deposition. It should be noted that there is recent evidence 
suggesting that the histological composition of EAT can vary according to proximity to the 
myocardium (Ishii et al., 2021). Therefore, for our study, we cannot exclude the effect of 
slight differences in the EAT section site within the whole EAT tissue influencing the non-
adipocyte area measurement. 
Finally, as mentioned earlier, adipose tissue also expands by adipocyte hyperplasia 
(Tandon et al., 2018). Recent prospective studies using adipocyte deuterium incorporation 
over an 8-week period have found independent correlations of new-adipocyte formation 
with body fat percentage and BMI (White et al., 2016, 2017). Similarly, cross-sectional 
analyses of SAT and VAT depots have found that the proportion of small adipocytes 
correlates with BMI in women (Michaud et al., 2016). Extrapolation of such findings to 
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EAT, which suggest that hyperplastic expansion can occur with increased BMI, requires 
caution due to depot-specificity and female-exclusivity of the results. Our cross-sectional 
study did not find a change in average adipocyte size when stratified into BMI categories 
(Figure 3.2A) or with BMI as a continuous variable (Figure 3.2B). When stratified into 
BMI categories and plotted as frequency distributions of size, the curve fitted from the 
adipocytes of the obese group showed a leftward and upward shift relative to the normal 
overweight curves (Figure 3.3B). Although only exploratory, these data might indicate that 
an increase in the proportion of smaller adipocytes (i.e., hyperplastic remodelling) underlies 
the increased EAT thickness in obesity. As adipocyte proliferation has been correlated with 
multiple indices of metabolic dysfunction in other depots (McLaughlin et al., 2014; Fang 
et al., 2015), this warrants further research. 
Epicardial adipocytes have an intrinsically high capacity for lipogenesis and 
lipolysis, as well as a uniquely increased expression of genes associated with pro- and anti-
inflammatory cytokines and brown fat-like thermogenesis (Marchington et al., 1989; 
Marchington & Pond, 1990; Iacobellis & Bianco, 2011). These features confer EAT the 
ability to buffer excessive fatty acid levels from the coronary circulation, signal to the 
myocardium via paracrine and vasocrine adipokine release, and regulate myocardial 
temperature (McAninch et al., 2015; Yim & Rabkin, 2017). Previous studies have 
correlated epicardial adipocyte size with inflammatory cytokine release and insulin 
resistance (Eiras et al., 2010; Bambace et al., 2011). Similarly, the EAT transcriptome has 
been found to be altered in patients with CAD, resulting in differential expression of 
inflammatory and apoptotic genes, which might alter the size of epicardial adipocytes 
(Camhi et al., 2011; Maghbooli & Hossein-nezhad, 2015). Clearly, EAT adipocyte size is 
associated with changes in the cellular biochemistry; however, how this relates to the 
potential hyperplastic remodelling in obesity reported in the current study requires direct 
investigation. Furthermore, this would provide insight into the mechanistic role of EAT in 
complications associated with obesity and the numerous cardiovascular diseases with 
which EAT deposition has been linked to. 
3.4.3 Limitations 
Our study was limited by the anatomical distinction between the site of 
echocardiographic EAT measurement and the site of intra-surgical EAT biopsy. As is 
standard within the field (Iacobellis, 2009), EAT was measured at the right ventricular free 




was taken at the atrioventricular groove. Despite this discrepancy, previous post-mortem 
analysis of EAT adipocytes from 10 distinct sampling sites, including from the right 
ventricular free wall and the atrioventricular groove, found no differences in regional 
adipocyte size. However, in a small subset of post-mortem cases, the authors reported that 
adipocyte size can vary intra-individually between sampling sites (Sons & Hoffmann, 
1986). Based on this, together with our study design, we cannot rule out the possibility that 
EAT adipocyte size is not homogenous between the site of EAT thickness measurement 
and the site of biopsy. A further limitation of our study was that we could not correlate 
EAT adipocyte size with measures of visceral obesity like waist circumference and VAT 
volume. Both measures, which associate with EAT thickness with greater strength than 
BMI (Rabkin, 2014), were not measured as part of routine pre-operative patient evaluation. 
Despite having a weaker association, the correlation of BMI with EAT thickness is still 
significant based on meta-analysis (Rabkin, 2014). Finally, only ~8% of the patients 
recruited for our study were female, thereby yielding a predominant male study population. 
While this limits the translatability of our results to the general population, it minimises 
potentially confounding effects of sex on the results (Camhi et al., 2011). 
3.5 Conclusion 
To the best of our knowledge, this is the first study to directly compare the 
macroscopic deposition of epicardial fat with the size of constituent fat cells. We have 
found that despite a strong positive correlation of EAT thickness with BMI in cardiac 
surgery patients, epicardial adipocyte size does not increase concurrently. This suggests 
that, unlike other subcutaneous and visceral adipose depots, adipocyte hypertrophy is not 
the predominant form of cellular remodelling that causes EAT expansion in obesity. 
Instead, our exploratory analysis suggests that hyperplasia might be the predominant EAT 
remodelling mechanism. How this differential site-specific remodelling influences the 
physiology and the metabolic and transcriptomic properties of EAT will be the basis of 
future research as it might provide insight into why excessive macroscopic EAT deposition 
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The adipocytokine resistin is released from EAT. Plasma resistin and EAT 
deposition are independently associated with AF. The EAT secretome enhances arrhythmia 
susceptibility and inotropy of human myocardium. Therefore, we aimed to determine the 
effect of resistin on the function of human myocardium and how resistin contributes to the 
pro-arrhythmic effect of EAT. EAT biopsies were obtained from 36 cardiac surgery 
patients. Resistin levels were measured by ELISA in 24-hour EAT culture media (n=8). 
The secretome resistin concentrations increased over the culture period to a maximal level 
of 5.9 ± 1.2 ng/mL. Co-culture with β-adrenergic agonists isoproterenol (n=4) and 
BRL37344 (n=13) had no effect on EAT resistin release. Addition of resistin (7, 12, 20 
ng/mL) did not significantly increase the spontaneous contraction propensity of human 
atrial trabeculae (n=10) when given alone or in combination with isoproterenol. Resistin 
dose-dependently increased trabecula developed force (maximal 2.9-fold increase, P < 
0.0001), as well as the maximal rates of contraction (2.6-fold increase, P = 0.002) and 
relaxation (1.8-fold increase, P = 0.007). Additionally, the post-pause potentiation capacity 
of human trabeculae was reduced at all resistin doses, suggesting that the inotropic effect 
induced by resistin might be due to altered sarcoplasmic reticulum Ca2+-handling. EAT 
resistin release is not modulated by common arrhythmia triggers. Furthermore, exogenous 
resistin does not promote arrhythmic behaviour in human atrial trabeculae. Resistin does, 
however, induce an acute dose-dependent positive inotropic and lusitropic effect. 
4.1 Introduction 
Resistin is a pro-inflammatory adipocytokine that is associated with several CVDs, 
including HF and AF (Baker et al., 2006; Gungor et al., 2011; Özcan et al., 2014; Ermakov 
et al., 2016). Circulating resistin has been positively correlated with hypertrophic 
myocardial remodelling and negatively with indices of ventricular function (Bobbert et al., 
2012; McManus et al., 2012; Norman et al., 2015). Furthermore, plasma resistin levels are 
reported to be predictive of AF risk following CABG surgery (Gungor et al., 2011; 
Rachwalik et al., 2019). Translational work has established that chronic resistin 
overexpression promotes hypertrophic cardiomyopathy in rodent models, as well as 
depressions in cardiomyocyte Ca2+ signalling and myocardial contractility (Kim et al., 
2008; Chemaly et al., 2011). Whether this negative inotropic effect also occurs following 
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acute exogenous resistin exposure is unknown. Additionally, a direct role of resistin in the 
pathogenesis of arrhythmias has yet to be investigated. 
EAT is recognized as a source of pro-inflammatory adipocytokines, including 
resistin (Langheim et al., 2010). Like resistin, increased EAT deposition is strongly 
associated with ventricular dysfunction and AF risk and is predictive of adverse 
postoperative outcomes (Wong et al., 2016; Nerlekar et al., 2018). EAT is a highly active 
secretory tissue that shares a unique contiguity with the myocardium and coronary 
vasculature that it surrounds (Sacks & Fain, 2007). Physiologically, this anatomical 
intimacy facilitates the delivery of cardioprotective EAT-derived factors and the 
maintenance of lipid and nutritional homeostasis via paracrine and vasocrine signalling 
mechanisms (Yudkin et al., 2005). In CVD, however, the unique proximity and activity of 
EAT is hypothesized to become detrimental to cardiac health due to an augmented release 
of pro-inflammatory EAT-derived factors (Mazurek et al., 2003; Baker et al., 2006; 
Langheim et al., 2010). We have recently shown that superfusion of human atrial 
myocardium with secretome derived from human EAT stimulated with β-adrenergic 
triggers promotes arrhythmia-like behaviour and alters contractility kinetics (Babakr et al., 
2020). From our previous work it was not possible to determine the role of specific EAT-
derived adipocytokines. 
Therefore, for the current study we aimed to investigate the interaction of resistin 
with the arrhythmogenic and inotropic effects of EAT and the EAT secretome. In doing so, 
we (1) determined the effect of arrhythmogenic triggers on the expression of resistin in the 
EAT secretome. We then assessed the propensity for recombinant resistin to (2) induce 
arrhythmic behaviour and (3) alter the contractility of human atrial myocardium. 
4.2 Methods 
4.2.1 Patients 
Right atrial appendage (RAA) or EAT biopsies were obtained from consenting 
patients undergoing CABG surgery, or aortic or mitral valve replacements (N = 46) at 
Dunedin Hospital, New Zealand. All use of human tissue was done in accordance with the 
local human ethics board (ethics no. LRS12-01-001AM1-AM13) and the Declaration of 
Helsinki. Patients diagnosed with preoperative AF or undergoing emergency surgery were 
excluded. Samples from all other patients were included to minimise bias toward or away 




this study. Preoperative patient characteristics, echocardiographic values, and medications 
are summarised in Table 4.1. 
4.2.2 EAT culture 
During surgery, an EAT biopsy was obtained from the right atrioventricular groove 
(n = 36). The EAT was collected in standard chilled KHB containing (in mM) 118.5 NaCl, 
4.5 KCl, 1.0 MgCl26H2O, 0.33 NaH2PO4, 25 NaHCO3, 11 glucose, and 0.5 CaCl2 that was 
previously bubbled with carbogen. The sample of EAT was divided into 2 parts and both 
were cultured for 24 hours in M199 medium containing antibiotics (5000 units of 
penicillin/5 mg of streptomycin/mL) (Sigma-Aldrich, Australia) (Experimental schematic 
shown in Figure 4.1A) (Mazurek et al., 2003; Venteclef et al., 2014). For the first set of 
experiments both parts were left untreated and the culture medium (comprising the EAT 
secretome) was collected at 1, 5, 15, and 30 minutes, and 1, 6, 12, 18 and 24 hours. For the 
second set of experiments one part of the EAT sample was left untreated, and the other 
treated with either the β1/2-adrenergic agonist, isoproterenol (ISO) (10
-5 M) or with the β3-
adrenergic agonist, BRL37344 (BRL) (10-6 M). After 24 hours, the EAT culture medium 
was collected for resistin concentration measurement. 
4.2.3 Resistin measurement (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) was conducted according to the 
manufacture’s recommendation (Aviscera Bioscience, Santa Clara, USA). Concentrations 
were read at 450 nm using a plate reader (BioTek Instruments, USA). The minimum 
reference concentration was 15.6 pg/mL (Aviscera Bioscience, Santa Clara, USA). 
4.2.4 Trabecula isolation 
Myocardial function was assessed in human RAA trabeculae, which were isolated 
and mounted in a custom-built organ bath as described previously (Lamberts et al., 2014; 
Bussey et al., 2020). Myocardial preparations from RAA, such as trabeculae, have been the 
predominant preparations used to characterise structural and functional alterations found in 
the atria of patients with AF and other arrhythmias (Voigt et al., 2012; Lebek et al., 2018); 
therefore, this model was deemed appropriate to assess the arrhythmogenic effects of 
resistin. Trabeculae were superfused with a 37 °C 1 mM Ca2+ KHB (components as above) 
that was continuously oxygenated with carbogen (95% O2 + 5% CO2). Contraction was 
stimulated continuously at 1 Hz (suprathreshold voltage, 5 ms duration) using paired 
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horizontal platinum electrodes. Each trabecula was stretched until an increase in muscle 
length was not accompanied by an increase in developed force (which estimates a 
sarcomere length of 2.1-2.2 µM). Stimulated trabeculae were equilibrated for 1 hour prior 
to protocol initiation. 
Table 4.1. Patient characteristics (N = 46). 
Clinical characteristics 
Age (years) 67.8 (9.4) 
Gender (male/female) 32/14 (70%/30%) 
BMI (kg/m
2
) 28.7 (4.9) 
Type 2 DM (Yes/No) 11/35 (24%) 
HbA1
c
 (mmol/mol) 41.5 (14.3) 
Blood glucose (mmol/L) 6.9 (3.0) 
Hypertension (Y/N) 25/21 (54%) 
Systolic blood pressure (mmHg) 137 (25) 
Diastolic blood pressure (mmHg) 75 (14) 
Heart rate (beats/min) 74 (15) 
Smoker (no/current/ex) 21/4/21 
Echocardiography 
E (m/sec) 0.78 (0.36) 
A (m/sec) 0.77 (0.24) 
E/A 1.04 (0.52) 
e’ (m/sec) 0.06 (0.02) 
E/e’ 13.4 (4.7) 
Deceleration (ms) 236 (60) 
Ejection fraction (%) 57 (14) 
Medications 
Insulin (Y/N) 4/42 (9%) 
Metformin (Y/N) 7/39 (15%) 
Ca
2+
 channel blocker (Y/N) 12/34 (26%) 
ACE inhibitor (Y/N) 29/17 (63%) 
β-blocker (Y/N) 32/14 (70%) 
Statin (Y/N) 35/11 (76%) 
Continuous variables presented as means (SD) and categorical variables as proportions 
(Yes/No) (% of total patients). BMI = body mass index; DM = diabetes mellitus; HbA1c = 
glycated haemoglobin A1c; E = early ventricular filling velocity; A late ventricular filling 
velocity; E/A = the ratio of early to late left ventricular filling pressure; e’ = early ventricular 
relaxation velocity; E/e’ = ratio of early filling and relaxation velocities; Deceleration = early 
ventricular deceleration time; Ejection fraction = ejection fraction measured by transthoracic 





4.2.5 Experimental protocol 
Once developed force stabilised, baseline muscle arrhythmia propensity was 
assessed under different stress conditions (experimental schematic shown in Figure 4.1B). 
Arrhythmias were assessed by the presence of spontaneous trabecula contractions during a 
1-minute rest period (cessation of external stimulation). Trabeculae that developed any (≥ 
1) spontaneous contractions during a rest interval were classified as spontaneously active 
at the associated stress condition. Note that we have previously validated spontaneous 
contraction as an ex vivo ectopic arrhythmia proxy by showing that RAA trabeculae 
develop spontaneous contractions when exposed to well-established pro-arrhythmic 
conditions, such as β-adrenergic challenge or intracellular Ca2+ overload (Babakr et al., 
2020). Spontaneous contractions were assessed following 1 Hz equilibration, then again in 
the presence of an arrhythmia trigger, ISO (10-5 M). Once the ISO effect was washed out 
and steady state 1 Hz contractions were resumed, increasing doses of recombinant human 
resistin were added to the superfusate (7, 12, 20 ng/mL) for 20-minutes per dose. The 
spontaneous contractions tests (including with ISO) were repeated at each resistin dose to 
determine the direct arrhythmogenic effect of the adipocytokine on human atrial 
myocardium. The concentrations of exogenous resistin used are analogous to those 
measured in the blood of AF patients (Gungor et al., 2011; Özcan et al., 2014; Ermakov et 
al., 2016). Contractility was assessed by determining the mean developed force (maximal 
systolic force minus minimal diastolic force) at each resistin dose. Furthermore, the 
maximal rates of contraction (+dF/dtmax) and relaxation (-dF/dtmax) were measured from the 
contraction peak kinetics. The post-pause potentiation capacity (PPP, measured after 1-
minute pause) for each trabecula was determined from the change in developed force 
amplitude of the first post-pause contraction relative to the pre-pause contraction.  
4.2.6 Statistics 
All functional data were analysed using Lab Chart 8 software (AD Instruments, 
Dunedin, NZ) and statistical analysed were performed using Prism 8 (GraphPad, 
California, USA). Trabecula force was normalised to muscle cross-sectional area (width x 
thickness x π). Data are presented as percentages or mean values ± standard deviation (SD) 
or error (SEM) as appropriate. All statistics were performed using raw data. Differences in 
proportion of trabeculae with spontaneous contractions was assessed by Fisher’s exact 
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tests. All other differences were assessed by repeated-measures one-way ANOVA with 
Dunnett post hoc test. P < 0.05 was considered statistically significant. 
 
Figure 4.1. Schematic experimental timeline for human epicardial adipose tissue (EAT) culture 
and atrial trabeculae superfusion. A, fresh human EAT was cultured in antibiotic-supplemented 
M199 media for a 24-hour period before the media (comprising secretome of EAT-derived 
factors) was collected and resistin levels were measured by ELISA. The culture media of one 
EAT group was collected at various time points (1, 5, 15, 30 minutes and 1, 6, 12, 18, 24 hours) 
to determine the resistin release by EAT over time. Separate groups of EAT were cultured 
undisturbed for 24-hours (untreated) or treated with the β1/2-adrenergic receptor agonist 
isoproterenol (ISO, 10-5 M) or β3-adrenergic receptor specific agonist BRL 37344 (10-6 M) to 
determine the effect of EAT stimulation on EAT resistin release. B, trabeculae were isolated from 
human right atrial appendage and stimulated at 1 Hz in a 37 °C physiological buffer. 
Recombinant human resistin was added incrementally at extracellular concentrations of 7, 12, 
and 20 ng/mL (20-minutes exposure time for each dose). At each resistin concentration, external 
stimulation was ceased for 1-minute to determine the spontaneous contraction (arrhythmia proxy) 
propensity and to assess the post-rest potentiation capacity. This protocol was then repeated in 






4.3.1 Resistin levels in fresh human EAT 
We have previously reported that fresh human EAT enhances myocardial 
automaticity when placed upstream of the atrial trabeculae and stimulated with the β3-
adrenergic agonist, BRL37344 (BRL) (Babakr et al., 2020). Therefore, to determine if 
resistin is released by the fresh EAT and whether this is modulated by BRL stimulation 
(10-6 M), the concentration of resistin in the superfusion media before and after BRL 
addition was measured. Resistin could not be detected by ELISA as the measured levels 
were below the minimum standard concentration (data not shown, n = 11). This aligns with 
previous reports of undetectable resistin protein in freshly isolated (non-cultured) mature 
human adipocytes (Janke et al., 2002; Toczylowski et al., 2019). 
 
Figure 4.2. Resistin levels in human epicardial adipose tissue (EAT) secretome. A, EAT 
secretome resistin levels measured using ELISA throughout a 24-hour culture period. Resistin is 
gradually released into the secretome over the 24-hour culture duration. Average resistin 
concentration in EAT secretome from 8 patients following 24-hours culture = 5.9 ± 1.2 
ng/mL/100mg of EAT. Data is fitted with one-phase association curve. B, Effect of β1/2- (ISO, 
10-5 M) and β3-adrenergic (BRL37344, BRL, 10-6 M) stimulation on resistin release from EAT. 
Neither treatment affected the secretome resistin levels relative to paired controls. N values as 
shown. Differences assessed using paired t-tests, P values as indicated. For A & B, data are mean 
values ± SEM. 
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4.3.2 Resistin levels in cultured human EAT secretome 
In addition to the arrhythmogenic effect of fresh EAT, 24-hour cultured human EAT 
secretome was also found to enhance spontaneous contraction propensity when superfused 
over human trabeculae and stimulated with BRL (Babakr et al., 2020). Furthermore, others 
have found acute inotropic changes in isolated cardiomyocytes and Langendorff rat hearts 
perfused with 24-hour cultured subcutaneous adipose secretome (Lamounier-Zepter et al., 
2006; Look et al., 2011). To determine if resistin is released as part of the cultured EAT 
secretome, measurements of resistin were taken throughout the 24-hour culture period of 
EAT from 8 patients (Figure 4.2A). Resistin could be detected by ELISA within 5-minutes 
of culture and the level gradually increased during the 24-hour culture. The average EAT 
secretome resistin concentration after 24-hour culture was 5.9 ± 1.2 ng/mL, which is within 
the normal plasma range (Jamaluddin et al., 2012). To then determine if EAT resistin 
release is modulated by arrhythmogenic triggers, we measured resistin in 24-hour cultured 
EAT treated with either BRL (10-6 M, n = 13 patients) or the β1/ β2-adrenergic receptor 
agonist ISO (10-6 M, n = 4 patients) and compared to it untreated controls. As shown in 
Figure 4.2B, relative to paired untreated controls, neither ISO (untreated 5.2 ± 2.1 ng/mL 
vs. 4.3 ± 7.5 ng/mL with ISO, P = 0.6) nor BRL treatment (untreated 7.1 ± 1.7 ng/mL vs. 
7.3 ± 1.7 ng/mL with BRL, P = 0.8) significantly altered EAT secretome resistin levels. 
Together, these findings indicate that resistin comprises part of the EAT secretome; 
however, the release of resistin is not altered by β-adrenergic stimulation. 
4.3.3 Direct effect of resistin on spontaneous contractions in human trabeculae  
Although not specifically upregulated in the treated EAT secretome, resistin levels 
have previously been reported to be upregulated in the plasma of patients with AF. The 
plasma concentration in these cases has ranged from 7.6 ng/mL up to 21.0 ng/mL (Gungor 
et al., 2011; Özcan et al., 2014; Ermakov et al., 2016). Therefore, to determine the direct 
effect of resistin on ex vivo arrhythmia susceptibility, recombinant human resistin was 
superfused over human atrial trabeculae from 10 patients and the propensity for 
spontaneous muscle contractions was assessed. Resistin was superfused at concentrations 
of 7, 12, and 20 ng/mL to be analogous to that measured previously in AF patients. During 
the 1-minute pause interval (cessation of external 1 Hz stimulation) at baseline, no 
trabeculae developed spontaneous contractions (0/10) (Figure 4.3A). Addition of resistin 




spontaneous contractions, nor the number of spontaneous contractions exhibited during the 
rest period (Figure 4.3A, B).  
 
 
Figure 4.3. Effect of resistin on the arrhythmogenic behaviour in human right atrial myocardium. 
Arrhythmias were measured as spontaneous contraction (SC) propensity and number of 
spontaneous contractions during 1-minute pause interval. Resistin alone at any concentration did 
not significantly increase the proportion of trabeculae with SCs (A) or the number of SCs 
exhibited by those with spontaneous behaviour (B). C & D, Furthermore, resistin did not enhance 
the pro-arrhythmic effect of isoproterenol (ISO, 10-5 M) on human atrial trabeculae. For A & C, 
statistical differences were assessed using Fisher’s exact tests. For B & D, differences in number 
of SCs were determined using repeated measures one-way ANOVA with post hoc Dunnett test. 
*= p < 0.05 vs. baseline (no resistin), n = 10. Data are represented as percentages or mean ± SEM. 
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β-adrenergic stimulation is a trigger for in vivo autonomous atrial muscle activity. 
We have previously validated this in ex vivo human atrial trabeculae, whereby ISO 
treatment acutely increased the proportion of spontaneously contracting trabeculae as well 
as the average number of spontaneous contractions exhibited by each trabecula (Babakr et 
al., 2020). Therefore, we next tested whether resistin treatment enhanced spontaneous 
trabecula contractions in the presence of an arrhythmogenic ISO trigger (10-5 M). As shown 
in Figure 4.3C & D, exposure to ISO alone significantly increased the proportion of 
trabeculae exhibiting spontaneous contractions relative to baseline (baseline 0/10 vs. 5/10 
with ISO, P = 0.03, Fisher’s exact test). Co-treatment of ISO and resistin did not alter the 
number of spontaneously active muscles or the number of spontaneous contractions 
exhibited by each muscle (Figure 4.3C, D). This was consistent at each resistin 
concentration. Therefore, treatment of human atrial trabeculae with resistin concentrations 
measured in the plasma of AF patients does not significantly enhance ex vivo arrhythmic 
muscle activity when given alone or in combination with a spontaneous contraction trigger. 
4.3.4 Direct effect of human resistin on myocardial function of human trabeculae  
Although recombinant resistin did not enhance the propensity for spontaneous 
trabeculae contractions, previous research has found that resistin overexpressed within the 
rat heart significantly depresses in vitro and in vivo contractility (Kim et al., 2008; Chemaly 
et al., 2011). Furthermore, we and others have shown that cardiac contraction and 
relaxation kinetics are altered by EAT and subcutaneous 24-hour cultured secretomes 
(Lamounier-Zepter et al., 2006; Look et al., 2011; Babakr et al., 2020). Therefore, for the 
present study, we also assessed the effect of exogenous resistin (7, 12, 20 ng/mL) on human 
atrial trabeculae developed force, +dF/dtmax and -dF/dtmax. As shown in Figure 4.4, resistin 
induces an acute positive inotropic effect in the human atrial myocardium. Relative to 
baseline values (4.2 ± 1.0 mN/mm2), the developed force was significantly increased by 
exogenous resistin doses of 12 ng/mL (9.4 ± 2.0 mN/mm2, P = 0.006) and 20 ng/mL (12.2 
± 2.1 mN/mm2, P < 0.0001), but not by the 7 ng/mL dose (6.6 ± 1.9 mN/mm2, P = 0.3) 
(Figure 4.4B). This increase in developed force was accompanied by dose-dependent 
increases in the +dF/dtmax and -dF/dtmax of the human trabeculae (Figure 4.4C, D). Baseline 
contraction (92 ± 20 mN/mm2/s) and relaxation rates (-69 ± 20 mN/mm2/s) were 
significantly increased at 12 (193 ± 44 mN/mm2/s, P = 0.008; -104 ± 22 mN/mm2/s, P = 
0.02) and 20 ng/mL doses (239 ± 46 mN/mm2/s, P < 0.001; -125 ± 19 mN/mm2/s, P = 




36 mN/mm2/s, P = 0.3 vs. baseline) or -dF/dtmax (-98 ± 28 mN/mm
2/s. P = 0.05 vs. baseline) 
(Figure 4.4C, D). As with the effect of resistin on spontaneous contraction propensity, 
exogenous resistin did not further alter changes in developed force, +dF/dtmax, or -dF/dtmax 
induced by ISO treatment (10-5 M) (data not shown). These data suggest that exogenous 
resistin has an acute positive inotropic effect on the human atrial myocardium. 
 
Figure 4.4. Effect of resistin on the contractile function of human right atrial trabeculae. A, 
representative traces of trabecula contractions in the absence (no resistin) and presence of 7, 12, 
and 20 ng/mL recombinant resistin. Contractions were paced at 1 Hz with trabeculae stretched 
to optimal working length in 37°C superfusion buffer. Exogenous resistin significantly increased 
trabecula developed force, the maximal contraction rate (+dF/dtmax), and maximal relaxation rate 
(-dF/dtmax) at 12 ng/mL and 20 ng/mL doses (see body text for raw values). All contractility 
values are normalized to trabecula cross-sectional area. Concentration differences were 
determined using repeated measures one-way ANOVA with Dunnett post hoc test. *P < 0.05, 
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4.3.5 Effect of resistin on post-pause contractility of human atrial trabeculae 
A key determinant of cardiac contractility is cellular Ca2+-handling (Bers, 2002). 
Therefore, because exogenous resistin induced an acute positive inotropic effect (Figure 
4.4), we next determined whether this could be associated with a concurrent alteration in 
sarcoplasmic reticulum (SR) Ca2+ dynamics. To test this, we assessed the PPP capacity of 
the human trabeculae following a 1-minute pause interval, which provides an indirect 
assessment of SR Ca2+ load (Bers, 1989; Lebek et al., 2018). There was a significant 
increase in developed force of the first post-pause contraction relative to the respective pre-
pause contraction at each baseline and with resistin treatment (P < 0.001 for each condition) 
(Figure 4.5A). However, when compared to the baseline PPP capacity (474 ± 105 %), the 
307 ± 82 %, 241 ± 77 %, and 232 ± 75 % potentiation induced by 7, 12, and 20 ng/mL 
resistin, respectively, were all significantly reduced (7 ng/mL P = 0.04, 12 ng/mL P = 
0.003, 20 ng/mL P = 0.002) (Figure 4.5B). Exogenous resistin superfusion, therefore, 
dose-dependently attenuates the capacity for PPP in human atrial trabeculae, which could 
indirectly suggest a reduction in SR Ca2+ load. 
 
Figure 4.5. Recombinant resistin impairs the post-pause potentiation capacity of human atrial 
trabeculae. Following 1-minute pause intervals, the developed force of the first post-pause 
contraction (PP) was compared to the pre-pause steady state contraction (SS). A, under each 
condition there was a potentiation of trabeculae developed force in the PP contraction relative to 
the respective SS contraction. *P < 0.0001 vs. respective SS contraction, as measured by two-
way ANOVA with Sidak’s post hoc test. However, the average potentiation was significantly 
reduced in trabeculae treated with any resistin dose when compared to no resistin controls (B). 
*P < 0.05, **P < 0.01 vs. no resistin, repeated measures one-way ANOVA with Dunnett post 






Our main finding is that human recombinant resistin does not significantly enhance 
the propensity for arrhythmic contractions in human atrial trabeculae. It does, however, 
acutely induce an acute positive inotropic and lusitropic effect. Furthermore, β-adrenergic 
stimulation of EAT does not increase the content of resistin within the cultured EAT 
secretome. These findings suggest that our previous finding of ex vivo arrhythmias induced 
by β-adrenergic stimulated EAT secretome is not due to upregulated resistin release 
(Babakr et al., 2020). These data do support previous findings of a resistin effect on the 
myocardium (Kim et al., 2008; Chemaly et al., 2011) and, to the best of our knowledge, 
are the first to show an acute effect of exogenous resistin on non-ischaemic human 
myocardial contractility. 
4.4.1 Role of EAT and the interaction with resistin in arrhythmias 
Meta-analyses have confirmed that non-invasively imaged EAT deposition is a 
strong predictor of AF incidence, AF severity, and postoperative AF risk (Wong et al., 
2016). Furthermore, EAT deposition has been found to correlate with sites of high 
dominant frequency and complex fractionation, as well as P-wave dispersion and 
prolongation, suggesting that EAT may promote arrhythmogenic electrical remodelling 
within the myocardium (Friedman et al., 2014; Kanazawa et al., 2014; Nakatani et al., 
2015). Circulating resistin levels are also associated with pre- and postoperative AF risk 
(Gungor et al., 2011; Özcan et al., 2014; Ermakov et al., 2016; Rachwalik et al., 2019) and 
the EAT secretome is known to have an upregulated resistin concentration in CVD (Baker 
et al., 2006; Langheim et al., 2010). We have previously shown that the cultured EAT 
secretome promotes arrhythmic atrial muscle behaviour (Babakr et al., 2020); therefore, 
we hypothesised that application of exogenous resistin at concentrations measured in AF 
patients would also enhance ex vivo muscle arrhythmias. Recombinant resistin did not 
significantly increase the proportion of spontaneously contracting atrial trabeculae either 
when applied alone or in combination with an arrhythmic β-adrenergic trigger (Figure 4.3). 
These results, therefore, do not support our hypothesis of a direct, acute arrhythmogenic 
effect of exogenous resistin. Deductively, this also suggests that resistin within the cultured 
EAT secretome is not responsible for atrial arrhythmias we have previously reported 
(Babakr et al., 2020). Although not acutely promoting spontaneous contractions, resistin 
may be arrhythmogenic via promotion of fibrotic remodelling of the atrial myocardium. 
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Chronic resistin overexpression has been found to increase fibrotic deposition in rat 
ventricle (Chemaly et al., 2011). Moreover, 1-week exposure of cultured rat myocytes to 
human EAT secretome is known to promote fibrotic remodelling at the interface between 
EAT and the adjacent myocardium (Venteclef et al., 2014). Therefore, the pro-fibrotic 
nature of resistin, in combination with the increased EAT resistin release in CVD, could 
explain the elevated resistin levels in AF patients and atrial electrical remodelling that 
occurs in AF.  
4.4.2 Resistin effect on contractility 
Long-term adenoviral resistin overexpression has been found to induce 
hypertrophic myocardial remodelling that is associated with depressed contractility and 
impaired intracellular Ca2+-handling (Kim et al., 2008; Chemaly et al., 2011). When 
combined with the extensive clinical correlations of blood resistin with LV hypertrophy 
and impaired LV function (McManus et al., 2012; Toczylowski et al., 2019), the literature 
strongly suggests that resistin has a negative inotropic effect. Our finding of an acute 
positive inotropic effect of exogenous resistin (Figure 4.4), therefore, directly contrasts 
with these previous reports. This discrepancy could be due to the short duration resistin 
exposure used in our study (20-minutes per resistin dose). Subsequent investigations of 
chronic resistin-mediated ventricular hypertrophy and myocardial dysfunction linked the 
remodelling to a Ca2+-dependent activation of kinases and transcription factors implicated 
in cellular hypertrophy (Kang et al., 2011; Singh et al., 2018). However, induction of this 
pathway was associated with a relatively long exposure period (minimum 4-hours). 
Therefore, the human atrial trabeculae exposure duration to recombinant resistin used in 
the current study may have been insufficient to activate the resistin-modulated hypertrophic 
pathways that are detrimental to myocardial function. And although the clinical use of 
resistin in the long-term might not be beneficial (Kim et al., 2008; Chemaly et al., 2011), 
the resistin-induced increase in contractility without an increase in spontaneous 
contractions might indicate that resistin could be used as a short-term positive inotropic 
agent. The translational efficacy of this effect will, however, depend on the mechanistic 
targets underlying the acute resistin-induced inotropy. This cannot be conclusively deduced 
from the current study and will require further investigation. 
Because resistin induced inotropy without enhancing trabecula spontaneity, one 
possible explanation for the observed effects could be an increased myofilament Ca2+ 




2013). Based on the results of our study, we cannot exclude this as an acute target of resistin 
treatment. However, our finding of enhanced maximal contraction and relaxation rates 
following resistin treatment (Figure 4.4C, D) suggest that an increased myofilament Ca2+ 
sensitivity cannot be the solely modulated cardiac contraction mechanism. Further insight 
into a possible mechanism of resistin-mediated positive inotropy was achieved by 
determining the PPP capacity of human atrial trabeculae as a surrogate estimate of SR Ca2+ 
load (Bers, 1989; Ravens et al., 1995; Ravens et al., 1997; Lebek et al., 2018). Previous 
work in human and rat trabeculae has found that the increased force induced by positive 
inotropes is often paralleled by an increase in PPP capacity. Likewise, agents that decrease 
myocardial force also decrease the PPP capacity (Ravens et al., 1995; Ravens et al., 1997). 
For the current study we have found that exogenous resistin decreases the PPP capacity of 
human atrial trabeculae (Figure 4.5). This suggests a decreased SR Ca2+ load, which aligns 
with decreased Ca2+ transient amplitudes and decay kinetics found in rat models of resistin 
overexpression (Kim et al., 2008). However, it contrasts with the effect on PPP capacity 
found with other positive inotropes (Ravens et al., 1995; Ravens et al., 1997). Interestingly, 
the increase in developed force induced by some positive inotropes is accompanied by only 
a minor increase in PPP capacity, due to the pre-pause shift in inotropy limiting the capacity 
for contraction potentiation post-pause (Ravens et al., 1995; Ravens et al., 1997). The 
paradoxical results of our study could therefore be due to an exhausted capacity to increase 
trabeculae force. However, as the resistin effect on post-pause behaviour we observed was 
negative, instead of even slightly positive, an alternative explanation is required.  
The PPP capacity also estimates diastolic SR Ca2+ leak and is therefore a useful 
measure when investigating ex vivo arrhythmias (Lebek et al., 2018). Pharmacological 
inhibition of SR Ca2+ leak in human atrial trabeculae is known to reduce spontaneous Ca2+ 
spark frequency and arrhythmic contraction events in parallel with increases in PPP 
capacity (Lebek et al., 2018). Therefore, the reduction in PPP capacity induced by resistin 
could be due to enhanced SR Ca2+ leak. Although this did not translate to an enhanced 
spontaneous contraction rate, this could be due methodological limitations of spontaneous 
muscle activity as an arrhythmia proxy. Investigation of altered Ca2+-handling protein 
expression and post-translational modification status following resistin treatment would 
provide valuable insight into the altered PPP capacity and, in turn, the inotropic and 
potential arrhythmic effects of the adipocytokine. Considering the dependence on SR Ca2+-
ATPase (SERCA2a)-mediated Ca2+-handling in myocardial remodelling associated with 
long-term resistin overexpression (Singh et al., 2018), as well as previous reports of acute 
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modulations in Ca2+-handling protein activities by other EAT-derived adipokines like 
activin A (Greulich et al., 2012), further directed study of protein changes acutely induced 
by resistin is required. 
4.4.3 Limitations 
Our investigation of the arrhythmogenic effects of recombinant resistin was limited 
to one assessment of arrhythmic RAA muscle behaviour. Although spontaneous trabeculae 
contractions are known to be induced by potent arrhythmogenic triggers like β-adrenergic 
stimulation and intracellular Ca2+ overload (Babakr et al., 2020), ex vivo arrhythmias can 
also be quantified by the presence and frequency of spontaneous electrical activity and 
premature contraction events during pacing (Lebek et al., 2018). These alternate measures 
could reveal microscopic arrhythmic effects of resistin that are not evident in macroscopic 
spontaneous contraction. 
4.5 Conclusion 
We have shown for the first time a direct effect of recombinant resistin on the 
contractility of non-ischaemic human myocardium. Contrary to findings in animal models 
with chronic resistin overexpression, exogenous resistin treatment has an acute positive 
inotropic effect. Despite several clinical associations of circulating resistin levels with AF, 
contractility changes induced by resistin are not paralleled by an enhanced propensity for 
arrhythmic spontaneous contractions. Finally, although EAT actively releases resistin, the 






General Discussion of EAT Findings 
5.1 Summary of findings 
In the recent decade, an extensive body of clinical research has identified 
associations between EAT deposition and CVD risk. Macroscopic EAT deposition, 
whether measured as EAT thickness or volume, is associated with greater risk of CAD and 
AF. As such, assessment of macroscopic EAT morphology has diagnostic and prognostic 
utility in the clinic. The efficacy of targeting EAT as therapeutic strategy in CVD is, 
however, less clear, which can be attributed to the limited pre-clinical understanding of 
EAT biology. This thesis has addressed this limitation by investigating microscopic EAT 
adipocyte morphology in relation to a key CVD risk factor, obesity (Aim 1). Additionally, 
this thesis has investigated the role of EAT as a secretory tissue that can directly modulate 
the contractility and rhythmicity (Aim 2). 
Aim 1 was to determine the effect of obesity on microscopic EAT adipocyte 
morphology. Several key findings were made. Firstly, EAT adipocyte size did not correlate 
with BMI in post-mortem cases as is characteristic of adipocytes from other VAT and SAT 
depots (Chapter 2). Secondly, EAT adipocyte size was found to have no correlation with 
EAT thickness (Chapter 3). These findings indicate that EAT expansion in obesity is not 
dependent on hypertrophy of EAT adipocytes, suggesting a unique remodelling tendency 
for EAT adipocytes in obesity. Exploratory investigation published as part of Chapter 3 
found that EAT from obese patients has a greater proportion of smaller adipocytes, 
suggesting that adipocyte hyperplasia could underlie EAT expansion in obesity.  
Aim 2 was to determine the role of the EAT-derived pro-inflammatory 
adipocytokine, resistin, on cardiac muscle function (Chapter 4). Since plasma resistin 
levels are increased in AF patients and the EAT secretome is hyper-inflammatory in CVD, 
it was hypothesised that resistin would drive the arrhythmogenic effects of the EAT 
secretome, especially after β3-adrenergic receptor stimulation. I found that: (1) human EAT 
releases resistin; however, the amount of resistin secreted is not altered by β3-adrenergic 
stimulation. (2) Unlike the EAT secretome, recombinant resistin does not significantly 
increase the propensity for arrhythmogenic contractions in human atrial myocardium. (3) 
Resistin does, however, increase myocardial contractility. These findings are the first to 
 General Discussion of EAT Findings 
63 
 
determine the acute effect of resistin on human cardiac function. Furthermore, they provide 
pre-clinical insight into the putative paracrine signalling relationship between EAT and the 
heart. 
Overall, these findings address key gaps in the pre-clinical understanding of EAT 
biology. As the clinical interest in EAT continues to grow, it is pertinent that the basic 
understanding of EAT is developed in order to determine the significance of the EAT in 
the cardio-metabolic disease pathogenesis. Although a simple research question, Aim 1 
clarifies the relationship between microscopic EAT morphology and a fundamental obesity 
index. These results can be utilised to inform future multivariate modelling of EAT 
adipocyte morphology. More excitingly, the findings generate further questions about EAT 
biology and the role that adipocyte remodelling plays in cardio-metabolic disease.  
The secretory capacity of EAT is generally accepted to play a role in cardiac 
pathophysiology. However, the empirical evidence supporting this function of EAT lags 
behind the theoretical framework. Aim 2 shows that a well-established EAT-derived factor 
can directly alter cardiac muscle function, while also clarifying the specific role (or lack 
thereof) of resistin in the acutely pro-arrhythmic effect of the EAT secretome. Like the 
results of Aim 1, these findings establish a platform for future pre-clinical investigations 
of EAT to build from.  
5.2 Adipocyte remodelling in obesity 
5.2.1 Adipose deposition vs. adipocyte size relationship 
Evidence from other adipose depots suggests that hypertrophy is the predominant 
form of adipocyte remodelling in obesity. Adipocyte sizes measured from SAT abdominal, 
femoral, and gluteal depots, and the VAT omental depot positively correlate with BMI, 
WC, and body fat percentage (Tchernof et al., 2006; Tchoukalova et al., 2008; 
Tchoukalova et al., 2010a; Veilleux et al., 2011; Michaud et al., 2016). I have recapitulated 
these findings by showing that adipocytes from VAT appendix and paracardial depots and 
the SAT clavicular depot have positive size correlations with BMI (Chapter 2); albeit with 
the expected regional heterogeneity (Tandon et al., 2018). When combined with previous 
findings that SAT and VAT adipocyte sizes correlate with SAT and VAT volume, our 
findings strengthen the paradigm that adipocyte hypertrophy underlies adipose expansion 
in obesity (Tchernof et al., 2006; Tchoulalova et al., 2008; Tchoukalova et al., 2010a; 




5.2.2 EAT adipocyte hypertrophy does not underlie EAT expansion in obesity 
Meta-analysis has confirmed that EAT also expands in obesity (Rabkin, 2014), 
hence I hypothesised that this will be associated with hypertrophy of the comprising EAT 
adipocytes. My results refute this hypothesis, instead suggesting that EAT adipocytes do 
not hypertrophy in obesity. EAT adipocyte size did not correlate with BMI or with EAT 
thickness despite EAT thickness showing a positive correlation with BMI. My findings 
align with that of Eiras et al. and Bambace et al. who also found no correlation of EAT 
adipocyte size with BMI in cardiac surgery patients (Eiras et al., 2010; Bambace et al., 
2011). Additionally, my work clarifies the absence of EAT adipocyte hypertrophy in 
obesity, as previous reports speculated that the coefficient of the EAT adipocyte size to 
BMI correlation represented a trend towards significance (Eiras et al., 2010).  
 
Figure 5.1. Post hoc analysis of data from Sons & Hoffman, 1986 (Anatomischer Anzeiger 161). 
Correlation between epicardial adipose tissue (EAT) adipocyte size and body mass index (BMI) 
in post-mortem cases. BMI vs. average EAT adipocyte size from 10 sampling sites (A), vs. 
average size from site #1 only (B) (corresponds to site used in Manuscript #1), and vs. average 
size from site #5 only (C) (corresponds to site used in Manuscript #2). D-E, effect of limiting the 
post-mortem case BMI range to that used in our studies (19.0-35.5 kg/m2) on the correlations 
from each sampling location(s). 
 General Discussion of EAT Findings 
65 
 
In contrast to my findings are those of Sons & Hoffman who found that EAT 
adipocytes are larger in obese post-mortem cases relative to non-obese cases (Sons & 
Hoffman, 1986). Additionally, they reported a correlation between adipocyte size and body 
weight deviation from “ideal”, thereby supporting the hypothesis of EAT adipocyte 
hypertrophy in obesity. This discrepancy from our findings could be due to several factors. 
Firstly, body weight was used to categorise obesity instead of BMI, which could generate 
a false positive correlation. To evaluate this, I did my own post hoc analysis of Sons & 
Hoffman’s data whereby the BMI was calculated for each post-mortem case. I found that 
the original positive association of EAT adipocyte size and obesity reported by the authors 
holds true (r = 0.8, P < 0.0001) (Figure 5.1A). Secondly, the EAT adipocyte size values 
used in their study were calculated as an average size from ten sampling locations. For my 
studies, I was limited to single sampling sites due to ethical and procedural issues, which 
could generate variations in my results. Further post hoc analysis of adipocyte sizes from 
only sites analogous to those sampled for Chapters 2 and 3 does not change the positive 
correlation with BMI reported by Sons & Hoffman (Figure 5.1B, C). The discrepancy in 
our findings, therefore, is not due to differences in obesity metric or specific EAT sampling 
locations.  
A third source of variation could stem from the ranges of BMI used in each study. 
Sons & Hoffman’s study included post-mortem cases at extremes of the BMI scale, 
including cases with BMI ≥ 40 kg/m2 and with BMI ≤ 15 kg/m2, which is indicative of 
cachexia. For my post-mortem study, severely obese cases were not examined due to health 
and safety regulations, while no emaciated cases were examined during the data collection 
period (Chapter 2). To determine whether the correlations found in the Sons & Hoffman 
study were skewed by extreme cases, I excluded post-mortem cases with BMI outside the 
range found in my studies (19.0-35.5 kg/m2) from post hoc analysis. Doing so weakened 
the correlation coefficients in the overall average EAT adipocyte size and the sites 
corresponding with my sampling sites; however, the correlations remained significant 
(Figure 5.1D-F). Therefore, the discrepancy in our findings cannot be attributed to 
confounding by data skewing. 
A fourth potential source of variation could be from differences in adipocyte size 
measurement. Sons & Hoffman used a cellular measurement software, while I used blinded 
manual adipocyte measurements. A notable outcome of this difference is that the average 




the software used in their study might not have been sensitive enough to detect smaller 
adipocytes falling below the size detection threshold.  
Finally, the cohort sizes used in my studies (N = 43 and N = 49) are greater than 
that used by Sons & Hoffman (N = 34). Additionally, they did not perform any multivariate 
adjustments for other variables. Consequently, factors known to affect adipocyte biology, 
such as age and gender, were not controlled for in the analyses as they were for my studies. 
Since publication, the number of EAT adipocyte measurements done by our group has 
grown, which has improved the strength of our univariate and multivariate associations (or 
lack-there-of). To date, EAT adipocyte size has been measured from 91 post-mortem cases 
and 78 cardiac surgery patients. In each cohort, there remains no correlation of EAT 
adipocyte size with BMI (Figure 5.2). Interestingly, with the greater statistical power, there 
seems to be positive associations of EAT adipocyte size with age and with being male 
(Lamberts lab, unpublished observations, data not shown). However, these findings require 
further investigation. 
 
Figure 5.2. Current analysis of epicardial adipose tissue (EAT) adipocyte size relationship with 
body mass index (BMI). The absence of association between EAT adipocyte size and BMI is 
retained with larger sample size in post-mortem cases (A, N = 91, r = 0.04, P = 0.7) and cardiac 








My finding of no association between EAT adipocyte size and BMI aligns with 
contemporary studies of EAT morphology but contradicts a seminal study that framed the 
original dogma about EAT adipocyte remodelling in obesity. If not adipocyte hypertrophy 
that underlies EAT expansion obesity, an alternative form of remodelling must occur to 
underlie the 58.7% increase in EAT thickness found in obese cardiac surgery patients.  
5.3 Alternative remodelling underlying EAT expansion obesity 
5.3.1 EAT fibrosis 
For this thesis, interstitial EAT fibrosis was assessed by quantifying the relative 
‘non-adipocyte area’ within each EAT section. This represents the stromal vascular 
fraction, which is the composite of extracellular matrix components, immune cells, and 
vascular tissue. As discussed in more detail in Chapter 3, previous studies have reported 
an association between expression of pro-fibrotic genes and interstitial fibrosis within VAT 
and SAT samples from obese subjects (Divoux et al., 2010; Alligier et al., 2012). My 
analysis of the EAT stromal vascular fraction found that EAT interstitial fibrosis is not 
associated with BMI and therefore cannot explain EAT expansion in obesity. This is a bit 
surprising due to the reports of extensive EAT fibrosis in AF patients that also have 
increased EAT thickness (Haemers et al., 2015; Wong et al., 2016; Abe et al., 2018). 
Furthermore, the secretome of EAT from AF patients is known to induce fibrosis in 
cultured rat atrial tissue (Venteclef et al., 2014; Haemers et al., 2015; Abe et al., 2018; 
Nalliah et al., 2019).  
Several factors could explain why my results contrast with these other reports. The 
first regards the differences in complexities of the pathologies investigated. For instance, 
AF can be self-reinforcing when electrical abnormalities caused by fibrosis in the atria 
promotes further fibrosis, thereby allowing the AF to beget AF (Hatem & Sanders, 2014). 
Therefore, the interstitial EAT fibrosis reported in AF could be due to the AF disease 
process independent of the patient’s degree of obesity. From my cohort, 12 patients were 
diagnosed with AF (any form) pre-operatively. Although limited by sample size, inclusion 
of all forms of AF in the multivariate model of EAT adipocyte size did not highlight AF as 
a predictor of adipocyte size (P = 0.98).  
Above, my post hoc analyses suggest that the discrepancy in EAT adipocyte size 




study (Sons & Hoffman, 1986) is maintained if EAT sampling sites are matched (Figure 
5.1). As part of their study, Sons and Hoffman found that EAT adipocyte size can vary at 
different sampling sites on the heart (Sons & Hoffman, 1986). For Chapter 3, EAT was 
procured from the right atrioventricular groove, which contrasts with the peri-atrial EAT 
used in previous investigations of EAT fibrosis in AF (Haemers et al., 2015; Abe et al., 
2018; Nalliah et al., 2019). Therefore, the unexpected absence of EAT fibrosis found in 
obesity in my thesis could be related to differences in EAT sampling location that might 
have differences in fibrosis susceptibility. This is supported by the recent finding that 
regional differences in EAT deposition are associated with regional differences in 
myocardial fibrosis and electrical conduction in AF patients (Nalliah et al., 2019).  
5.3.2 EAT adipocyte hyperplasia 
EAT adipocyte size was not different when stratified into BMI categories in 
Chapters 2 and 3, suggesting that EAT adipocyte size does not change in obesity. 
However, the profile of EAT adipocyte size frequency distribution curve of obese patients 
was shifted leftward (Chapter 3). My interpretation of this finding is that EAT from 
patients with obesity contains a greater proportion of ‘smaller’ adipocytes, which could be 
indicative of adipocyte hyperplasia. This resembles previous reports of BMI associating 
with the percentage of ‘small’ adipocytes within other adipose depots, suggesting that 
expansion of these adipose tissues occurs via adipocyte hyperplasia in parallel with 
hypertrophy (Michaud et al., 2016). It should be noted that the automated cell measurement 
systems used in these studies contrasts with the manual cell measurements I have used. A 
consequence of this is that my adipocyte size frequency distributions follow a unimodal 
profile, while the other methodology generates bi- or tri-modal distributions (Laforest et 
al., 2017). From these multi-modal distributions, ‘nadirs’ can be identified to demarcate 
‘small’ adipocytes from ‘large’ and thus the proportion of small adipocytes can be 
calculated as a proxy for hyperplastic remodelling. My analysis of unimodal size frequency 
distributions instead relies on the relatively weaker semi-quantitative directional shifts to 
assess hyperplasia (LaForest et al., 2017). Future study of the hyperplastic remodelling 
capacity of EAT will have to utilise these other methodologies in order to appropriately 
contextualise EAT within the framework of other adipose depots (further discussion in 
Future Directions). Regardless, my exploratory finding of EAT adipocyte hyperplasia 
raises questions about how this form of remodelling affects the putative functions of EAT 
and in turn its relationship with the heart. 
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The balance between adipocyte hypertrophy and hyperplasia in adipose expansion 
is dictated by the ‘critical fat cell size theory’ (Marques et al., 1998). By this paradigm, 
early adipose expansion in response to nutrient excess occurs by adipocyte hypertrophy. 
With continued excess, however, adipocytes reach a critical size threshold whereby further 
energy sequestration cannot occur, leading to paracrine signalling that initiates recruitment 
and maturation of pre-adipocytes (adipogenesis) (Marquez et al., 1998). This phenomenon 
has been mapped using an inducible adipocyte tagging system to highlight the 
heterogeneity in the threshold for ‘switching on’ hyperplasia that exists between adipose 
depots (Wang et al., 2013). For instance, the switch to hyperplasia in epididymal VAT 
precedes the switch in abdominal SAT, suggesting a greater hypertrophy capacity of the 
adipocytes comprising the latter depot (Wang et al., 2013).  
Contextualising my results within this paradigm is challenging. I found a possible 
association between EAT expansion and EAT adipocyte hyperplasia. However, along the 
continuum of obesity severity I found no evidence of adipocyte hypertrophy. One 
explanation could be that the capacity for EAT adipocyte hypertrophy is smaller relative to 
other depots, which would limit the potential for increases in cell size. EAT adipocytes are 
known to be smaller than other SAT and VAT adipocytes but to exhibit paradoxically 
greater rates of fatty acid flux (Marchington et al., 1989; Marchington & Pond, 1990). 
Because EAT comprises only ~1% of total fat mass it is hypothesised that the high rate of 
fat metabolism in EAT protects the myocardium against fatty acid toxicity (Marchington 
& Pond, 1990; Rabkin, 2007). Therefore, unlike other adipose depots that regulate systemic 
lipid metabolism via changes in cell size, EAT might not have the capacity to increase as 
the expression of fat-handling machinery is already exhausted. Hence, during sustained 
fatty acid excess within the coronary circulation, as occurs in obesity, EAT adipocytes 
might remodel via hyperplasia to prevent fatty acid toxicity. 
A second explanation for the absence of EAT adipocyte hypertrophy in obesity is 
that VATs like EAT are physically constrained by surrounding tissues (Haczeyni et al., 
2018). EAT is surrounded by the myocardium beneath and the pericardium superficially. 
Based on the hypothesis by Haczeyni et al., the rigidity of these structures could impede 
the growth of EAT adipocytes (Haczeyni et al., 2018). This theory could also be extended 
to the physical impedance to growth caused by the intra-cardiac pressures generated during 
the cardiac cycle. Not supporting this hypothesis, however, are reports of EAT adipocyte 




increase in size without impedance from physical structures or intra-pericardial pressures 
(Vianello et al., 2016).  
5.3.3 Summary 
Exploratory results of this thesis suggest that adipocyte hyperplasia might underlie 
EAT expansion in obesity (see Figure 5.3 for schematic summary). In addition, my indirect 
analyses suggest that changes in interstitial fibrosis do not contribute to EAT expansion in 
obese patients.  
 
Figure 5.3. Summary of epicardial adipose tissue (EAT) deposition and EAT adipocyte 
remodelling in obesity. A, EAT thickness is increased in obesity, as evidenced in Chapter 3 by 
the positive correlation of EAT thickness with body mass index (BMI). B, EAT adipocyte size 
is not correlated with BMI (Chapters 2 & 3) or with EAT thickness (Chapter 3). C, this suggests 
that changes in EAT adipocyte size (hypertrophy) do not underlie EAT expansion. Furthermore, 
I found that interstitial EAT fibrosis is not different in obesity (Chapter 3). D, exploratory 
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5.4 Relation to EAT function as a secretory tissue 
5.4.1 EAT adipocyte hypertrophy and adipokine secretion 
Discussion of how the absence of EAT hypertrophy relates to the metabolic 
properties of EAT was included in Chapter 2; therefore, it will not be discussed further 
here. Instead, the following will focus on how EAT adipocyte morphology dictates the 
secretory capacity of the tissue. EAT adipocyte size has been positively correlated with 
plasma levels of the pro-inflammatory factors monocyte chemoattractant protein 1 (MCP-
1) and leptin and negatively with the anti-inflammatory factor adiponectin (Eiras et al., 
2010; Bambace et al., 2011). Whether the relationship of EAT adipocyte size with the 
secretion of EAT-derived factors is altered in obesity is currently unknown. From studies 
where EAT adipocyte size was not measured, the expression levels of MCP-1 and leptin in 
EAT have been shown to correlate positively with BMI (Bambace et al., 2014). Similarly, 
EAT adiponectin expression has been found to correlate with circulating adiponectin levels, 
which independently shares an inverse correlation with BMI (Matsubara et al., 2002; 
Iacobellis et al., 2005b; Bambace et al., 2014). Therefore, based on the evidence it is 
expected that EAT adipocyte secretion of inflammatory factors is associated with adipocyte 
size and with indices of obesity. This would, however, also suggest that EAT adipocytes 
should hypertrophy in obesity, which contradicts what I have found in this thesis. 
5.4.2 Hyperplasia and adipokine secretion 
How then could EAT adipocyte hyperplasia relate to the secretory capacity of EAT? 
Insight from other depots regarding this is limited. Circulating leptin, which is positively 
correlated with EAT adipocyte size, is also positively correlated with SAT abdominal and 
femoral adipocyte sizes. In addition, plasma leptin levels are associated with estimates of 
SAT adipocyte number, suggesting that hypertrophy and hyperplasia of SAT adipocytes 
associate with hyper-leptinaemia (Couillard et al., 2000). Plasma adiponectin levels are 
known correlate negatively with SAT abdominal adipocyte size. However, adiponectin 
levels positively correlate with the percentage of small cells in SAT, suggesting an inverse 
association between adipocyte hypertrophy and hyperplasia (Meyer et al., 2013). 
Extrapolating these findings to EAT requires caution as there are depot-specific properties 
of adipocytokine secretion (Mazurek et al., 2003). To determine how hyperplastic 
remodelling of EAT alters the secretory capacity of the tissue, correlations between 




proliferation. Similarly, concentrations of factors within the cultured EAT secretome can 
be quantified and compared across the classifications of obesity. 
Of relevance to this thesis is how EAT adipocyte remodelling might affect release 
of resistin. Circulating resistin levels are increased in obesity and in several CVDs (Butler 
et al., 2009; Gungor et al., 2011; Bobbert et al., 2012; Norman et al., 2020). Furthermore, 
EAT secretion of resistin is increased in CAD (Baker et al., 2006; Langheim et al., 2010). 
Therefore, determining the contribution of EAT adipocyte remodelling in elevating 
circulating resistin levels is pertinent for understanding the pathophysiology of cardio-
metabolic diseases. 
5.5 Resistin 
Plasma resistin levels have been associated with AF risk (Gungor et al., 2011; 
Özcan et al., 2014; Ermakov et al., 2016). To complement this, I have shown that when 
applied at concentrations measured in AF patients, resistin does not enhance the propensity 
for arrhythmic contractions in human atrial myocardium. Furthermore, I found an acute 
positive inotropic effect of resistin in human heart tissue, which I speculate is due to 
alterations in SR Ca2+-handling. As described in Chapter 4, this contrasts with previous 
reports using rodent models of chronic resistin expression (Kim et al., 2008; Chemaly et 
al., 2011; Singh et al., 2018). These models exhibit myocardial oxidative stress and fibrosis, 
ventricular hypertrophy, as well as impaired cardiomyocyte Ca2+-handling and contractility 
(Kim et al., 2008; Chemaly et al., 2011; Singh et al., 2018). For further discussion of how 
my findings relate to the previous investigations of how resistin affects the heart see 
Chapter 4. The following discussion will focus on the role of resistin in the EAT 
secretome. 
5.5.1 Relation to EAT-myocardium signalling relationship 
Previously, we found that β3-adrenergic-stimulated human EAT secretome triggers 
spontaneous contractions in human atrial myocardium (Babakr et al., 2020). These findings 
suggested that EAT-derived factors affect cardiac rhythmicity and illustrate the 
arrhythmogenic potential of the EAT-myocardium paracrine/vasocrine signalling 
relationship (Yudkin et al., 2005; Sacks & Fain, 2007). Without characterising the EAT 
secretome, I hypothesised that EAT-derived, resistin, would play a role in the pro-
arrhythmic effect due to its association with AF. I found that EAT releases resistin; 
however, the amount of resistin released was not altered by β3-adrenergic stimulation. 
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When combined with the ineffectiveness of resistin to induce spontaneous contractions, my 
results suggest that resistin, at least under my conditions, does not contribute to arrhythmias 
triggered by the EAT secretome.  
Our previous investigation also revealed that the EAT secretome induces a positive 
inotropic effect (Babakr et al., 2020). I now show that resistin also increases the 
contractility of human atrial trabeculae. This was paralleled by a reduction in the PPP 
capacity, which indirectly suggests an increased SR Ca2+ leak (Ravens et al., 1997; Lebek 
et al., 2018). Therefore, my findings suggest that paracrine/vasocrine signalling of EAT-
derived resistin could directly alter cardiomyocyte Ca2+-handling, leading to a change in 
contractility. They also suggest that EAT-derived resistin could contribute to other 
components of arrhythmogenesis, such as alterations in myocardial conduction properties 
that promote re-entry arrhythmias. Furthermore, the paracrine resistin signalling 
relationship between EAT and the myocardium could compound the deterioration in Ca2+-
handling, fibrosis, and hypertrophy that begets arrhythmia development and maintenance. 
5.5.1.1 Other considerations 
Further considerations are required when appreciating the clinical and 
pathophysiological associations of resistin and EAT-derived resistin with CVD. Firstly, the 
release of resistin is not specific to EAT as all adipose tissues synthesise the adipocytokine 
(Fain et al., 2003; Jamaluddin et al., 2012). Thus, the clinical associations of plasma resistin 
levels with CVD could be indicative of increased resistin release from other adipose depots. 
As mentioned earlier, EAT typically comprises ~1% of all body fat (Rabkin, 2007); 
therefore, it is unlikely that excessive secretion of resistin by EAT contributes significantly 
to systemic plasma levels. Further study is required to determine the associations between 
EAT expression of resistin, EAT secretion of resistin, and the levels of resistin in the 
systemic and coronary circulations. Such correlations have been drawn for the EAT-
derived adrenomedullin and adiponectin where EAT expression levels parallel intra-
coronary levels (Iacobellis et al., 2009a; Iacobellis et al., 2009b; Teijeira-Fernandez et al., 
2011).  
A second consideration when interpreting my results relates to the source of resistin 
within EAT. Study of SAT and VAT depots shows that ~99% of resistin secretion comes 
from non-fat cells (i.e., immune cells) (Fain et al., 2003). Similarly, immunohistochemical 
analysis of EAT from patients with CAD has revealed co-localisation of resistin with 




factors like adiponectin and leptin, it appears that resistin is not derived from EAT 
adipocytes but rather from immune cells within the tissue. Because of this, investigation of 
the relationship between microscopic EAT morphology and resistin secretion will be better 
suited to analysis of the stromal vascular fraction of EAT instead of the adipocyte size. This 
is especially relevant in AF research where macrophage infiltration and a hyper-
inflammatory EAT secretome have been implicated in myocardial and interstitial EAT 
fibrosis and atrial conduction abnormalities (Haemers et al., 2015; Abe et al., 2018; Nalliah 
et al., 2019).  
5.5.2 Summary 
The pro-arrhythmic effect of the stimulated EAT secretome is not caused by 
increased release of resistin from EAT. Resistin does, however, acutely enhance 
myocardial contractility, suggesting a direct paracrine link between EAT and the 
myocardium. Further study is required to determine how changes in microscopic EAT 
morphology relate to changes in EAT secretion of resistin.  
5.6 Limitations 
My studies of human EAT were limited in several key aspects, most of which have 
been discussed in the experimental chapters. An overarching limitation when investigating 
microscopic EAT morphology in obesity is the inability to perform longitudinal studies. 
Unlike SAT depots, serial sampling of EAT in humans is not feasible, thus assessing EAT 
adipocyte morphological changes over time cannot be done. Longitudinal study of SAT 
adipocytes has confirmed that increases in adipocyte size that occur with over-feeding 
correlate with increases in the comprising adipose volume (Tchoukalova et al., 2010b). A 
potential strategy for circumventing this limitation could be to use adipocytes from readily 
accessible depots as a proxy for EAT adipocytes. This would require a tight correlation to 
exist between EAT adipocytes and the accessible adipocytes. Post hoc analysis of Chapter 
2 indicates a modest correlation exists between EAT adipocyte size and PAT and AAT 
adipocyte sizes, while there was no correlation with SAT adipocyte size (Figure 5.4). This 
suggests that PAT and AAT adipocytes could be measured to reflect EAT adipocytes; 
however, procurement of these tissues also requires invasive procedures. Therefore, study 
of human EAT adipocyte morphology will be limited to cross-sectional study for the 
foreseeable future. 




Figure 5.4. Correlations of epicardial adipose tissue (EAT) adipocyte size with adipocytes from 
other depots. EAT adipocyte size correlated against subcutaneous clavicular (SAT), paracardial 
(PAT), and appendix adipose tissue (AAT) adipocyte sizes. N = 43 post-mortem cases for each 
correlation. Data generated from post hoc analysis of Chapter 3. 
 
A second limitation is the use of BMI as a measure of obesity. EAT thickness is 
best predicted firstly by measures of VAT volume, followed by WC, then BMI (Iacobellis 
et al., 2003b). For both cohorts used in this thesis, neither VAT volume nor WC were 
available to us; therefore, BMI was used. Importantly, in each of my studies several well-
established associations were recapitulated, including the positive association of BMI with 
SAT adipocyte size (Chapter 2) and with EAT thickness (Chapter 3). By corroborating 
these findings, I retained confidence in my use of BMI as an obesity measure, despite its 
weakness relative to other indices.   
Another limitation is the methodology of adipocyte size measurement. Three 
primary methods of adipocyte size measurement are performed: (1) measurement after 
collagenase digestion, (2) osmium tetroxide fixation and automated measurement, and (3) 
manual measurement of histological sections (Laforest et al., 2017). Techniques (1) and 
(2) allow for measurement of more cells as greater cell dissociation occurs, which generates 
bi- or tri-modal size frequency distributions. In contrast, technique (3), as I have used, 
counts fewer cells and utilises several assumptions. This includes assuming that cell 
distribution within the histological section is uniform throughout the entire adipose tissue. 
Additionally, it assumes that the measured adipocytes are showing their largest diameter; 
although, this might not be true as the adipocytes are not dissociated and thus not always 




that key correlations of fat cell size are retained regardless of technique, including the 
positive association with BMI (Laforest et al., 2017).  
5.7 Future directions 
In light of these limitations, several lines of future research emerge. With regard to 
longitudinal assessment of EAT adipocyte morphology, exploration and/or development of 
animal models that natively produce EAT should be undertaken. Currently, rodent models 
are not used due to the inability to differentiate EAT from PAT. Sheep models of AF have 
been used previously to demonstrate the association of EAT deposition with atrial 
conduction abnormalities (Mahajan et al., 2015). Future studies could utilise such large 
animal models at different stages of a long-term study to assess longitudinal changes in 
EAT adipocyte morphology. 
With regard to assessment of EAT hyperplasia in obesity, osmium tetroxide fixation 
and automated measurement should be utilised. Firstly, this will generate a multi-modal 
cell size frequency distribution and determination of ‘small’ and ‘large’ adipocytes as 
described above. Secondly, as this technique is used in more thoroughly researched adipose 
depots, the contextualising of EAT within the framework of adipose biology can be 
improved. When combined with measurement of genetic EAT adipogenesis and 
hyperplasia markers, this will provide an assessment of adipocyte hyperplasia that matches 
standards used in other depots. 
Continued collection of EAT adipocyte data will enhance the sensitivity of 
statistical analyses that can be utilised. From my studies, multivariate models adjusted for 
variables that shared univariate correlations with BMI or EAT thickness and for classical 
confounding factors. With a growing sample size, more variables can be included in 
multivariate models, thereby controlling for confounding more appropriately. Furthermore, 
novel associations of EAT adipocyte morphology can be explored with appropriate 
statistical power. This could include determining ethnicity- or gender-specific properties of 
EAT adipocytes and the remodelling in disease. Moreover, when these relationships 
between EAT adipocyte morphology and key anthropometric indices have been determined 
they can be applied appropriately to multivariate models investigating specific CVDs. 
Future research of the EAT secretome will require proteomic analysis to determine 
which EAT-derived factors are upregulated in different disease conditions. Such analysis 
has been undertaken for the EAT secretome in CAD (Langheim et al., 2010). Analogous 
proteomic profiling is required to determine how the EAT secretome changes in AF 
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patients. Then, instead of using a simplistic methodology like that in Chapter 4, specific 
EAT-derived factors could be targeted using neutralising antibodies while part of the total 
EAT secretome. This method was used previously to show that the EAT-derived adipokine, 
activin A, partially mediates the inotropic effect of the secretome (Greulich et al., 2012).  
5.8 Conclusions 
In this thesis I found that EAT expansion in obesity is not associated with EAT 
adipocyte hypertrophy. This absence of cell hypertrophy paints EAT adipocytes in a unique 
light by suggesting that cell hyperplasia might underlie EAT expansion. By determining 
this feature of microscopic EAT morphology I have established a starting point for future 
pre-clinical research of EAT and how the fat depot contributes to cardio-metabolic disease 
development. I also found that resistin acutely alters myocardial contractility, thereby 
supporting the hypothesis of paracrine/vasocrine signalling between EAT and the heart in 
the pathogenesis of CVD. Resistin does not promote arrhythmic contractions in human 
atrial myocardium, indicating that EAT-derived resistin does not play a role in driving the 
arrhythmias associated with EAT. This study also provides a starting point for future 
research of the EAT secretome and for resistin. Continued study of the EAT-myocardium 
signalling relationship will provide pathophysiological insights into the associations of 
EAT with arrhythmias and other CVDs.  
5.9 Bridging Parts one & two of the thesis 
Part one of this thesis was an investigation of EAT anatomy and function. I show 
that EAT adipocyte hypertrophy does not underlie the expansion of macroscopic EAT 
deposition in obesity (Aitken-Buck et al., 2019a; Aitken-Buck et al., 2019b). I also show 
in Chapter 4 that the EAT-derived adipocytokine, resistin, can directly affect the 
contractile function of human atrial myocardium (Aitken-Buck et al., 2020a). The latter 
was an investigation of the paracrine signalling relationship between EAT and the 
myocardium and how this relationship facilitates arrhythmogenesis and inotropy. My 
findings suggest that EAT-derived resistin might influence cardiac contractility. My 
findings also suggest, however, that resistin released by EAT does not underlie the 
arrhythmogenic effect of the EAT secretome.  
An important caveat of our previous work (Babakr et al., 2020) is that the EAT 
secretome elicited a pro-arrhythmic effect only when it was stimulated with a β3-adrenergic 




(Lopaschuk et al., 2010). Therefore, for the follow up investigations it was pertinent to 
determine the role of known EAT-derived fatty acid metabolites in the development of 
arrhythmias and inotropy. For this thesis, the candidate fat metabolites I investigated were 
long-chain acylcarnitines (LCACs) (McCoin et al., 2015). The metabolome of EAT has not 
been comprehensively studied. However, our pilot data shows that cultured EAT secretes 
several LCAC species (Figure 5.5). Furthermore, the levels of LCAC within the EAT 
secretome are not dissimilar to the levels measured in the plasma.  
As detailed in the following sections, LCACs are long-known to directly promote 
arrhythmogenic electrical derangement and inotropic modulation in the mammalian 
myocardium (Aitken-Buck et al., 2020b). Additionally, circulating levels of particular 
LCAC species have been associated with important CVDs, including heart failure (Ahmad 
et al., 2016; Hunter et al., 2016) and atrial fibrillation (Harskamp et al., 2019; Smith et al., 
2020). Therefore, LCACs are a novel target for pre-clinical research in the context of the 
EAT secretome, but are well-established in pre-clinical, translational, and clinical aspects 
of arrhythmias and contractility. For this reason, LCACs present a logical choice for 
investigation in the context of EAT. 
 
Figure 5.5. Human epicardial adipose tissue (EAT) releases long-chain acylcarnitines (LCACs). 
A, EAT procured from cardiac surgery patients was cultured for 24 hours before the cultured 
EAT media was analysed by mass spectrometry to determine the relative concentrations of 
LCACs 16:0 and 18:1. B, Absolute concentrations of LCAC 16:0 in the plasma (Bi) of cardiac 
surgery patients and in the EAT secretome (Bii). C, Absolute concentrations of LCAC 18:1 in 




Introduction to Long-Chain Acylcarnitines 
LCACs are intermediates of oxidative metabolism that have been clinically 
implicated in numerous CVDs and cardio-toxic fatty acid oxidation disorders (FAODs) 
(Chace et al., 2001; McHugh et al., 2011; Ruiz‐Canela et al., 2017). In addition to these 
clinical associations, LCACs are long-known to affect the function of the mammalian 
myocardium in a manner that modulates contractility and enhances arrhythmia 
susceptibility (Corr et al., 1984; DaTorre et al., 1991). A pleiotropy of direct LCAC effects 
on cardiac excitation-contraction coupling (ECC) and ion-handling have been 
hypothesised; however, several key limitations remain in the understanding the LCAC-
myocardial interaction. These details will be discussed in the following sections. 
6.1 LCAC biogenesis 
LCACs are the product of carnitine O-palmitoyltransferase (CPT) I-catalysed long-
chain fatty acyl CoA (LCFA-CoA) esterification to a free carnitine molecule; a process that 
occurs at the outer mitochondrial membrane (Figure 6.1) (Reuter & Evans, 2012; McCoin 
et al., 2015). LCACs are shuttled across the mitochondrial membranes by the carnitine-
acylcarnitine translocase (CACT) and into the matrix where the esterification process is 
retroconverted by CPTII, thus yielding a free carnitine and LCFA-CoA that can enter β-
oxidation. Both CPTII and CACT are bi-directionally catalytic, meaning that LCACs can 
be generated within the mitochondria and exported into the cytosol and the circulation 
(Noland et al., 2009; Makrecka-Kuka et al., 2017). Cardiac muscle has a relatively high 
LCAC content due to the preference of LCFAs for oxidative metabolism (Lopaschuk et al., 
2010; Makrecka-Kuka et al., 2017). Furthermore, myocardial LCAC content is positively 
correlated to plasma LCAC concentrations – a feature that remains proportional during 
metabolic challenge and in CVD (Lai et al., 2014; Makrecka et al., 2014; Makrecka-Kuka 
et al., 2017). LCAC nomenclature is defined by the length of the LCFA chain length and 
by the presence/number of double bonds along the chain (Figure 6.1). This thesis has a 
particular focus on LCACs 16:0 and 18:1, which have 16 and 18 carbon acyl chains with 0 






Figure 6.1. Long-chain acylcarnitine (LCAC) structure and biogenesis. A, chemical structure of 
LCACs. Structure is specific to LCAC 18:1 (oleoylcarnitine); however, general structure and 
nomenclature is common to all LCACs. Indicated within figure: a, fatty acyl group (number of 
carbons in chain denotes LCAC length (i.e., 18); b, double bond of acyl group (number of double 
bonds denoted in nomenclature as :1, :2, etc.); c, (within box), L-carnitine protein to which acyl 
group is esterified. B, LCACs are the product of long-chain fatty acyl-CoA (LCFA-CoA) 
esterification to a free cytosolic carnitine, which is catalysed by carnitine O-palmitoyltransferase 
I (CPTI) at the outer mitochondrial membrane (OMM). LCAC translocation across the inner 
mitochondrial membrane (IMM) and into the mitochondrial matrix occurs via the action of 
carnitine acylcarnitine translocase (CACT). Once in the matrix, the LCAC genesis reaction is 
reversed by CPTII to yield the constituent LCFA-CoA and carnitine. The LCFA-CoA can then 
continue to oxidative metabolism via β-oxidation. Note, that the reactions of CPTII and CACT 
are bi-directionally catalytic and cytosolic LCACs can be exported, presumably via a member of 
the solute carrier family (SLC). 
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6.2 Metabolomic associations with CVD 
A growing body of evidence has associated circulating LCACs with CVD risk 
(Table 6.1). Plasma/serum LCAC levels have been independently associated with HF, 
CAD, and AF (Shah et al., 2010; Shah et al., 2012; Zordoky et al., 2015; Ahmad et al., 
2016; Hunter et al., 2016; Lanfear et al., 2017; Luo et al., 2017; Ruiz et al., 2017; Harskamp 
et al., 2019; Verdonschot et al., 2019; Smith et al., 2020). Many of these associations are 
proportional to disease severity and are evident in CVDs with both ischaemic and non-
ischaemic aetiologies (Zordoky et al., 2015; Ahmad et al., 2016; Hunter et al., 2016; 
Lanfear et al., 2017; Ruiz et al., 2017; Verdonschot et al., 2019). Importantly, the 
associations of circulating LCACs with CVD are maintained when adjusted for standard 
predictors, including age, sex, BMI, and N-terminal pro b-type natriuretic peptide (Zordoky 
et al., 2015; Hunter et al., 2016; Ruiz et al., 2017; Lanfear et al., 2017). In addition, 
inclusion of LCAC levels in hazard modelling of CVD risk alongside classical predictors 
significantly strengthens diagnostic sensitivity (Lanfear et al., 2017). In addition to CVD 
diagnosis, LCAC levels have been positively correlated with LV mass and negatively with 
LV ejection fraction (Elmariah et al., 2018). From a prognostic perspective, circulating 
LCAC levels are predictive of hospitalisation and survival in HF cohorts (Kalim et al., 
2013; Ahmad et al., 2016; Lanfear et al., 2017). Furthermore, LCAC levels elevated in 
CVD have been found to normalise following surgical intervention (Ahmad et al., 2016; 
Elmariah et al., 2018). The association of circulating LCACs with cardiac arrhythmias is 
relatively under-researched. However, recent studies have found that plasma LCAC 16:0 
and 18:1 levels are independently predictive of incident AF risk in large patient cohorts, 
even after adjustment of classical risk factors (Harskamp et al., 2019; Smith et al., 2020). 
This is recapitulated in preliminary findings from our group, whereby serum LCAC levels 
have been associated with risk of persistent AF in European (Krause et al., 2018) and New 





Table 6.1. Metabolomic associations of LCACs with cardiovascular disease. 
Author Year N LCACs Notes 





Patient samples from CATHGEN 
Biorepository. First to show metabolite 
profiles are associated with CVD. 
Shah 2012 Cases: 2039 
C16:0, C16:1, 
C18:0, C18:1 
Samples from CATHGEN Biorepository. 
First to show LCAC-CVD associations 







Samples from Alberta HEART Study. 
Showed that plasma LCACs in HFpEF > 






Samples from CATHGEN Biorepository. 
Showed that plasma LCACs in HFrEF > 
HFpEF > no HF in a large cohort. 
Ahmad 2016 Cases: 494 
C16:0, C18:0, 
C18:1 
Samples from HF-ACTION Study. 
Showed LCAC levels are > End-stage HF 
vs. chronic HF. First to show that LCAC 





Samples from HFHF registry. First to 
show plasma LCACs correlated to patient 
information, NYHA class, and 6MWD. 
Verdonschot 2020 Cases: 273 C16:0, C18:1 







Samples from European BiomarCaRE 
consortium. First to show association of 





Samples from CATHGEN Biorepository. 
First original article detailing LCAC 





Samples from Malmö Diet and Cancer 





Samples from HeartOtago biorepository, 
comprising NZ surgery patients. 
All authors et al. Notes column indicates clinical study data gathered from and/or novel findings 
from the study. Abbreviations: N = total sample size(s); LCACs = long-chain acylcarnitines 
implicated in the study; HF = heart failure; EF = ejection fraction; LV = left ventricle; HFpEF = 
HF with preserved EF; HFrEF = HF with reduced EF; LVAD = LV assist device; NYHA = New 
York Heart Association classification; 6MWD = 6-minute walking distance; DCM = dilated 
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6.2.1 Quantification of circulating LCACs in health and disease 
Normal circulating LCAC concentrations vary depending on LCAC species. All 
LCAC species concentrations are < 1 µM and the most consistently abundant individual 
species are LCAC 16:0 (0.08-0.13 µM) and LCAC 18:1 (0.09-0.34 µM) (see Table 6.2 for 
references). Circulating LCAC levels are influenced by several variables; therefore, 
absolute species concentrations vary between studies (Makrecka-Kuka et al., 2017). 
Furthermore, calculation of total blood LCACs is dependent on how many species are 
measured and whether hydroxylated forms are included. Metabolomic association studies 
that report absolute LCAC 16:0 and 18:1 plasma concentration are presented in Table 6.3. 
HF patients have a ~1.4-fold increase in absolute circulating LCAC levels; however, the 
individual species concentrations in diseased patients remains < 1 µM (Zordoky et al., 
2015; Ahmad et al., 2016; Hunter et al., 2016). This is also found in our own HeartOtago 
AF patient cohort (e.g., LCAC 18:1 = 0.20 µM vs. 0.26 µM in controls and AF, 
respectively) (unpublished observations). Multi-micromolar increases in plasma LCAC 
18:1 have been reported in end-stage renal disease (ESRD) patients with CVD relative to 
non-diseased controls (2.70 µM vs. 0.34 µM) (Kalim et al., 2013). Dramatically increased 
LCAC levels are found in patients with certain FAODs that manifest with cardiac 
mechanical and electrical defects (Chace et al., 2001; McHugh et al., 2011). Dried blood 
specimens sourced as part of pre- or post-mortem CPTII or CACT deficiency diagnoses 
reveal that LCAC 16:0 and 18:1 can reach values of 44 µM and 21 µM, respectively (Chace 
et al., 2001; McHugh et al., 2011). Similar marked fold-increases in LCACs have been 
reported in the plasma of CPT deficient cases (Isackson et al., 2008).  
Table 6.2. Circulating LCAC concentration range from human control cohorts. 
LCAC Name Normal (µM) References 
C14:0 Myristoylcarnitine 0.02-0.22 1,2,4,9 
C14:1 Tetradecenoylcarnitine 0.01-0.11 1,2,8,9 
C16:0 Palmitoylcarnitine 0.08-0.13 1,2,4,5,6,9 
C16:1 Palmitoeoylcarnitine 0.02-0.08 2,8,9 
C18:0 Stearoylcarnitine 0.04-0.07 1,2,5,6,8,9 
C18:1 Oleoylcarnitine 0.09-0.34 1-9 
C18:2 Linoleoylcarnitine 0.03-0.20 1,2,4,5,6,8,9 
*Approx. total concentration range 0.31-1.24  
1Costa et al., 1997, 2Reuter et al., 2005, 3Kalim et al., 2005, 4Zordoky et al., 2015, 5Ahmad et al., 






Circulating LCAC profiles are associated with HF, CAD, AF, and total CVD risk. 
The upregulation in LCACs is proportional to disease severity and is predictive of 
hospitalisation and mortality. LCAC species circulate at concentrations < 1 µM under 
normal conditions and do not typically increase beyond 1 µM in CVDs. However, in ESRD 
and FAODs adjacent to CVDs, individual LCAC levels can increase dramatically, resulting 
in multi-micromolar concentrations. The following sections detail what is understood about 
the pathophysiological effects of LCACs on cardiac electrophysiology and contractility. 
Table 6.3. Absolute circulating LCAC concentrations in human disease (µM). 
Author Year Sample Disease C16:0 C18:1 
Cardiovascular disease (CVD) 
Zordoky 2015 Serum HF 0.14 (1.2) 0.20 (1.4) 
Ahmad* 2016 Plasma HF 0.11 (1.4) 0.18 (1.5) 
Hunter 2016 Plasma HF 0.10 (1.3) 0.19 (1.2) 
HeartOtago UP Plasma AF 0.16 (1.2) 0.26 (1.3) 
Renal disease 
Kalim 2013 Plasma ESRD  2.70 (7.9) 
Reuter 2005 Plasma ESRD 0.35 (3.9) 0.51 (5.7) 




CPTIIdef 9.6 (14)  
Isackson 2011 Plasma 
CPTdef 39.7 (360) 19.0 (158) 
CPTdef 15.6 (141) 32.1 (268) 




CACTdef 31.0 (38) 6.80 (14) 
CPTIIdef 44.0 (55) 21.0 (43) 
Data are absolute LCAC concentrations with fold-change from respective control values in 
parentheses. HF = heart failure (HFrEF), AF = atrial fibrillation, ESRD = end-stage renal 
disease, CPTIIdef = carnitine O-palmitoyltransferase II deficiency, CACTdef = carnitine 
acylcarnitine translocase deficiency, UP = unpublished. Note, values from FAODs were 
measured in neonates or infants presenting with systemic organ dysfunction, including severe 
cardiovascular defects (cardiomegaly, tachyarrhythmias, conduction blocks). *Ahmad, values 
are that measured in end-stage HF and fold-change is relative to patients with chronic HF. 
§McHugh, values are of the most extreme (99th percentile) of cases and fold-change is relative 
to 99th percentile ‘normal’ cases. 
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6.3 LCAC effects on electrophysiology and arrhythmias 
Complementing these clinical findings is literature detailing the effects of LCACs 
on cardiac function. In contrast with the modernity of CVD metabolomics, much of the 
translatable research is age-old and based in animal models. LCAC exposure has been 
reported to alter cardiac electrophysiological and arrhythmia susceptibility stereotypically 
(Corr et al., 1984; DaTorre et al., 1991). As shown in Figure 6.2, this includes reductions 
in the amplitude and duration of cardiac action potentials (APA and APD, respectively), as 
well as a decreased rate of depolarization (Vmax of phase 0) and, often, a depolarization of 
the resting membrane potential (RMP). Furthermore, these alterations can establish a 
substrate for electrical arrhythmias (Knabb et al., 1986; Corr et al., 1989; Sakata et al., 
1989; Meszaros & Pappano, 1990). 
 
Figure 6.2. Long-chain acylcarnitine (LCAC) effects of electrophysiology and arrhythmia. A, 
LCACs stereotypically alter the cardiac action potential (AP). Normal ventricular AP schematic 
represented in black, LCAC-altered AP in red hatched line. Characteristic effects of LCACs 
include reductions in AP duration (APD), amplitude (APA), the maximal rate of depolarisation 
(Vmax), and a depolarisation of the resting membrane potential (RMP). These AP alterations 
predispose cardiac muscle to arrhythmias. B, induction of early- and delayed afterdepolarisations 
(EADs, DADs) following LCAC superfusion of guinea pig ventricular cardiomyocytes. Trace 
reproduced from (Wu & Corr, 1992) (Am J Physiol – Heart Circ Physiol 32). C, representative 
trace from echocardiogram implanted in a mouse model infused with 10 µM LCAC. Relative to 
control trace, observable electrical arrhythmia occurs with LCAC infusion, notable are premature 





6.3.1 Endogenous LCAC upregulation 
Relative to normoxic conditions, total LCAC content has been found to increase 3- 
to 70-fold in the ischaemic mammalian myocardium depending on the myocardial 
compartment and hypoxia duration/severity (Idell-Wenger et al., 1978; Liedtke et al., 1978; 
Knabb et al., 1986; Corr et al., 1989; McHowat et al., 1993). Ischemia acutely (within 
minutes) reduces the APA and APD, Vmax, and RMP of mammalian cardiomyocytes, 
leading to a predisposition for ventricular complexes and fibrillations (Corr et al., 1978; 
Pogwizd & Corr, 1987). In ischaemic muscle preparations, pre-hypoxic treatment with 
sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) or oxfenicine, both 
inhibitors of CPTI, prevents membrane and cytosolic LCAC accumulation in early 
ischaemia and the genesis of electrophysiological derangements (Knabb et al., 1986; Corr 
et al., 1989; Yamada et al., 1994). These early reports therefore implicate endogenous 
LCAC upregulation in early ischaemic arrhythmogenesis. Interestingly, many have 
reported a reversibility of LCAC-mediated effects in ischaemia following normoxic 
reperfusion, suggesting direct enzymatic or ionic modulation by LCACs (Corr et al., 1989).  
6.3.2 Exogenous LCAC treatment 
Exogenous LCAC application has also been found to reduce the APA, APD, Vmax, 
and RMP across a large range of doses (1-300 µM), mammalian species (canine, guinea 
pig, rabbit), and with an effect latency analogous to that found in the ischaemic 
myocardium (2-10 minutes). Additionally, as with endogenous LCAC upregulation, 
exogenous LCAC delivery induces spontaneous electrical and mechanical arrhythmias, 
while also reducing gap junction conductance (see Figure 6.2) (Hayashi et al., 1982; 
Nakaya & Tohse, 1986; Aomine et al., 1988; Sakata et al., 1989; Meszaros & Pappano, 
1990; Mèszàros, 1991; Wu & Corr, 1992; Sato et al., 1993; Wu & Corr, 1994; Shen & 
Pappano, 1995; Wu & Corr, 1995; Roussel et al., 2015). The effects of exogenous LCAC 
treatment are reversible with LCAC wash out; although, this is more common at lower 
doses, presumably due to detergent-like effects at high LCAC doses (Nakaya & Tohse, 
1986; Busselen et al., 1988; Sakata et al., 1989). Others have reported less straight-forward 
LCAC effects. LCAC superfusion at a 1-10 µM range has been shown to increase the APD 
in guinea pig cardiomyocytes (Meszaros & Pappano, 1990; Xu & Rozanski, 1998); 
however, the effect was biphasic, progressing to an eventual APD decrease within 15-
minutes of treatment (Meszaros & Pappano, 1990).   




In summary, whether endogenously upregulated or applied exogenously, LCACs 
dose- and time-dependently alter cardiac electrophysiology and promote arrhythmic 
muscle behaviour. LCAC exposure depolarises the RMP, decreases the Vmax, and retards 
the APA and APD, while promoting muscle electrical automaticity and conduction deficits 
(Corr et al., 1984; DaTorre et al., 1991). These effects are reversible with LCAC wash out, 
suggesting a direct LCAC effect on the myocardium and not a general detergent-like effect. 
6.4 LCAC effects on contractility 
In addition to acute electrophysiological derangements induced by LCAC exposure, 
LCACs are also reported to affect myocardial contractility. However, the direction of 
inotropic modulation induced by LCACs is inconclusive (Figure 6.3). 
6.4.1 Positive inotropy 
Many have reported a positive inotropic effect, with exogenous LCAC 
concentrations as low as 1-10 µM reported to increase guinea pig papillary muscle tension 
by 15% to 100% dose-dependently (Clarke et al., 1996). Higher LCAC doses (30-300 µM), 
which are sufficient to induce electrical automaticity, augment this positive contractility 
effect to ~200% and ~600% of pre-exposure levels (Nakaya & Tohse, 1986; Aomine et al., 
1988; Sakata et al., 1989; Clarke et al., 1996). LCAC superfusion has been found to 
increase isolated guinea pig myocyte shortening by 47% and 100% when administered at 
1 µM and 3 µM doses, respectively (Shen & Pappano, 1995). Additionally, positive 
inotropy has been reported in avian ventricular muscle strip and beating myocyte 
aggregates treated with exogenous LCACs at 2-300 µM concentrations, indicating the 
effect has some consistency across species (Inoue & Pappano, 1983; Patmore et al., 1989). 
The latency of these positive contractility effects is inversely related to LCAC 
concentration. Inotropic modulations of multicellular preparations typically manifest 
within 10-20 minutes at higher exogenous doses (100-300 µM), while lower doses (1-30 
µM) require relatively longer exposure durations ranging from 30-120 minutes (Inoue & 
Pappano, 1983; Nakaya & Tohse, 1986; Aomine et al., 1988; Sakata et al., 1989; Clarke et 
al., 1996). At equivalent lower doses, inotropic latency is reduced in isolated myocytes and 
myocyte aggregates (Patmore et al., 1989; Shen & Pappano, 1995), most likely due to a 





Figure 6.3. Long-chain acylcarnitine (LCAC) effects on cardiac contractility. LCAC effects on 
cardiac contractility are controversial. A positive inotropic effect has been reported by some (A); 
however, this appears to be limited to investigations of multicellular preparations, such as guinea 
pig papillary muscles (schematic Aa). A representative developed force trace from a papillary 
muscle is shown in Ab, which highlights the increase in contractility and reversal of effect with 
wash out of the LCAC. Trace derived from Sakata et al., 1989 (Cardiovasc Res 23). Ac, dose- 
and time-dependency of exogenous LCAC effect on papillary muscle contractility. Redrawn 
from Clarke et al., 1996 (J Mol Cell Cardiol 28). Others have shown a negative inotropic effect 
of LCACs (B); although almost exclusively in Langendorff-perfused rat hearts (intact heart Ba). 
Bb & Bc show time-dependency of deterioration in left ventricular pressures (LVP) at 5 µM and 
10 µM LCAC doses. Redrawn from Hara et al., 1996 (J Pharmacol Exp Therap 279). 
 
6.4.2 Negative inotropy 
Others have provided evidence for a negative inotropic effect of LCACs. 
Exogenous LCAC superfusion at concentrations analogous to those found to increase 
papillary muscle contractility have been found to induce mechanical dysfunction in 
Langendorff-perfused isolated rodent hearts. One group consistently reported that LCAC 
doses as low as 2.5 µM reduces left ventricular systolic pressures (Hara et al., 1996; Xiao 
et al., 1997), while at slightly higher doses (4-10 µM) both systolic and diastolic 
dysfunction is apparent (Hara et al., 1996; Arakawa et al., 1997; Hara et al., 1997; Xiao et 
al., 1997; Arakawa & Hara, 1999; Maruyama et al., 2000). Similarly, a separate group 
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found that LCAC exposure of isolated rat hearts promotes irreversible ventricular 
contracture at a dose range of 1.6 to 9.7 µM (Busselen et al., 1988). A further study utilised 
papillary muscles from rabbits, finding an overall negative inotropic effect following 50 
µM LCAC superfusion (Patel et al., 1999). The latency required for negative inotropy in 
isolated rat hearts is notably reduced relative to the equivalent lower (20-60 minutes for 
negative inotropy) and higher doses (5-15 minutes) that increase papillary muscle 
contractility (Busselen et al., 1988; Criddle et al., 1990; Hara et al., 1996; Arakawa et al., 
1997; Hara et al., 1997; Xiao et al., 1997; Arakawa & Hara, 1999; Wu et al., 2009). 
6.4.3 Biphasic response 
A biphasic inotropic effect has also been reported across a range of LCAC doses, 
species, and tissue preparations. Many have reported a transient increase precedes the 
sustained decline in ventricular pressure of isolated rat or rabbit hearts induced by 4-50 µM 
administration (Hara et al., 1996; Xiao et al., 1997; Patel et al., 1999; Maruyama et al., 
2000). Similarly, positive inotropy induced in guinea pig papillary muscles, canine Purkinje 
fibres, and avian myocyte aggregates by higher LCAC doses (30-300 µM) often exhibits a 
progressive decline in force output following the initial force increase (Nakaya & Tohse, 
1986; Patmore et al., 1989; Sakata et al., 1989; Clarke et al., 1996). 
6.4.4 Summary 
LCACs alter myocardial contractility; however, whether the inotropic effect of the 
acylcarnitine is positive or negative appears to depend on the several factors, including the 
type of myocardial preparation used, the mammalian species, and the LCAC concentration. 
This will be discussed in greater detail later (Chapter 9). Regardless, further study using 
human myocardium is required to adequately translate the unanimous electrophysiological 





6.5 Effect of LCACs on cardiac excitation-contraction coupling 
Cardiomyocyte contractility and electrophysiology, and the induction of 
arrhythmias, is dependent on a paradigm of ion-handling processes known as ECC. LCACs 
have previously been investigated as modulators of many key enzymatic and channel ion 
fluxes. Central to the putative mechanism underlying the effects of LCACs on cardiac 
function is Ca2+ overload within the cardiomyocyte cytosol. How LCACs are proposed to 
alter cardiomyocyte Ca2+-handling will be reviewed in the following sections. Before doing 
so, however, a brief prefacing introduction of the amphiphilic nature of LCACs and their 
proposed membrane perturbing effects is necessary. 
6.5.1 Membrane perturbing effects of LCACs 
The fatty acyl chain of the LCAC compound is hydrophobic and thus readily 
embeds into lipid membranes. This has been reported in artificial lipid bilayers superfused 
with exogenous LCACs (Requero et al., 1995; Anwer et al., 2020) or in ischaemic 
myocardium with endogenous LCAC upregulation (Knabb et al., 1986). LCAC membrane 
incorporation is postulated to affect membrane fluidity in proportion to the LCAC to 
phospholipid mole ratio. Requero et al. found that LCAC membrane saturation eventually 
induces vesicle leakage and complete solubilisation, indicating that LCACs act like 
surfactant compounds within cell membranes that disrupt the packing of adjacent 
phospholipids (Requero et al., 1995). If the incorporation of LCACs into cardiomyocyte 
membranes contributes to the electrophysiological and inotropic effects of LCACs is not 
completely understood and forms part of the basis of this thesis (discussed in greater detail 
in Chapter 9). However, as will now be introduced, LCACs have been proposed to 
modulate the activity of specific ECC ion channels and enzymes. Whether these effects 
occur due to direct protein interactions or as a result of membrane disruption cannot be 
deduced. In the following sections, LCACs are described as altering specific cardiac ECC; 
however, whether the effects on protein function are direct or indirect is unclear and should 
be interpreted as such.  
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6.5.2 Effects of LCACs on cardiac Ca2+-handling 
The key ionic link between cardiomyocyte excitation and contraction is Ca2+. 
Appropriate timing and amplitude of extracellular Ca2+ influx and intracellular Ca2+ release 
determines the rhythmicity of activation and the strength of contraction (Bers, 2002). A 
central mechanistic hypothesis to the effects of LCACs on cardiac function is Ca2+ overload 
within the cardiomyocyte cytosol. This has been shown to be concentration-dependent, as 
well as consistent across species and myocardial preparations (Clarke et al., 1996; 
Netticadan et al., 1999).  
6.5.2.1 Extracellular Ca2+ influx 
The arrhythmic and positive inotropic manifestations of myocardial LCAC 
superfusion have been reported to increase in amplitude and frequency proportionally with 
increases in extracellular Ca2+ concentration (Patmore et al., 1989; Sakata et al., 1989; 
Meszaros & Pappano, 1990). Furthermore, delayed afterdepolarisations (DADs) and 
aftercontractions induced by LCACs are prevented in a low (0.1 mM) Ca2+ superfusion 
medium (Sakata et al., 1989). In Fura-2 loaded rat myocytes, the dose-dependent (5-20 
µM) increase in cytosolic Ca2+ acutely evoked by LCAC superfusion was significantly 
blunted with EGTA chelation of extracellular Ca2+ (Netticadan et al., 1999). These findings 
demonstrate a dependence on extracellular Ca2+. The mechanism of Ca2+ entry, however, 
is less clear. 
L-type Ca2+ channels (LTCCs) facilitate Ca2+ influx during late myocyte 
depolarisation, provoking the Ca2+-induced Ca2+ release (CICR) that sustains the action 
potential plateau and catalyses myofilament interaction (Bodi et al., 2005). LCAC 
superfusion has been found to dose- (1-25 µM) and time- (2-10 minutes) dependently 
reduce current density, as well as activation and inactivation kinetics of LTCCs (Wu & 
Corr, 1992; Liu & Rosenberg, 1996; Ziolo et al., 2001). This inhibitory effect occurs 
regardless of intra- or extracellular LCAC delivery, is completely reversible following 
wash-out, and is consistent across species and preparations (Wu & Corr, 1992; Liu & 
Rosenberg, 1996; Ziolo et al., 2001). A biphasic effect of LCACs on LTCC function has 
been reported, whereby a transient LTCC current and open probability increase occurs at a 
1-10 µM dose; however, this progresses to channel inhibition within 3-minutes of 
incubation (Liu & Rosenberg, 1996). Paradoxically, LTCC inhibition using verapamil or 




accumulation (Netticadan et al., 1999). Furthermore, LCAC superfusion acutely reverses 
the negative inotropic effects of verapamil in a manner resembling that of the LTCC 
agonist, Bay K 8644, suggesting a stimulatory effect of LCACs on channel function 
(Patmore et al., 1989). In contrast, others have found no effect of verapamil on ex vivo 
arrhythmias provoked by LCACs despite an inhibition of arrhythmias in low extracellular 
Ca2+ (Sakata et al., 1989). This discrepancy in reports of LTCC dependence in LCAC-
provoked Ca2+ overload could be due to differences in LCAC and verapamil doses, as well 
as the myocardial preparation used (i.e., isolated myocyte vs. multicellular preparation). 
6.5.2.2 RyR2-mediated Ca2+ release 
Recent work by Roussel et al. has found that 10 µM LCAC superfusion enhances 
the rate of cardiomyocyte SR Ca2+ leak, resulting in reductions in the SR Ca2+ content and 
cytosolic Ca2+ transients. Additionally, this Ca2+ leak enhanced spontaneous Ca2+ spark and 
Ca2+ wave propensity, which was linked to LCAC-mediated in vivo premature ventricular 
complexes (Roussel et al., 2015). These findings support earlier reports of rapid, dose-
dependently enhanced 45Ca2+ release from cardiac and skeletal muscle SR vesicles exposed 
to LCACs (El-Hayek et al., 1993; Dumonteil et al., 1994; Yamada et al., 1994). The direct 
dependence on RyR2-mediated Ca2+ release is controversial. Pre-treatment with low 
micromolar doses (0.1-5 µM) of ryanodine, which depletes SR Ca2+ (Meissner, 1986), 
attenuates the ex vivo arrhythmia incidence and cytosolic Ca2+ accumulation induced by 
LCAC superfusion (Sakata et al., 1989; Meszaros & Pappano, 1990; Netticadan et al., 
1999). In addition, LCACs are reported to dose-dependently enhance [3H]ryanodine 
binding within skeletal muscle SR membranes and increase RyR1 open probability, while 
the spontaneous 45Ca2+ release from these membrane preparations is partially blocked by 
ruthenium red co-treatment (RyR inhibitor) (El-Hayek et al., 1993). Conversely, neither 
ruthenium red nor high micromolar (100 µM) ryanodine, which inhibits RyR2 function 
(Meissner, 1986), affects [3H]ryanodine binding or 45Ca2+ release from cardiac SR vesicles 
induced by LCAC treatment (Yamada et al., 2000). Therefore, there is a common 
dependence on SR Ca2+ release in both skeletal and cardiac muscle; however, the direct 
effect of LCACs on RyR activity differs.  
6.5.2.3 Sarcoplasmic reticulum Ca2+ uptake 
Coupled to the SR Ca2+ release induced by LCAC treatment is a well-established 
inhibition of SERCA2a. Monophasic inhibition of SERCA2a activity has been reported in 
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SR vesicles from canine, rabbit, and rat cardiac tissues at a variable concentration range (Pitts 
et al., 1978; Pitts & Okhuysen, 1984; Dhalla et al., 1991; Yamada et al., 2000). Pitts et al. 
found a half-maximal SERCA2a inhibition at ~20 µM LCAC in canine SR (Pitts et al., 1978), 
which is analogous to the dose-dependent (10-50 µM) inhibition reported by Yamada et al. 
and Dhalla et al. in rabbit and rat SR vesicles, respectively (Dhalla et al., 1991; Yamada et 
al., 2000). Similarly, Dumonteil et al. reported inhibition of SERCA1a in skeletal muscle; 
however, this required a slightly higher LCAC dose range (20-100 µM) (Dumonteil et al., 
1994). Biphasic inhibition of SERCA2a has also been reported. Early work found that lower 
LCAC concentrations (5-50 µM) stimulated SERCA2a activity; however, doses ≥ 50 µM 
induced dose-dependent inhibition of enzyme function (Adams et al., 1979). In isolated rat 
myocytes, pharmacological blockade of SERCA2a with thapsigargin was found to 
significantly attenuate the increase in cytosolic Ca2+ concentration induced by LCAC 
superfusion (Netticadan et al., 1999). Taken together with the dependence on Ca2+ release 
from the SR, regardless of RyR2-dependency, LCACs appear to alter both SR Ca2+ uptake 
and release in a manner that promotes cytosolic Ca2+ overload and can be translated to other 
reports of arrhythmogenic and inotropic effects of LCACs. 
6.5.2.4 Mitochondrial Ca2+ 
As in the sarcolemma and cytosol, mitochondrial LCAC content is increased in 
ischaemia or with exogenous LCAC superfusion (Idell-Wenger et al., 1978; Knabb et al., 
1986). The increased LCAC content is associated with a dose-dependent (5-50 µM) 
decrease in mitochondrial Ca2+ uptake rate and increase in Ca2+ release rate (Wolkowicz & 
McMillin-Wood, 1980; Piper et al., 1984; De Villiers & Lochner, 1986; Baydoun et al., 
1988). The contribution of dysfunctional mitochondrial Ca2+ flux to Ca2+ overload induced 
by LCACs is unknown. Work in isolated mitochondria and Langendorff-perfused rat hearts 
has linked LCAC-mediated dysfunctional mitochondrial Ca2+-handling with a decrease in 
oxidative metabolism and ATP production (Piper et al., 1984; Baydoun et al., 1988; Xiao 
et al., 1997; Hara et al., 1997; Arakawa et al., 1999). Furthermore, inhibition of LCAC 
generation is reported to prevent metabolic deficits in the ischaemic myocardium in parallel 
with normalisation of myocyte electrophysiology and in vivo function (Lopaschuk et al., 
1988; Yamada et al., 1994). These findings suggest a link between mitochondrial Ca2+, 
metabolic inhibition, and cardiac dysfunction during excessive LCAC exposure; however, 
others have reported that action potential alterations induced by LCACs persist with 





The electrical and mechanical alterations to cardiac muscle induced by LCAC 
exposure have been linked to changes in cardiomyocyte Ca2+ handling. Several Ca2+ 
handling proteins have been proposed as targets of LCACs; however, controversy exists 
for each of them. Despite the lack of clarity around the specific proteins affected, there is 
relative consensus that LCAC treatment induces cytosolic Ca2+ overload and SR Ca2+ 
release in cardiomyocytes. As part of addressing the other gaps in the literature (described 
below), this thesis will examine the roles of Ca2+ overload and SR Ca2+ leak in mediating 
the effects of LCACs. In doing so, the roles of cytosolic Ca2+ influx and RyR2-mediated 
Ca2+ release as independent and intertwined mechanisms will be investigated. 
6.6 Limitations of the literature 
A limitation of the reviewed literature is that all research was performed using non-
human models of the mammalian myocardium. Exogenous LCACs affect multiple proteins 
and mechanisms of cardiac ECC, many of which are differentially expressed between 
animal models and/or function with a divergent ionic stoichiometry (Bers, 2002; Milani-
Nejad & Janssen, 2014). Such differences alter the dynamics of ion homeostasis, rendering 
species-specificities in electrophysiology, in inotropic responses to extrinsic stimuli, and in 
arrhythmia susceptibility that limit the translatability of the findings (Milani-Nejad & 
Janssen, 2014). Additionally, there is a dearth of investigation into the effects of LCACs 
on atrial myocardium, which has significantly different Ca2+ propagation, membrane 
distribution, and re-entry susceptibility when compared to ventricular myocardium 
(Gaborit et al., 2007; Grandi et al., 2011; Heijman et al., 2016). A further limitation is that 
much of the literature has focussed on the myocardial action of one LCAC species, 
palmitoylcarnitine (LCAC 16:0), due to its relative abundance in the ischaemic 
myocardium (Idell-Wenger et al., 1978). In turn, the concentration of exogenous LCAC 
16:0 used in many studies is based on measurements of total LCAC content, rather than 
that of the specific LCAC species (see Tables 6.2 & 6.3). Moreover, the concentration of 
exogenous LCACs used greatly exceed those recorded in healthy and CVD patients. 
Evidence suggests there might be differences in ECC mechanism alterations between 
LCAC species and that biphasic electrophysiological and contractile responses occur at 
lower LCAC doses (Meszaros & Pappano, 1990; Liu & Rosenberg, 1996; Ferro et al., 
2012). However, in each case there is an incomplete understanding.   




This review is a collation and summary of basic science investigations into the 
direct effects of LCACs on cardiac function. LCACs induce a pleiotropy of effects on key 
ion-handling processes within the mammalian myocardium, manifesting in stereotypical 
alterations to the cardiac action potential that enhance the propensity for arrhythmic muscle 
activity. These metabolites also alter myocardial contractility; however, whether the effect 
is positively or negatively inotropic is inconclusive. Despite an extensive body of work 
establishing LCACs as effectors of cardiac muscle, several key limitations exist that form 
an incomplete understanding of the role of LCACs on the human heart. The evidence 
presented in this review highlights how these intermediates of metabolism can affect the 
function of the ischaemic and non-ischaemic myocardium and provides a 
pathophysiological context to the growing body of metabolomic implications of LCACs in 





6.8 Aims and objectives of Part two 
Part two of this thesis aims to address fundamental gaps in the understanding of the 
fatty acid metabolites, LCACs, in cardiac pathophysiology. 
Aim Three 
To determine the effect of LCAC 18:1 on the function of human atrial myocardium. 
Objectives for Aim Three 
Determine the effect of LCAC 18:1 on: 
1. The arrhythmia propensity of human atrial myocardium. 
2. The force and kinetic parameters of myocardial contractility. 
Hypothesis for Aim Three 
LCAC 18:1 at high exogenous doses will enhance the propensity for spontaneous 
trabeculae contractions, while concurrently inducing a negative inotropic effect. 
Aim Four 
To determine the effect of LCAC 18:1 on cardiac Ca2+-handling. 
Objectives for Aim Four 
Determine the effect of physiological and pathological levels of: 
1. LCACs 16:0 and 18:1 on membrane perturbation in recombinant HEK293 cells. 
2. LCACs 16:0 and 18:1 on cytosolic Ca2+ handling in recombinant HEK293 cells. 
3. LCACs 16:0 and 18:1 on RyR2-mediated Ca2+ release in recombinant HEK293 
cells. 
Hypothesis for Aim Four 
LCACs 16:0 and 18:1 will induce cytosolic Ca2+ overload in vitro via a disruption of the 
cell membrane that facilitates Ca2+ influx. This effect will be dependent on the LCAC fatty 
acyl chain length. At high exogenous concentrations, LCACs 16:0 and 18:1 will promote 
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LCACs are known to directly alter cardiac contractility and electrophysiology. 
However, the acute effect of LCACs on human cardiac function is unknown. We aimed to 
determine the effect of LCAC 18:1, which has been associated with cardiovascular disease, 
on the contractility and arrhythmia susceptibility of human atrial myocardium. 
Additionally, we aimed to assess how LCAC 18:1 alters Ca2+ influx and spontaneous Ca2+ 
release in vitro. Human right atrial trabeculae (N = 32) stimulated at 1 Hz were treated with 
LCAC 18:1 at a range of concentrations (1-25 µM) for a 45-minute period. Exposure to the 
LCAC induced a dose-dependent positive inotropic effect on myocardial contractility 
(maximal 1.5-fold increase vs. control). At the 25 µM dose (n = 8) this was paralleled by 
an enhanced propensity for spontaneous contractions (50% increase). Furthermore, all 
LCAC 18:1 effects on myocardial function were reversed following LCAC 18:1 wash-out. 
In fluo-4-AM loaded HEK293 cells, LCAC 18:1 dose-dependently increased cytosolic Ca2+ 
influx relative to vehicle controls and the short-chain acylcarnitine C3. In HEK293 cells 
expressing RyR2, this increased Ca2+ influx was linked to an increased propensity for 
RyR2-mediated spontaneous Ca2+ release events. Our study is the first to show that LCAC 
18:1 directly and acutely alters human myocardial function and in vitro Ca2+-handling. The 
metabolite promotes pro-arrhythmic muscle contractions and increases contractility. The 
exploratory findings in vitro suggest that LCAC 18:1 increases pro-arrhythmic RyR2-
mediated spontaneous Ca2+ release propensity. The direct effects of metabolites on human 
myocardial function are essential to understand cardio-metabolic dysfunction. 
7.1 Introduction 
LCACs are amphipathic intermediates of lipid metabolism long-proposed to 
promote electrophysiological and contractile derangements in mammalian cardiac muscle 
(as we and others have recently reviewed (McCoin et al., 2015; Aitken-Buck et al., 2020b). 
In the recent decade, metabolomic studies have identified specific LCACs that are 
upregulated in the plasma of patients with CVD. This includes the LCAC species 18:1 
(oleoylcarnitine), which has been associated with CVDs like non-ischaemic hypertrophic 
and dilated cardiomyopathies, as well as HF and cardio-toxic FAODs (Kalim et al., 2013; 
Lai et al., 2014; Zordoky et al., 2015; Ahmad et al., 2016; Ruiz‐Canela et al., 2017; Ruiz 
et al., 2017; Verdonschot et al., 2019). For many of these clinical associations, the LCAC 
18:1 plasma content is increased proportionally with disease severity and is attenuated with 
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therapy. Despite these associations with CVD risk, it is not known if high circulating levels 
of LCAC 18:1 translates to a direct alteration of human myocardial function. Therefore, 
due to the expanding use of clinical metabolomics it is important to determine if there is a 
direct pathophysiological consequence of elevated LCACs on heart health. 
Previous investigation of exogenous LCAC effects on myocardial function has been 
almost exclusively limited to another LCAC species, LCAC 16:0 (palmitoylcarnitine). 
Acute exposure to LCAC 16:0 has been found to alter the ventricular cardiomyocyte action 
potential profile in a manner that enhances the propensity for spontaneous and DADs and 
in vivo arrhythmias (Corr et al., 1981; Sakata et al., 1989; Meszaros & Pappano, 1990; 
Roussel et al., 2015). Exogenous LCAC 16:0 exposure is also reported to affect myocardial 
contractility. However, whether the LCAC induces a positive or negative inotropic effect 
in the myocardium is inconclusive as both have been widely reported (Aomine et al., 1988; 
Sakata et al., 1989; Criddle et al., 1990; Clarke et al., 1996; Hara et al., 1996; Xiao et al., 
1997; Wu et al., 2009). The limited investigation of LCAC 18:1 suggests that this LCAC 
species alters the action potential profile in HEK293 cells similarly to LCAC 16:0 (Ferro 
et al., 2012). However, any effects on contractility or arrhythmia susceptibility of LCAC 
18:1 have yet to be determined. 
A pleiotropy of effects of LCAC 16:0 have been suggested to underlie the 
electrophysiological and contractile changes (Aitken-Buck et al., 2020b). The best 
characterised of these effects is an alteration of cardiomyocyte Ca2+-handling, which is a 
key determinant of the timing and amplitude of excitability and contractility in the heart 
(Dobrev & Wehrens, 2017). LCAC 16:0 has been found to induce cytosolic Ca2+ overload 
in mammalian ventricular cardiomyocytes via mechanisms dependent on the extracellular 
Ca2+ concentration ([Ca2+]O) and enhanced SR Ca
2+ release (Netticadan et al., 1999; 
Roussel et al., 2015). As such, the amplitude of DADs induced by LCAC 16:0 is 
proportional to the [Ca2+]O, while the electrophysiological derangements are prevented by 
extracellular Ca2+ chelation (Meszaros and Pappano, 1990; Wu and Corr, 1995). Recently, 
LCAC 16:0 has been shown to modify the SR Ca2+ release channel, RyR2, leading to an 
increased propensity for spontaneous RyR2-mediated SR Ca2+ release events and in vivo 
arrhythmia susceptibility (Roussel et al., 2015). Spontaneous RyR2-mediated SR Ca2+ 
release is well-known to occur under conditions of SR Ca2+ overload via a process termed 
store overload-induced Ca2+ release (SOICR) (Jiang et al., 2004). The propensity for 
SOICR can be modelled in recombinant HEK293 cells expressing RyR2, as has been used 




RyR2 mutations on SOICR propensity and therefore to aberrant Ca2+-handling in 
arrhythmogenesis (Jiang et al., 2004; Zhang et al., 2014; Chakraborty et al., 2019).  
For the current study, we aimed to address the hypothesis that LCAC 18:1 at 
exogenous concentrations previously characterized with LCAC 16:0 would acutely induce 
arrhythmia-like contraction propensity in human atrial myocardium and a decrease in 
contractility. Using RyR2-expressing HEK293 cells we also aimed to determine if 
equivalent LCAC 18:1 concentrations enhance the propensity for SOICR. Additionally, we 
sought to assess the role of cytosolic Ca2+ influx in driving LCAC 18:1-mediated SOICR 
in this cell model, as well as the dependence on RyR2 expression. We found that LCAC 
18:1 reversibly enhances the propensity for spontaneous contractions in human atrial 
myocardium, while concurrently inducing a modest positive inotropic effect. In vitro, this 
was linked to an increase in Ca2+ influx that provided the driving force an increased 
propensity for RyR2-mediated SOICR. 
7.2 Materials and Methods 
7.2.1 Patients 
RAAs were collected from consenting patients undergoing elective cardiac surgery 
(N = 32) at Dunedin Hospital, New Zealand in accordance with the use of human tissue 
outlined by the local ethics board (#LRS12-01-001AM1-AM13) and the Declaration of 
Helsinki. Surgery types included CABG surgery, as well as atrial and/or mitral valve 
replacements. Pre-operative patient characteristics, including anthropometric, biochemical, 
haemodynamic, and echocardiographic information was accessible for our study (Table 
7.1). Exclusion of patient tissue was determined prospectively when available, or 
retrospectively based on a low ejection fraction (< 45 %) or any form of pre-operative AF. 
7.2.2 Atrial myocardium samples 
As we have described previously (Babakr et al., 2020; Aitken-Buck et al., 2020a), 
prior to the initiation of cardiac bypass, RAA of each patient was excised and collected in 
a low Ca2+ (0.5 mM), ice-cold arresting KHB containing (in mM): 118.5 NaCl, 4.5 KCl, 
1.0 MgCl26H2O, 0.33 NaH2PO4, 25 NaHCO3, 11 glucose, and 25 2,3-butanedione 
monoxime (BDM) (bubbled adequately with carbogen [95% O2 + 5% CO2], pH 7.4). 
Within 5-10 minutes, the excised RAA was transferred to a dissection stage and submerged 
in fresh ice-cold arresting KHB (components as above). 
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7.2.3 Trabecula dissection and stimulation 
From each patient a thin (assessed by fitted micrometer eyepiece), linear, non-
branching trabecula was isolated and mounted in a custom-built (2.5 mL volume) single-
channel organ bath (SI Heidelberg, World Precision Instruments, Heidelberg, Germany). 
The trabeculae were immersed in and superfused with pre-warmed (37 °C) 1.5 mM Ca2+ 
KHB (components as above without BDM). Isometric contraction was induced using a 
Grass Stimulator that delivered biphasic, suprathreshold 5 ms stimuli at 1 Hz via paired 
horizontal platinum electrodes. Trabecula force output was measured using a force 
transducer (SI Heidelberg, World Precision Instruments, Heidelberg, Germany), then 
amplified, integrated and displayed using AD Instruments hardware (PowerLab 4/26, AD 
Instruments, NZ) and software (LabChart 8©, AD Instruments, NZ). Once stimulated 
successfully, each trabecula was stabilised for 45-60 minutes, or until steady-state 
contractions were achieved. During this time, the trabeculae were stretched incrementally 
until the average force developed by the trabeculae failed to increase with further stretching 
(approximates 2.1-2.2 µm sarcomere length, the optimal sarcomere working length 
(Kentish et al., 1986)). Force output was normalized to trabecula cross-sectional area 
(CSA), which assumed an elliptical muscle cross-section.  
7.2.4 Experimental protocol 
Following stabilisation, baseline measurements were taken of muscle contraction 
(developed force and maximal contraction rate (+dF/dtmax)) and relaxation parameters 
(maximal contraction rate (-dF/dtmax) and decay constant of relaxation (tau)). The 
propensity for spontaneous muscle contractions, which we used as a proxy for arrhythmic 
behaviour was assessed by 30-second cessation of external stimulation (Babakr et al., 
2020). This was then repeated following 45-minute superfusion with 1.5 mM Ca2+ KHB 
containing either 25 µM acylcarnitine C3 or LCAC 18:1 (Advent Bio., Crystal Chem., 
USA) at concentrations of 1, 5, 10, or 25 µM. The acylcarnitine was then washed-out for 
30-minutes before a final spontaneous contractions test. Trabeculae that developed 
spontaneous contractions (≥ 1 contraction) during any pause interval were categorized as 
spontaneously active. Trabeculae were either aborted during experimentation or excluded 
retrospectively if a consistent deterioration in developed force (> 15% reduction per hour, 





7.2.5 In vitro cytosolic Ca2+ imaging 
Cytosolic Ca2+ was measured in recombinant HEK293 cells with or without 
tetracycline-inducible (0.1 µg/mL) expression of RyR2 (generated as previously described 
(Chakraborty et al., 2019)). If RyR2 expression was induced this was done 14-18 hours 
prior to experimentation. Cells were incubated with 2 µM fluo-4-AM (Life Technologies) 
(dissolved in anhydrous dimethyl sulphoxide (DMSO) and 12% (w/vol) Pluronic F127 
(Life Technologies)) at room-temperature for 10-minutes in a loading buffer of 0 mM Ca2+ 
Krebs-Ringer Hepes (KRH) solution (base components [in mM]: 125 NaCl, 5 KCl, 25 
HEPES, 6 glucose, and 1.2 MgCl2, adjusted to pH 7.4 using NaOH) supplemented with 
bovine serum albumin (1 mg/ml). The fluo-4 was then de-esterified for a further 10-minutes 
in KRH (0 mM Ca2+, unless otherwise stated) at room temperature. Fluo-4 was excited at 
470 nm every 2 s with an exposure time of 100 ms. Fluorescence of fluo-4 was detected 
through a long-pass emission filter (> 515 nm) by a CoolSNAP HQ2 charge-coupled device 
camera (Photometrics, AZ). Reported cytosolic Ca2+ fluorescence measurements from any 
time (F) are normalized to the average Ca2+ fluorescence recorded in 0 mM Ca2+ KRH 
solution (F0). 
For experiments in HEK293 cells without RyR2 expression, cells were 
continuously superfused with KRH containing various concentrations of CaCl2 (0.5-2 mM, 
as indicated) before application of the Ca2+ ionophore, A23187 (10 µM) (Sigma-Aldrich, 
USA), to induce a maximal cytosolic Ca2+ fluorescence. For experiments in HEK293 cells 
with RyR2 expression, cells were continuously superfused with KRH containing either an 
increasing concentration of CaCl2 (0.1-1.0 mM, as indicated) or a constant 1 mM CaCl2 
concentration before application of 20 mM caffeine to deplete the intracellular Ca2+ store. 
The RyR2 blocker, tetracaine (2 mM) (Sigma-Aldrich, USA), was used to determine the 
role of RyR2 in effects found in vitro. All HEK293 cells were superfused with LCAC 18:1 
(1, 10, or 25 µM), acylcarnitine C3 (25 µM only) (Sigma-Aldrich, USA), LCAC 16:0 (25 
µM only) (Sigma-Aldrich, USA), or equivalent volume vehicle controls.  
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7.2.6 Data analysis 
Extraction of data from human atrial trabeculae was undertaken using LabChart 
software (LabChart 8©, AD Instruments). Measurement of trabecula contractility was 
performed on contractions comprising the final 1-minute of each condition (i.e., 60 
contractions at 1 Hz). Cytosolic Ca2+ fluorescence was visualised and captured using NIS 
Elements software (Nikon Instruments, NY). Parameters measured from HEK293 cell 
experiments without RyR2 expression induced included the peak Ca2+ fluorescence 
following the introduction of extracellular CaCl2 (normalized to maximal fluorescence 
induced by A23187) and the Ca2+ influx rate (dCa2+/dt). For experiments in HEK293 cells 
with RyR2 expression, parameters analysed included the proportion of cells exhibiting 
distinct SOICR events (termed oscillating cells) at each [Ca2+]O, as well as the total peak 
area (calculated as area under the curve), which we used as a semi-quantitative measure of 
the cytosolic Ca2+ level. Only cells responsive to caffeine were included in analysis. 
7.2.7 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 9 software (Prism 
9©, GraphPad Software, CA). For data acquired from human trabeculae and HEK293 cells, 
normality of the raw data distribution was determined using the Shapiro-Wilk test. Results 
are presented as mean values ± or standard error (SEM). Differences in patient 
characteristics were determined using one-way ANOVA with post hoc Tukey’s test for 
continuous variables and Fisher’s exact test for categorical variables. Data from human 
trabeculae were analysed using repeated-measures (RM) or ordinary one-way ANOVA 
(with post hoc Tukey’s multiple comparisons) as appropriate. Differences in spontaneous 
contraction propensity between conditions and LCAC 18:1 doses were assessed using Χ2 
tests. Data from HEK293 cells not expressing RyR2 were analysed using ordinary one-way 
or two-way ANOVA (with post hoc Tukey’s or Šídák’s multiple comparisons tests, 
respectively) or linear regression. Data from HEK293 cells expressing RyR2 were analysed 
using unpaired t-tests, Mann-Whitney tests, or Kruskal-Wallis tests or ordinary one-way 
ANOVA (with post hoc Dunn’s or Tukey’s multiple comparisons tests, respectively). Each 
P value was adjusted to account for multiple comparisons. All analyses were performed on 
raw data; however, for Figures 7.1 & 7.2, data are presented as fold-changes relative to 





7.3 Results  
7.3.1 Patient characteristics 
Trabeculae were isolated from the RAA of 39 consenting cardiac surgery patients. Each 
trabecula was superfused with a single LCAC 18:1 (n = 8 for each concentration) or C3 
concentration (n = 7). As shown in Table 7.1, there was no difference between each of the 
LCAC 18:1 or C3 concentration groups in any patient characteristics, including in patient 
age, body mass index, or left ventricular ejection fraction. There was no difference in mean 
trabecula CSA between LCAC 18:1 and C3 concentration groups. 
 
Table 7.1.  Patient characteristics in LCAC 18:1 concentration groups. 
 
1 µM 
(n = 8) 
5 µM 
(n = 8) 
10 µM 
(n = 8) 
25 µM 
(n = 8) 
C3 
(n = 7) 
Age (years) 74.4 ± 10.1 66.3 ± 14.2 65.1 ± 11.4 70.8 ± 8.9 71.3 ± 3.2 
Gender (M/F) 4/4 6/2 3/5 4/4 7/1 
BMI (kg/m2) 30.7 ± 8.8 31.4 ± 3.8 34.3 ± 8.5 30.7 ± 4.9 28.7 ± 2.7 
Type 2 diabetes (%) 14 14 14 38 29 
HbA1c (mmol/mol) 40.8 ± 6.2 44.0 ± 9.9 43.3 ± 14.0 41.0 ± 8.8 45.1 ± 20.6 
Blood glucose 
(mmol/L) 
7.4 ± 2.4 7.6 ± 2.4 8.1 ± 2.6 7.6 ± 2.5 7.3 ± 2.0  
SBP (mmHg) 134 ± 18 127 ± 10 125 ± 9 145 ± 23 129 ± 8 
DBP (mmHg) 69 ± 12 74 ± 16 76 ± 11 77 ± 10 77 ± 8 
LVEF (%) 57.7 ± 6.3 51.6 ± 5.4 57.1 ± 7.6 58.1 ± 9.4 57.2 ± 10.3 
Cholesterol (mmol/L) 4.2 ± 0.5 3.9 ± 1.4 4.2 ± 1.3 3.7 ± 1.1 4.2 ± 1.3 
Triglycerides (mmol/L) 1.4 ± 0.4 1.5 ± 0.7 2.2 ± 0.8 1.5 ± 0.7 1.9 ± 1.0 
HDL/LDL ratio 3.3 ± 0.6 3.5 ± 0.5 3.7 ± 0.9 3.3 ± 1.2 4.1 ± 1.0 
Pre-operative AF (%) 0 0 0 0 0 
Post-operative AF (%) 57 57 57 75 43 
M = male, F = female, BMI = body mass index, HbA1c = glycated haemoglobin, SBP = systolic 
blood pressure, DBP = diastolic blood pressure, LVEF = left ventricular ejection fraction 
measured by transthoracic echocardiography, HDL = high-density lipoprotein, LDL = low-
density lipoprotein, AF = atrial fibrillation. Patient characteristics are presented as means ± 
standard deviation. Differences between group patient characteristics were assessed by ordinary 
one-way ANOVA with post hoc Tukey’s test for continuous data or by multiple Fisher’s exact 
tests for categorical data. 
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7.3.2 LCAC 18:1 has a positive inotropic effect on human atrial trabeculae 
LCAC 16:0 has been previously shown to alter contractility acutely in myocardial 
preparations (Sakata et al., 1989; Hara et al., 1996). Whether LCAC 18:1 also induces an 
inotropic effect in the myocardium is, however unknown. To test this, trabeculae from 
human atrial myocardium were stimulated at 1 Hz and treated with a single concentration 
of LCAC 18:1 (1, 5, 10, or 25 µM) or with the acylcarnitine C3 (25 µM). As shown in 
Figure 7.1, 25 µM LCAC 18:1 induced a significant and acute positive inotropic effect in 
human atrial myocardium. Repeated measures analyses showed that trabeculae developed 
force was increased relative to baseline control levels after 15-minutes of 25 µM LCAC 
18:1 treatment, which remained increased after 30- and 45-minute treatment periods 
(Figure 7.1B). This increase in myocardial contractility was then reversed back to control 
levels after 30-minute LCAC 18:1 wash-out (Figure 7.1B). All lower concentrations of 
LCAC 18:1 tested induced significant increases in developed force relative to the respective 
control conditions, which were also reversible following a wash-out period (Figure 7.1C). 
The positive inotropy induced by these lower doses, however, was significantly less than 
that induced by 25 µM LCAC 18:1. Unlike LCAC 18:1, 25 µM of the short-chain 
acylcarnitine C3 had no effect on myocardial contractility after 45-minutes of superfusion 
(Figure 7.1C). Further analysis of the contraction kinetics revealed that LCAC 18:1 also 
enhanced the maximal rate of contraction (+dF/dtmax) in a dose-dependent manner (Figure 
7.2A). Treatment with 10 µM or 25 µM LCAC 18:1 significantly increased the +dF/dtmax 
relative to control conditions (paired analyses), while neither the lower LCAC 18:1 
concentrations (1 µM or 5 µM) or 25 µM C3 affected the contraction rate (Figure 7.2A). 
In the same trabeculae, LCAC 18:1 at any superfusion concentration had no effect on the 
kinetics of myocardial relaxation, including the maximal relaxation rate (-dF/dtmax) and the 





Figure 7.1. Long-chain acylcarnitine 18:1 (LCAC 18:1) reversibly increases human atrial 
contractility. A, representative contraction peaks from human right atrial trabeculae following 
stabilisation, after 45-minute exposure to 25 µM LCAC 18:1 and following 30-minute wash-out 
(WO). B, absolute developed force values from control (Ctrl) values after 15-, 30-, and 45-minute 
LCAC 18:1 superfusion, and after WO. C dose-dependency of 1, 5, 10, and 25 µM LCAC 18:1 
concentrations on human atrial trabecula force, as well as 25 µM short-chain acylcarnitine C3. 
Note, at all LCAC 18:1 doses with significant positive inotropy relative to control values there is 
a significant reduction toward Ctrl developed force with LCAC 18:1 WO. Trabecula contractility 
is normalized to muscle cross-sectional area (mN/mm2). For B & C, differences between effect 
of 25 µM LCAC 18:1 relative to respective Ctrl and WO values assessed using RM one-way 
ANOVA with post hoc Tukey’s; *P < 0.05 vs. indicated. For C, intra-muscle effect of LCAC 
18:1 on developed force vs. respective control tested with RM one-way ANOVA with Tukey’s; 
δP < 0.05, δδP < 0.01. Inter-muscle (i.e., concentration differences) assessed using ordinary one-
way ANOVA with Tukey’s; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. indicated. 
N = 8 for all LCAC 18:1 doses, N = 7 for C3. Data are presented as mean ± SEM. 
 




7.3.3 LCAC 18:1 induces spontaneous contractions in human atrial trabeculae 
In addition to previous reports of LCAC 16:0 altering contractility of the 
mammalian myocardium, LCAC 16:0 also altered the isolated cardiomyocyte action 
potential profile in a manner that increases the propensity and frequency of delayed 
afterdepolarizations (Sakata et al., 1989; Meszaros and Pappano, 1990; Ferro et al., 2012). 
Moreover, these LCAC 16:0-induced electrical derangements have been associated with in 
vivo arrhythmias in animal models (Roussel et al., 2015). For this study, we determined the 
effect of LCAC 18:1 on the propensity for spontaneous contractions in human atrial 
trabecula, which we have validated previously as an ex vivo measure of arrhythmia 
susceptibility (Babakr et al., 2020; Aitken-Buck et al., 2020a). As depicted in Figure 7.3A, 
25 µM LCAC 18:1 induced spontaneous trabecula contractions during a 30-second rest (no 
external stimulation) interval (tested after 45-minute LCAC 18:1 treatment). Categorical 
analysis of trabeculae with spontaneously contracting trabeculae vs. those without found 
that 25 µM LCAC 18:1 significantly increased the propensity for spontaneous contraction 
relative to control conditions (4/8 trabeculae with spontaneous contractions vs. 0/8 without) 
(Figure 7.3B). Like the increase in developed force induced by LCAC 18:1, this pro-
 
Figure 7.2. Contraction kinetics changes induced by exposure of human atrial trabeculae to long-
chain acylcarnitine 18:1 (LCAC 18:1). Concentration-dependency of LCAC 18:1 effect on 
maximal contraction rate (+dF/dtmax, A), maximal relaxation rate (-dF/dtmax, B), and the time 
constant of relaxation (Tau, C). Note, each trabecula is exposed to a single LCAC 18:1 dose. 
Effect of short-chain acylcarnitine C3 was also assessed. Intra-muscle comparisons between 
respective control conditions, LCAC 18:1 or C3 exposure, and wash-out (wash-out not shown 
for clarity) assessed using RM one-way ANOVA with post hoc Tukey’s; δP < 0.05 vs. respective 
control. Inter-muscle comparisons (i.e., concentration differences) assessed using ordinary one-
way ANOVA with post hoc Tukey’s, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. indicated. 
Statistical analyses performed only on absolute values; fold-change values relative to control 
conditions are shown for presentation purposes. N = 8 for all LCAC 18:1 concentrations, N = 7 




arrhythmic effect was reversed completely with 30-minute LCAC 18:1 wash-out (Figure 
7.3B). However, unlike the positive inotropic effect induced by LCAC 18:1 in the same 
muscles, only the 25 µM concentration significantly increased spontaneous contraction 
propensity (Figure 7.3C). These findings suggest that high exogenous LCAC 18:1 
concentrations induce a pro-arrhythmic effect on the human atrial myocardium concurrent 
to a positive inotropic effect. This supports the previous findings of pro-arrhythmic 
electrical derangements induced by LCAC 16:0 and extends it into the human atrial 
myocardium (Sakata et al., 1989; Meszaros and Pappano, 1990). 
 
Figure 7.3. Long-chain acylcarnitine 18:1 (LCAC 18:1) reversibly enhances human atrial 
trabeculae spontaneous contraction propensity. A, representative traces of 30-second rest interval 
(no external stimulation) under control conditions (top) and following 45-minute 25 µM LCAC 
18:1 exposure (bottom). Note the presence of spontaneous contractions following LCAC 18:1 
exposure. B, in trabeculae exposed to 25 µM LCAC 18:1 the number of trabeculae with any 
spontaneous contractions increased from 0/8 under control conditions (Ctrl) to 4/8 with LCAC 
18:1 exposure in the same muscles. This was reversed back to 0/8 with wash-out (WO). C, dose-
dependency of LCAC 18:1 effect on spontaneous contraction propensity relative to respective 
control conditions. Effect of short-chain acylcarnitine C3 was also assessed. Note, in all 
trabeculae that developed spontaneous activity with LCAC 18:1 exposure, WO of LCAC 18:1 
reversed this to Ctrl levels. Intra-muscle and inter-concentration statistical differences assessed 
using Χ2 tests. *P < 0.05 vs. Ctrl; δP < 0.05 vs. LCAC 18:1. N = 8 for each LCAC 18:1 
concentration, N = 7 for C3. 
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7.3.4 LCAC 18:1 acutely promotes Ca2+ influx in vitro 
A key determinant of the strength and timing of myocardial contractility is the flux 
of Ca2+ ions into and within the cardiomyocyte (Dobrev and Wehrens, 2017). As such, 
aberrant fluxes of Ca2+, especially from the SR, are well-known to drive the formation of 
delayed afterdepolarizations that induce spontaneous myocardial contractions. RyR2-
mediated SOICR is well-known to facilitate the development of delayed 
afterdepolarizations. LCAC 16:0 has recently been found to alter RyR2-mediated Ca2+ 
release in isolated cardiomyocytes, while many of the magnitude of the electrical and 
inotropic alterations induced by LCAC 16:0 are dependent on the [Ca2+]O (Patmore et al., 
1989; Meszaros and Pappano, 1990; Roussel et al., 2015). Therefore, we sought to assess 
the effect of LCAC 18:1 on Ca2+ influx into HEK293 cells and how this relates to SOICR 
propensity and the inotropic and arrhythmogenic effects of LCAC 18:1 on the myocardium. 
HEK293 cells (without RyR2 expression) were loaded with fluo-4-AM (2 µM) and 
superfused with variable LCAC 18:1 or Ca2+ concentrations. As shown in Figure 7.4A, 
cytosolic Ca2+ influx promoted by introduction of 1 mM [Ca2+]O into the superfusion 
solution was enhanced when the cells were superfused with 10 µM or 25 µM, but not when 
superfused with 1 µM LCAC 18:1 or 25 µM C3. When quantified, the peak cytosolic Ca2+ 
fluorescence (Figure 7.4B) and Ca2+ influx rate (dCa2+/dt, Figure 7.4C) induced by LCAC 
18:1 was significantly increased and dose-dependent. To assess the dependence of the 
[Ca2+]O on these LCAC 18:1-induced effects, the LCAC 18:1 concentration was kept 
constant at 25 µM and the [Ca2+]O was varied from 0.5-2.0 mM (Figure 7.4D). The peak 
cytosolic Ca2+ fluorescence and Ca2+ influx rate induced by 25 µM LCAC 18:1 was 
dependent on the [Ca2+]O to a greater extent than vehicle controls (Figures 7.4E, F). These 
findings suggest that LCAC 18:1 concentrations that were positively inotropic and 






Figure 7.4. Long-chain acylcarnitine 18:1 (LCAC 18:1) increases cytosolic Ca2+ influx and 
spontaneous internal Ca2+ release in vitro. A-F, recombinant HEK293 cells not induced to 
expresses the cardiac ryanodine receptor (RyR2) were loaded with 2 µM fluo-4-AM then 
superfused with 0 mM extracellular Ca2+ ([Ca2+]O) solution followed by an increased [Ca2+]O 
solution. Finally, the HEK293 cells were treated with Ca2+ ionophore A23187 (10 µM) to induce 
a maximal Ca2+ fluorescence (not shown in A or D for visual clarity). A-C, effect of increasing 
LCAC 18:1 concentrations, short-chain acylcarnitine C3 (25 µM), or vehicle on passive cytosolic 
Ca2+ influx in HEK293 cells superfused with 1 mM [Ca2+]O solution. B, peak fluo-4 fluorescence 
induced by 1 mM [Ca2+]O (normalized to maximal fluorescence induced by A23187). C, Ca2+ 
influx rate, calculated as the change in Ca2+ fluorescence over the change in time (dCa2+/dt). D-
F, effect of increased [Ca2+]O on peak Ca2+ fluorescence and Ca2+ influx rate induced by 25 µM 
LCAC 18:1 or vehicle. G & H, recombinant HEK293 cells were induced to express RyR2 14-18 
hours prior to fluo-4-AM loading as above. Cells were superfused with increasing [Ca2+]O to 
induce spontaneous Ca2+ release events before exposure to 20 mM caffeine to assess cell 
viability. Continued. H, proportion of HEK293 cells exhibiting spontaneous Ca2+ release events 
at each [Ca2+]O following treatment with 25 µM LCAC 18:1, 25 µM C3, or vehicle. 
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7.3.5 Ca2+ influx promoted by LCAC 18:1 is linked to SOICR propensity in vitro 
To determine how this enhanced Ca2+ influx relates to SOICR propensity, 
recombinant HEK293 cells were induced to express RyR2 14-18 hours prior to fluo-4-AM 
loading. For this study, 25 µM LCAC 18:1 treatment significantly increased the proportion 
of RyR2-expressing HEK293 cells exhibiting SOICR (Figure 7.4G). This effect was 
evident at [Ca2+]O as low as 0.2 mM and increased proportionally as the [Ca
2+]O was 
increased incrementally to 1.0 mM (Figure 7.4H). These findings in HEK293 cells indicate 
that LCAC 18:1 promotes an increase in Ca2+ influx and an increased propensity for 
potentially pro-arrhythmic SOICR from the internal Ca2+ store.  To examine the 
concurrency of LCAC 18:1-induced Ca2+ influx and SOICR, HEK293 cells expressing 
RyR2 were again treated with 25 µM LCAC 18:1; however, the [Ca2+]O was maintained at 
1 mM. In line with the previous finding, 25 µM LCAC 18:1 significantly increased the 
proportion of HEK293 cells exhibiting distinct SOICR events (Figure 7.5A-C). As evident 
in Figure 7.5B and quantified in Figure 7.5C, the pro-SOICR effect of LCAC 18:1 was 
accompanied by a marked (4.8-fold) increase in peak area, which we have used as a proxy 
for cytosolic Ca2+ level. These findings confirm that LCAC 18:1 induces a concurrent 









Figure 7.4. For B & C, data were analysed using one-way ANOVA with Tukey’s multiple 
comparisons tests; #P < 0.0001 vs. vehicle, δP < 0.0001 vs. C3, *P < 0.0001 vs. indicated. 
Vehicle N = 10, N = 5 for C3 and each LCAC 18:1 concentration. For E & F, data were analysed 
using linear regression (Vehicle: R2 = 0.98; LCAC 18:1: R2 = 0.98), figures indicate differences 
in regression slopes vs. vehicle (**P < 0.01, ***P < 0.001). Vehicle N = 4 for each [Ca2+]O, 
LCAC 18:1 N = 5 for each [Ca2+]O. For H, data were analysed using two-way ANOVA with post 
hoc Šídák’s multiple comparisons test. **P < 0.01 vs. vehicle, ****P < 0.0001 vs. vehicle, #P < 
0.05 vs. C3, ####P < 0.0001 vs. C3. N = 7 for vehicle and LCAC 18:1, N = 6 for C3. Data are 





7.3.6 RyR2 expression is required for SOICR induced by LCAC 18:1 in vitro 
We next sought to confirm that RyR2 is required to mediate the SOICR events 
linked to the Ca2+ influx induced by LCAC 18:1. This was achieved by co-treating RyR2-
expressing HEK293 cells with the RyR2 blocker, tetracaine, during LCAC 18:1 treatment. 
In vehicle treated cells, blockade of RyR2 with tetracaine in 1 mM [Ca2+]O solution 
prevented any cells from exhibiting SOICR, as expected (Figure 7.5E). Tetracaine also 
prevented SOICR in LCAC 18:1-treated cells; however, it did not prevent the marked 
increase in peak area (Figure 7.5F). This suggests that while LCAC 18:1 promotes Ca2+ 
influx from the extracellular environment, RyR2 is required to release Ca2+ from the 
internal store and, therefore, facilitate SOICR. This is supported by the findings presented 
in Figures 7.5G-I, whereby LCAC 18:1 did not alter SOICR propensity or peak area when 
the cells were superfused with 0 mM [Ca2+]O solution. Together, the findings from HEK293 
cells treated with LCAC 18:1 suggest that LCAC 18:1 promotes potentially pro-arrhythmic 
SOICR events via RyR2 in manner dependent on Ca2+ influx from the extracellular 
environment.  
7.3.7 LCAC 16:0 induces analogous effects on in vitro Ca2+-handling  
To provide context for the findings with LCAC 18:1, the effect of the well-
researched LCAC 16:0 species on in vitro Ca2+-handling was investigated. Relative to 
vehicle controls and 25 µM short-chain acylcarnitine C3, 25 µM LCAC 16:0 induced a 
maximal increase in the proportion of RyR2-expressing HEK293 cells exhibiting distinct 
SOICR events, as well as a marked increase in peak area (Figure 7.6). Therefore, the 
increase in Ca2+ influx and SOICR propensity found with LCAC 18:1 also occurs after 
LCAC 16:0 treatment.  




Figure 7.5. Cardiac ryanodine receptor (RyR2) expression is required for long-chain 
acylcarnitine 18:1 (LCAC 18:1)-induced spontaneous internal Ca2+ release in vitro. Recombinant 
HEK293 cells were induced to express RyR2 14-18 hours prior to fluo-4-AM loading. As 
indicated, loaded cells were superfused with vehicle or 25 µM LCAC 18:1 in solution containing 
1 mM extracellular Ca2+ [Ca2+]O (A-C), 1 mM [Ca2+]O + 2 mM tetracaine (RyR2 blocker) (D-F), 
or 0 mM [Ca2+]O (G-I). At the end of each experiment, cells were superfused with 1 mM [Ca2+]O 
solution containing 20 mM caffeine to assess cell viability. Figures C, F, and I, indicate the effect 
of each condition on the proportion of cells exhibiting distinct spontaneous Ca2+ release events 
(termed oscillating cells) and on the mean area under the peaks (calculated as normalized fluo-4 
fluorescence (F/F0) area under the curve, termed peak area). Differences in proportion of 
oscillating cells or peak area were assessed using Mann-Whitney tests (#P < 0.0001) or unpaired 
t-tests (*P < 0.0001) where appropriate. For A-C, N = 13 for vehicle and LCAC 18:1. For D-F, 








Metabolomic studies have associated high circulating levels of LCAC 18:1 with 
increased absolute risk of CVD and CVD severity (Kalim et al., 2013; Lai et al., 2014; 
Zordoky et al., 2015; Ahmad et al., 2016; Ruiz‐Canela et al., 2017; Ruiz et al., 2017; 
Verdonschot et al., 2019). Acute application of other LCAC species, most commonly 
LCAC 16:0, is known to directly alter myocardial contractility and electrophysiology. 
However, these findings have been limited to small mammalian models and have not been 
extended to other LCAC species (Aitken-Buck et al., 2020b). Therefore, we aimed to 
determine the effect of exogenous LCAC 18:1 on the contractility and arrhythmia 
susceptibility of human atrial myocardium. We found that LCAC 18:1 superfusion at high 
doses acutely enhances the propensity for spontaneous human atrial muscle contractions, 
while concurrently inducing a dose-dependent positive inotropic effect. These results were 
complemented by exploratory findings in our HEK293 cell model, where equivalent LCAC 
18:1 doses promoted RyR2-mediated SOICR via an enhanced influx of Ca2+ from the 
 
Figure 7.6. Long-chain acylcarnitine 16:0 (LCAC 16:0) induces similar effects on Ca2+-handling 
in vitro. Recombinant HEK293 cells were induced to express RyR2 14-18 hours prior to fluo-4-
AM loading. Loaded cells were superfused with 1 mM extracellular Ca2+ [Ca2+]O solution 
containing 25 µM short-chain acylcarnitine C3 (A), 25 µM LCAC 16:0 (B), or vehicle control. 
At the end of each experiment, cells were superfused with 1 mM [Ca2+]O solution containing 20 
mM caffeine to assess cell viability. C shows the effect of each condition on the proportion of 
cells exhibiting distinct spontaneous Ca2+ release events (termed oscillating cells) and on the 
mean area under the peaks (calculated as normalized fluo-4 fluorescence (F/F0) area under the 
curve, termed peak area). Differences in proportion of oscillating cells or peak area were assessed 
using a Kruskal-Wallis test with post hoc Dunn’s multiple comparisons (#P < 0.05, ##P < 0.01) 
or ordinary one-way ANOVA with post hoc Tukey’s multiple comparisons (***P < 0.001, ****P 
< 0.0001) where appropriate. Vehicle N = 8, C3 N = 5, LCAC 16:0 N = 6. Data are mean ± SEM. 
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extracellular environment. Our findings support the hypothesis that LCACs can directly 
induce arrhythmias and positive inotropy in the heart and that this might occur via an 
enhanced Ca2+ influx (McCoin et al., 2015; Aitken-Buck et al., 2020b). Furthermore, our 
findings indicate that this hypothesis can be translated to human cardiac muscle and 
expanded to include LCAC 18:1.  
7.4.1 Enhanced arrhythmic muscle activity induced by LCAC 18:1 
Many studies have reported that exogenous LCAC 16:0 acutely and reversibly 
induces electrophysiological derangements in cardiomyocytes that increase the propensity 
for DADs and in vivo ventricular extra-systoles (Sakata et al., 1989; Meszaros and 
Pappano, 1990; Sato et al., 1993; Wu and Corr, 1995; Roussel et al., 2015). Our findings 
support this arrhythmogenic potential of LCACs in the heart, as exogenous LCAC 18:1 
reversibly enhanced the propensity for arrhythmic spontaneous contractions in human atrial 
myocardium. This effect was induced by 25 µM LCAC 18:1, which aligns with 
concentration ranges used to characterise the effect of LCAC 16:0. Furthermore, this 
concentration has been measured in the plasma of patients with arrhythmia-manifesting 
fatty acid oxidation disorders (Bonnet et al., 1999; McCoin et al., 2016). 
We have previously reported that spontaneous human atrial trabeculae contractions 
can be induced by exposure to classical arrhythmia triggers like β-adrenergic stimulation 
and Ca2+ overload. In fact, these triggers were necessary to promote the spontaneous 
mechanical events (Babakr et al., 2020). Interestingly, high exogenous LCAC 18:1 
enhanced trabecula automaticity in the absence of any supplementary arrhythmia triggers, 
suggesting a relative potency of the LCAC 18:1 arrhythmogenic effects. This is supported 
by previous investigations using LCAC 16:0. Although the electrical derangements 
induced by LCAC 16:0 can be modulated by arrhythmogenic triggers like decreases in 
electrical cycle length and delivery of high frequency stimuli, the derangements are present 
without any supplementary triggers (Corr et al., 1981; Sakata et al., 1989; Meszaros and 
Pappano, 1990; Wu and Corr, 1995). Whether the spontaneous contractions of human atrial 
myocardium induced by LCAC 18:1 can be modulated further by external triggers was not 
determined in the current study. However, as will be discussed in more detail later, it will 
be pertinent to determine if increasing the [Ca2+]O also increases trabecula automaticity as 
our exploratory in vitro data suggests that LCAC 18:1 increases SOICR via an increased 




7.4.2 LCAC 18:1 has a positive inotropic effect on human atrial myocardium 
Concurrent to the pro-arrhythmic effect of LCAC 18:1 in human atrial trabeculae 
was a modest, yet significant, dose-dependent positive inotropic effect. Previous studies of 
the inotropic effect of LCAC 16:0 in the heart have yielded differing results. Some report 
findings of an acute positive inotropic effect that align with the concentration- and time-
dependency similar found in our study (15-45 minutes) (Aomine et al., 1988; Sakata et al., 
1989; Clarke et al., 1996). However, others have reported a negative inotropic effect of 
LCAC 16:0 treatment across an analogous concentration and time range (Criddle et al., 
1990; Hara et al., 1996; Xiao et al., 1997; Wu et al., 2009).  
Interestingly, those that have reported positive inotropy predominantly utilised 
multicellular myocardium preparations such as isolated trabeculae or papillary muscles 
(Aomine et al., 1988; Sakata et al., 1989; Clarke et al., 1996). In contrast, negative inotropic 
effects of LCAC 16:0 have been reported from studies using Langendorff-perfused rat 
hearts (Criddle et al., 1990; Hara et al., 1996; Xiao et al., 1997). Further complexity arises 
as some have reported a biphasic inotropic effect of LCAC 16:0 in both papillary muscles 
and isolated hearts and at a range of doses in (2.5-30 µM) (Sakata et al., 1989; Clarke et 
al., 1996; Hara et al., 1996; Wu et al., 2009). Several factors could potentially explain why 
the inotropic effect of LCACs in the heart is controversial. Firstly, as has been proposed 
elsewhere (Busselen et al., 1988), due to the amphipathic nature of LCACs, the true 
concentration of metabolites in aqueous solutions is commonly incorrectly estimated. 
Therefore, divergent effects on cardiac contractility at analogous dose-estimations could be 
due to differences in the true dose being delivered to the myocardium. Secondly, substrate 
delivery in multicellular preparations is impaired by the greater diffusion distance that is 
normally limited by the coronary microvasculature in the Langendorff-perfused heart. The 
potency of LCAC effects on cardiomyocytes in multicellular preparations might therefore 
be reduced, leading to different a different contractility response.  
7.4.3 LCAC 18:1 and increased Ca2+ influx in HEK293 cells 
Cardiomyocyte Ca2+-handling is a key determinant of myocardial contractility and 
the rhythmicity of contractions. As such, modification of cardiomyocyte Ca2+-handling 
mechanisms is required to induce an inotropic response, while aberrations of these 
mechanisms enhances diastolic Ca2+ leak from the SR, which establishes the ionic substrate 
necessary for the generation of DADs (Dobrev and Wehrens, 2017). During SR Ca2+ 
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overload, spontaneous RyR2-mediated SR Ca2+ release occurs via a process termed SOICR 
(Jiang et al., 2004). This process can be modelled in RyR2-expressing HEK293 cells, as 
has been used by our group and others (Chakraborty et al., 2019). For the current study, 
this HEK293 cell model presented several advantages over isolated cardiomyocytes for 
addressing our research question. Firstly, this model has been used extensively to 
characterise the SOICR effect of pro-arrhythmic drugs, RyR2 mutations, and RyR2 post-
translational modifications, which our results obtained with LCAC 18:1 could be related to 
(Jiang et al., 2004; Waddell et al., 2016; Chakraborty et al., 2019). Secondly, as we have 
reviewed recently, LCACs have been proposed to modulate a pleiotropy of cardiac ion 
channels and transporters, with no consensus on an underlying mechanism (Aitken-Buck 
et al., 2020b). Many of these channels and transporters are not expressed natively in 
HEK293 cells. Therefore, by using this minimalistic cell model we could isolate the effects 
of Ca2+ influx and RyR2-mediated Ca2+ release without confounding effects of many of the 
other proteins purported to be affected by LCACs. 
Our findings in HEK293 cells show that LCAC 18:1 acutely increases intracellular 
Ca2+ influx, which provides the Ca2+ necessary to promote RyR2-mediated SOICR. LCAC 
18:1-induced Ca2+ influx was shown by the increased extent and rate of stimulated Ca2+ 
influx in HEK293 cells without RyR2 expression. Similarly, LCAC 18:1 was found to 
markedly increased the peak area in HEK293 cells expressing RyR2, which we have used 
as a semi-quantitative measure of cytosolic Ca2+. RyR2-mediated Ca2+ release was 
confirmed as the link between LCAC 18:1-induced Ca2+ influx and SOICR by showing 
that SOICR is prevented by RyR2 blockade while Ca2+ influx is not. Extracellular Ca2+ 
influx was confirmed as the ionic driving force for SOICR induced by LCAC 18:1 by 
showing that both SOICR is prevented if extracellular Ca2+ is removed. To provide context 
with the extensive previous studies using LCAC 16:0, we also tested the effect of 
exogenous LCAC 16:0 at 25 µM on Ca2+ influx and SOICR in our HEK293 cell model. 
These experiments show that LCAC 16:0 potently increases SOICR propensity and Ca2+ 
influx analogously to LCAC 18:1. These findings suggest LCACs alter Ca2+-handling in a 
similar manner in vitro. Whether such similarity can be extrapolated to isolated 
cardiomyocyte and in vivo preparations should, however, be done cautiously as LCAC-
specific effects on cardiac ion channels not expressed in HEK293 cells have been reported 
(Ferro et al., 2012). Overall, our in vitro findings with LCACs 16:0 and 18:1 align with 
previous reports of LCAC 16:0 stimulating passive Ca2+ influx in cardiac membrane 




Furthermore, our findings align with those found in in isolated cardiomyocytes treated with 
LCAC 16:0, whereby the extent of positive inotropy and frequency and amplitude DADs 
induced by the LCAC are dependent on the [Ca2+]O (Meszaros and Pappano, 1990; Wu and 
Corr, 1995).  
Our study indicates that RyR2 expression is necessary to link the increased rate of 
Ca2+ influx and propensity for SOICR induced by LCAC 18:1. From our results, however, 
it cannot be deduced whether LCAC 18:1 further promotes post-translational modification 
of RyR2, which in turn could be potentiating the SOICR propensity. Recently, oxidation 
of RyR2 induced by LCAC 16:0 was linked to an increased SR Ca2+ leak and spontaneous 
Ca2+ wave formation in isolated mouse cardiomyocytes (Roussel et al., 2015). In our 
recombinant HEK293 cell model, we have also previously shown that oxidation RyR2 
promotes SOICR (Waddell et al., 2016). Therefore, it is possible that the increased SOICR 
propensity and pro-arrhythmic effects of LCAC 18:1 are linked to oxidation of RyR2 in 
addition to changes in Ca2+ influx (Ferro et al., 2012). Besides oxidation, other forms of 
RyR2 post-translational modification by LCACs need to be investigated. Phosphorylation 
of RyR2 by protein kinase A (PKA) and Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) at serine residues 2808 and 2814, respectively, is well-established (Marx et al., 
2000; Wehrens et al., 2004). RyR2 phosphorylation at these sites is linked to increases in 
RyR2 open probability and SOICR propensity in SR vesicles and HEK293 cells and pro-
arrhythmic Ca2+-handling in isolated cardiomyocytes (Marx et al., 2000; Wehrens et al., 
2004; Xiao et al., 2007). To the best of our knowledge, it is unknown if LCACs modulate 
the activity of PKA or CaMKII in the heart. However, it is possible that the effects of 
LCACs 16:0 and 18:1 could be linked to changes in PKA and/or CaMKII-mediated RyR2 
phosphorylation, which should be addressed by future studies in vitro and in human atrial 
myocardium. It will be interesting to determine the effect of LCACs on CaMKII activity 
and RyR2 phosphorylation at serine 2814, which is implicated in heart failure and 
arrhythmia pathogenesis (Wu et al., 2002; Voigt et al., 2012), since we have found that 
LCACs increase intracellular Ca2+ influx.  
Pro-arrhythmic Ca2+ release from the SR is also influenced by the rate of Ca2+ 
uptake by SERCA2a and the phosphorylation status of the endogenous SERCA2a inhibitor, 
phospholamban (PLB) (Bers, 2002). Phosphorylation of PLB by PKA and/or CaMKII 
reduces PLB inhibition of SERCA2a, thereby allowing greater SR Ca2+ filling that 
increases SR Ca2+ leak via RyR2 (Bers, 2002). From our study we cannot deduce whether 
the increased SOICR propensity and arrhythmic contractions induced LCACs can be 
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attributed to altered PLB phosphorylation. However, we found that LCAC 18:1 had no 
effect on relaxation of human atrial myocardium (-dF/dtmax & tau), despite dose-
dependently increasing the contraction rate (+dF/dtmax). Furthermore, SOICR was potently 
induced in our HEK293 cell model, which does not natively express PLB. When combined 
with previous evidence showing that Ca2+ transient decay is unaffected by LCAC 16:0 in 
isolated cardiomyocytes (Roussel et al., 2015), our findings suggest that removal of 
SERCA2a inhibition by PLB phosphorylation is likely not required for pro-arrhythmic 
Ca2+-handling induced by LCACs. Despite this functional evidence, other investigations in 
SR vesicles have shown that LCAC 16:0 can modulate SERCA2a activity, albeit 
controversially (Aitken-Buck et al., 2020b). In light of this, further investigation is required 
to determine whether LCACs alter SERCA2a activity and in turn whether this is due to 
phosphorylation of PLB. 
7.4.4 LCAC 18:1 and Ca2+ entry into the cell 
Typically, the bulk of extracellular Ca2+ influx occurs via voltage-activation of the 
LTCC, which promotes SR Ca2+ release via Ca2+-induced Ca2+ release (Bers, 2002). As 
mentioned, the functional effects of LCAC 16:0 on the myocardium are dependent on the 
[Ca2+]O; however, whether this extracellular Ca
2+ is conducted via LTCCs is unclear. Some 
show the cytosolic Ca2+ overload induced by LCAC 16:0 in isolated cardiomyocytes can 
be blunted by pre-treatment with the LTCC blocker verapamil (Netticadan et al., 1999). 
Others, by contrast, show no effect of LTCC inhibition on LCAC 16:0-induced electrical 
derangements (Aomine et al., 1988; Sakata et al., 1989). Our finding of an enhanced 
maximal contraction rate in human atrial trabeculae might suggest that LCAC 18:1 could 
enhance LTCC-mediated Ca2+ influx, as is well documented for other positive inotropes 
like β-adrenergic agonists (Bers, 2002). However, Ca2+ influx was also increased in 
HEK293 cells, which, although expressing voltage-gated Ca2+ channels analogous to 
LTCCs (Berjukow et al., 1996), were electrically quiescent in our experiments, thereby 
supporting other reports of LTCC-independent mechanisms of Ca2+ entry. Such a LTCC-
independent Ca2+ current induced by LCAC 16:0 has been identified previously in 
ventricular cardiomyocytes (Wu & Corr, 1992). 
Besides LTCC-mediated Ca2+ entry, LCACs might increase cytosolic Ca2+ influx 
by altering the membrane permeability to Ca2+. As amphipathic metabolites, LCACs 
readily embed in lipid bilayers (Anwer et al., 2020). LCACs incorporate into 




myocardial ischaemia (Knabb et al., 1986; Anwer et al., 2020). Functional analysis of 
purified phospholipid vesicles indicates that this LCAC incorporation disrupts 
phospholipid arrangement, leading to vesicle leakage and solubilisation (Requero et al., 
1995). At high LCAC-to-phospholipid molar ratios, complete vesicle saturation and rupture 
can occur, suggesting that the detergent-like properties of LCACs might underlie 
detrimental effects on heart function (Requero et al., 1995). However, it should be noted 
that such high molar ratios grossly exceed those used in studies of LCAC effects on cardiac 
inotropy and arrhythmia susceptibility, such as the current study. If not acting solely like a 
Ca2+ ionophore, it is also possible LCACs alter Ca2+-handling protein function by 
incorporating into lipid rafts local to the proteins, as has been described for several cardiac 
ion channels (Maguy et al., 2006). Alternatively, increases in Ca2+ influx might arise via 
LCAC-mediated modulation of intracellular signalling processes like mitochondrial 
oxidative stress (Roussel et al., 2015), which could in turn alter Ca2+-handling mechanisms. 
Additionally, LCAC-mediated cytosolic Ca2+ influx might arise via an enhancement in 
sarcolemmal Na+/Ca2+ exchange, as proposed by previously (Wu and Corr, 1995). The poor 
understanding of how LCACs increase cytosolic Ca2+ influx detailed here highlights the 
need for further research in this area. 
7.4.5 Study limitations 
Hypoxia increases total myocyte LCAC content 3-fold and the sarcolemma- 
fraction 70-fold, both of which are associated with LCAC 16:0-mediated 
electrophysiological derangements (Knabb et al., 1986). A limitation of our study is the 
inability to discount the effect of LCAC upregulation that could arise due to the brief 
cessation of carbogen bubbling (~5-10 minutes) during transit from the operating theatre 
and the laboratory. Without measuring endogenous LCAC content we cannot completely 
rule out this potentially confounding effect on our findings. The KHB solutions used for 
our atrial trabeculae experiments have partial pressure of oxygen in excess of 800 mmHg, 
even after the transit period. Therefore, this potential confound should be limited. We also 
attempted to limit this by performing predominantly paired analyses and by excluding 
trabeculae with baseline spontaneous activity or with significant functional deterioration. 
A further limitation of our study is that LCAC uptake into human atrial trabeculae was not 
measured. A near linear relationship between exogenous LCAC concentration and LCAC 
uptake into isolated rat hearts has been reported previously (Busselen et al., 1988). 
However, from our study we cannot discount differences in LCAC uptake inherent to the 
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human myocardial samples used, which could influence the total LCAC accumulated 
within the myocardium and thus the potency of LCAC effects. Our use of human atrial 
trabeculae is an important improvement in translatability, although translation of our 
findings to ventricular myocardial function should be done cautiously. Significant regional 
heterogeneity exists between heart chambers in Ca2+-handling protein levels and cellular 
microarchitecture (Gaborit et al., 2007; Grandi et al., 2011). However, altered Ca2+-
handling remains an important trigger for atrial arrhythmias, despite the differences in Ca2+ 
wave propagation between atrial and ventricular cardiomyocytes. 
7.5 Conclusions 
To conclude, we have shown for the first time that exogenous LCAC 18:1 has direct 
and acute pro-arrhythmic and positively inotropic effects on human atrial myocardium. Our 
results begin to translate the extensive previous work performed on other LCAC species in 
mammalian models to the human setting. Findings from RyR2-expressing HEK293 cells 
suggested that these effects occur via a LCAC 18:1-mediated increase in Ca2+ influx that 
provides the Ca2+ necessary for RyR2-mediated SOICR. Investigations of metabolites 
implicated in CVD as direct effectors of human cardiac muscle will expand our 
understanding of the interaction between the circulating metabolome and the initiation and 
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Previous investigations of LCAC effects on cardiomyocyte Ca2+ handling and 
cardiac function have utilised non-translatable LCAC doses. We addressed this limitation 
by determining the effect of physiological and feasible LCAC concentrations on 
spontaneous Ca2+ release in a cardiac cell model. Furthermore, we examined the effect of 
LCACs on RyR2-mediated Ca2+ release and the interaction with LCAC-induced membrane 
disruption. Fluo-4 loaded HEK293 stably expressing RyR2 were treated with LCAC 
species 16:0 and 18:1 at physiological (0.1 µM), pathological (1.0 µM), and excessive (10 
µM) concentrations. LCACs 16:0 and 18:1 increased the propensity for SOICR at all 
concentrations. The pro-SOICR effect of excessive LCAC concentrations was linked to an 
increase in membrane disruption, as evidenced by an increase in non-specific Ca2+ and Zn2+ 
ion permeability. Conversely, the pro-SOICR effect of clinically translatable LCAC 
concentrations did not induce a measurable effect on cytosolic Ca2+ or Zn2+ influx. Intra-
endoplasmic reticulum (ER) Ca2+ imaging revealed that LCAC treatment at all exogenous 
doses increases SOICR frequency in HEK293 cells by reducing the thresholds for 
spontaneous Ca2+ release and release termination. Additionally, at all concentrations the 
latency period between extracellular Ca2+ introduction and the onset of ER filling was 
reduced, suggesting that all LCAC doses increase cytosolic Ca2+ influx. Interestingly, 
LCAC 18:1 had a greater pro-SOICR effect than LCAC 16:0 at all concentrations; 
however, this was not associated with LCAC-specific effects on RyR2-mediated Ca2+ 
release. Clinically translatable LCAC concentrations promote spontaneous Ca2+ release in 
RyR2-expressing cells by reducing the threshold for Ca2+ release via RyR2. This effect is 
likely linked to an increase in cytosolic Ca2+ influx caused by incorporation of LCACs into 
the cell membrane. These findings improve the translatability of LCACs and potential 
LCAC-specific effects on cardiac Ca2+ handling and cardiac function. 
8.1 Introduction 
LCACs are amphipathic intermediates of intracellular lipid metabolism (Reuter & 
Evans, 2012). In the recent decade, metabolomic profiling has revealed that circulating 
levels of LCACs, notably the LCAC species 16:0 (palmitoylcarnitine) and 18:1 
(oleoylcarnitine), are associated with increased risk of CVD, including HF (Ahmad et al., 
2016; Hunter et al., 2016; Verdonschot et al., 2019), and AF (Harskamp et al., 2019; Smith 




own in human myocardium (Aitken-Buck et al., 2021), has established circulating LCACs 
as direct acute effectors of cardiac function (Meszaros & Pappano, 1990; Wu & Corr, 1994; 
Roussel et al., 2015). Underlying the effects of LCACs on the heart are a multitude of 
putative mechanisms, each with a range of supporting evidence (Aitken-Buck et al., 
2020b). Central to most proposed mechanisms, however, is dysfunction in the handling of 
Ca2+ (Wu & Corr, 1995; Netticadan et al., 1999; Roussel et al., 2015; Aitken-Buck et al., 
2021). 
Dysfunctional Ca2+ handling, notably in the form of spontaneous Ca2+ leak from the 
internal Ca2+ store, the SR, is fundamental to the genesis of ectopic arrhythmias (Voigt et 
al., 2012; Voigt et al., 2014) and impaired contractility (Maier et al., 2003). SR Ca2+ is 
gated by RyR2, which responds to cytosolic and intra-SR Ca2+ fluctuations to release the 
Ca2+ needed for contraction (Jones et al., 2017). In cardiac SR vesicles, LCACs are well 
known to induce Ca2+ efflux (Yamada et al., 2000); however, the dependence on RyR2 in 
mediating this Ca2+ efflux is unclear. Some show that RyR2 blockade does not affect the 
extent of LCAC-induced SR Ca2+ efflux (Yamada et al., 2000). By contrast, others report 
that LCAC treatment induces oxidation of RyR2 and an increased propensity for RyR2-
mediated Ca2+ leak (Roussel et al., 2015). Our recent study found that LCAC treatment 
acutely increases cytosolic Ca2+ influx and promotes SOICR (Aitken-Buck et al., 2021), a 
form of spontaneous RyR2-mediated Ca2+ release (Jiang et al., 2004). Therefore, our 
findings support a role for RyR2 in mediating the effects of LCACs in the heart; however, 
the translatability of our work, and in the field at large, has been limited by several factors 
(Aitken-Buck et al., 2020b).  
Most importantly, the concentrations used to examine the effects of LCACs in the 
heart are significantly greater than those measured in vivo. Studies of LCACs 16:0 and 
18:1, including our own (Aitken-Buck et al., 2021), have utilised exogenous concentrations 
exceeding 10 µM (Sakata et al., 1989; Netticadan et al., 1999; Ferro et al., 2012; Roussel 
et al., 2015). Such high concentrations grossly exceed healthy LCAC 16:0 and 18:1 
circulating levels of ~0.1 µM (Costa et al., 1997; Reuter et al., 2005). LCACs are well 
known to embed into lipid membranes and alter membrane fluidity (Requero et al., 1995; 
Anwer et al., 2020). Furthermore, when applied at non-translatable concentrations, LCACs 
exert detergent-like effects by promoting membrane solubilisation (Requero et al., 1995) 
and irreversible damage to cardiomyocytes (Busselen et al., 1988). Therefore, as 
prevalence of metabolomic profiling for CVD increases, it is pertinent to determine if 
cardiomyocyte Ca2+ handling is also affected by clinically translatable LCAC 
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concentrations below the threshold for overt detergent-like effects. In addition, because 
LCACs 16:0 and 18:1 have independent associations with CVD risk, it is also important to 
identify LCAC-specific effects on the heart, as has been proposed by others (Ferro et al., 
2012). 
For this study, we aimed to determine the effect of physiologically and 
pathologically relevant LCAC concentrations on in vitro Ca2+ handling. Using a 
recombinant HEK293 cell model stably expressing RyR2 (Zhang et al., 2014; Chakraborty 
et al., 2019; Aitken-Buck et al., 2021), we sought to examine the role of membrane 
disruption and passive Ca2+ influx in LCAC-mediated effects, as well as the effect of acute 
LCAC treatment on RyR2-mediated Ca2+ release. We found that translatable levels of 
LCACs 16:0 and 18:1 promote SOICR by lowering the threshold for RyR2-mediated Ca2+ 
release without inducing a measurable increase in non-specific cytosolic ion influx, as was 
evident with excessive LCAC concentrations. These results suggest that LCACs can affect 
the gating of a critical Ca2+ handling protein independently of marked detergent-like 
effects, thereby providing an exploratory pre-clinical link to the associations of circulating 
LCACs with CVD risk. 
8.2 Methods and materials 
8.2.1 Tetracycline inducible human embryonic kidney (HEK293) cell line 
Recombinant HEK293 cells with tetracycline inducible RyR2 expression were 
generated and grown on glass coverslips as previously described (Jiang et al., 2004; Zhang 
et al., 2016). Induction of RyR2 expression was performed with tetracycline concentrations 
and at time points as indicated. 
8.2.2 Cytosolic Ca2+ imaging 
Cytosolic Ca2+ was imaged in recombinant HEK293 cells by loading with the 
cytosolic Ca2+ indicator, fluo-4-AM (2 µM) dissolved in anhydrous DMSO and 12% 
(w/vol) Pluronic 127 (Life Technologies). Cells were loaded with fluo-4 for 10 minutes, 
followed by 10-minute de-esterification in KRH solution containing (in mM): 125 NaCl, 5 
KCl, 25 HEPES, 6 glucose, and 1.2 MgCl2, adjusted to pH 7.4 using NaOH, supplemented 
with bovine serum albumin (BSA, 1 mg/ml). Loaded cells were continuously superfused 
with KRH containing CaCl2 to extracellular Ca
2+ concentrations ([Ca2+]O) of 0-1 mM, as 




ms. Fluorescence of fluo-4 was detected through a long-pass emission filter (> 515 nm) by 
a CoolSNAP HQ2 charge-coupled device camera (Photometrics, AZ). Reported 
fluorescence levels at any time point (F) are normalised to the average fluorescence in 0 
mM [Ca2+]O KRH solution (F0). All experiments were performed at room temperature (21 
± 2°C). 
8.2.2.1 Experiments with RyR2 expression induced 
For experiments with RyR2 expression induced, cells were treated with tetracycline 
(0.1 µg/mL) 14-18 hours prior to experimentation. After 2-minute superfusion with 0 mM 
[Ca2+]O KRH, the [Ca
2+]O was increased to 1 mM for 20 minutes to stimulate SOICR. 
Application of caffeine (20 mM, 2 minutes) was used to deplete the intracellular Ca2+ store 
at the end of each experiment. Cells were treated with LCAC 16:0 (palmitoylcarnitine, 
Sigma-Aldrich, USA), LCAC 18:1 (oleoylcarnitine, Advent Bio., Crystal Chem., USA), 
short-chain acylcarnitine C3 (Sigma-Aldrich, USA), or vehicle controls (all at 0.1-10 µM) 
during the 1 mM [Ca2+]O period. Parameters analysed included the proportion of cells 
exhibiting ≥1 discrete SOICR event(s) during the 1 mM [Ca2+]O period. Only cells 
responsive to caffeine were analysed. Additionally, the total peak fluorescence area 
(calculated as area under the curve) was used as a semi-quantitative measure of cytosolic 
Ca2+ (Aitken-Buck et al., 2021). 
8.2.2.2 Experiments without RyR2 expression induced 
Cells without RyR2 expression induced were superfused with 0 mM [Ca2+]O KRH 
for 2 minutes before addition of LCAC 16:0, LCAC 18:1, or vehicle (0.1-10 µM) for 5 
minutes. Passive Ca2+ influx was initiated by introduction of 1 mM [Ca2+]O for a further 2 
minutes. Experiments were ended by application of the Ca2+-specific ionophore, A23187 
(10 µM, 3 minutes, Sigma-Aldrich, USA), to induce a maximal cytosolic Ca2+ fluorescence 
(Fmax). Parameters analysed included the peak Ca
2+ fluorescence following 1 mM [Ca2+]O 
introduction (normalised to Fmax) and the Ca
2+ influx rate (change in Ca2+ fluorescence over 
time, dCa2+/dt), as used previously (Aitken-Buck et al., 2021). 
8.2.3 Cytosolic Zn2+ imaging 
Cytosolic Zn2+ was imaged with same protocol as for cytosolic Ca2+ measurements 
in HEK293 cells without RyR2 expression. Cells were loaded with cytosolic Zn2+ indicator 
fluozin-3-AM (3 µM) (Tuncay et al., 2011) for 10 minutes in BSA-supplemented KRH. 
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Passive Zn2+ influx was initiated by introduction of 1 mM Zn2+. Maximal cytosolic Zn2+ 
fluorescence was induced by application of Zn2+-specific ionophore, pyrithione (2-
Mercaptopyridine N-oxide sodium, 10 µM, 3 minutes, Fisher Scientific, USA). Parameters 
analysed were as for cytosolic Ca2+ imaging with RyR2 expression as above. 
8.2.4 Luminal (intra-endoplasmic reticulum (ER)) Ca2+ imaging 
Recombinant HEK293 cells induced to express RyR2 16-20 hours prior to 
experimentation. Cells were transfected with cDNA encoding the FRET-based intra-ER 
Ca2+ sensor, D1ER (Palmer et al., 2004), 24 hours prior to RyR2 induction, as used 
previously (Jones et al., 2008). Cells were continuously superfused with 0-2 mM [Ca2+]O 
KRH as indicated, with tetracaine (RyR2 blocker, 2 mM) and caffeine (20 mM) to 
generated maximal (Fmax) and minimal (Fmin) intra-ER Ca
2+ fluorescence levels, 
respectively. Fluorescence images were captured every 2 seconds with a 100 ms exposure 
time and 436 nm (20 nm bandwidth) excitation. Emissions of YFP and CFP were captured 
with a dual dichroic beamsplitter at 535 nm (40 nm bandwidth) and 480 nm (30 nm 
bandwidth), respectively. The amount of FRET was determined as the ratio of the emissions 
at 535 and 480 nm, as previously described (Waddell et al., 2016). Parameters analysed are 
illustrated in the relevant figure. This includes the Ca2+ store size (Fmax – Fmin), the 
thresholds for SOICR release and termination (both normalised to store size), and the 
SOICR frequency. Additional analyses included calculating the latency from extracellular 
Ca2+ introduction to the onset of ER Ca2+ filling, as well as the rate of Ca2+ uptake in the 
final Ca2+ uptake phase (calculated from decay constant of a fitted one-phase association 
curve, see relevant figure). All experiments were performed at room temperature. 
8.2.5 Statistical analysis 
For all experiments, independent data points were defined and analysed as the mean 
value from each experiment (i.e., each coverslip), with each experiment comprising 
typically 100-250 individual HEK293 cells. For this reason, data are presented as mean 
values ± SEM. Data normality was determined by Shapiro-Wilk test. For all figures, 
statistical differences were determined by two-way ANOVA, with Tukey’s multiple 
comparison tests used based on the ANOVA outcome. P values are indicated within each 
figure or as * or # as defined in the relevant figure legend. P < 0.05 was considered 





8.3.1 Translatable LCAC levels promote SOICR propensity but not marked 
Ca2+ overload 
Pro-arrhythmic Ca2+ handling effects of LCACs reported by us and others are 
limited in translatability by the high extracellular concentrations used (Roussel et al., 2015; 
Aitken-Buck et al., 2021). Therefore, the effects of physiological and feasible pathological 
LCAC doses remains unknown. For the current study, we addressed this by treating RyR2-
expressing HEK293 cells with LCACs 16:0 or 18:1 at extracellular concentrations that span 
the physiological to supra-pathological range (0.1-10 µM). As shown in Figure 8.1, all 
concentrations of LCACs 16:0 and 18:1 significantly increased the proportion of cells 
exhibiting discrete SOICR events relative to vehicle controls and to equivalent 
concentrations of the short-chain acylcarnitine C3 (Figure 8.1J). Despite all concentrations 
having a pro-SOICR effect, only the highest 10 µM dose increased the fluorescence peak 
area (Figure 8.1K), which we have used as proxy for cytosolic Ca2+ overload (Aitken-Buck 
et al., 2021). Comparison of the effects induced by the LCACs revealed that LCAC 18:1 
had a significantly greater SOICR effect than LCAC 16:0 at all concentrations (Figure 
8.1J). Similarly, LCAC 18:1 induced a greater increase in cytosolic Ca2+ peak area than 
LCAC 16:0 (Figure 8.1K). These findings suggest that the pro-SOICR effect of high 
LCAC doses is accompanied by membrane disruption that increases in intracellular Ca2+ 
influx. Conversely, the data suggests that translatable LCAC concentrations promote 
SOICR without increasing cytosolic Ca2+ overload to an extent measurable with fluo-4. 
  




Figure 8.1. Long-chain acylcarnitines (LCACs) induce spontaneous Ca2+ release and Ca2+ 
overload in HEK293 cells expressing the cardiac ryanodine receptor (RyR2). Recombinant 
HEK293 cells with RyR2 expression stably induced 14-18 hours prior to experiment were loaded 
with fluo-4-AM and continuously superfused with 0-1 mM Ca2+ solution. Caffeine application 
(20 mM) was used to deplete the intracellular Ca2+ store to end each experiment. Cells were 
treated with vehicle controls (A, D, G), LCAC 16:0 (B, E, H), LCAC 18:1 (C, F, I), or short-
chain acylcarnitine C3 (not shown for visual clarity) (all 0.1-10 µM). J, proportion of HEK293 
cells exhibiting discrete store overload-induced Ca2+ release (SOICR) events, termed oscillating 
cells. K, mean Ca2+ peak area from each condition, calculated using area under the curve 
measurement. Differences determined using two-way ANOVA with Tukey’s multiple 
comparisons tests. *P < 0.0001 vs. vehicle for that concentration, #P < 0.0001 vs. C3 for that 





8.3.2 Translatable levels of LCACs do not cause measurable membrane 
disruption 
To confirm that extracellular LCAC treatment acutely increases ionic influx 
potentially, we performed an analysis of passive Ca2+ influx in HEK293 cells not 
expressing RyR2, as previously reported (Aitken-Buck et al., 2021). In line with our 
previous findings with 25 µM LCAC 18:1, treatment with LCACs 16:0 (Figure 8.2A) or 
18:1 (Figure 8.2B) at 10 µM significantly increased the extent (Figure 8.2C) and rate 
(Figure 8.2D) of Ca2+ influx into the HEK293 cells. The extent of passive Ca2+ influx 
induced by LCAC 18:1 was greater than that induced LCAC 16:0. There was no detectable 
effect of lower LCAC concentrations on Ca2+ influx extent or rate (Figure 8.2C, D), 
suggesting that physiological LCAC doses do not induce an increase in cytosolic Ca2+ that 
is measurable with fluo-4. 
We next determined whether LCAC treatment also increases intracellular Zn2+ 
influx (Figure 8.3). By doing so, we could assess whether the effect on ionic permeability 
is specific to Ca2+ and, in turn, provide confirmation of a non-specific detergent-like 
membrane disruption effect of LCACs. As well as increasing intracellular Ca2+ influx, high 
dose LCAC treatment markedly increased the extent (Figure 8.33C) and rate (Figure 
8.3D) of Zn2+ influx in a LCAC species-dependent manner. Again, there was no detectable 
effect of lower LCAC 16:0 or 18:1 concentrations. Together, these findings suggest that 
extracellular LCACs at high doses disrupts the cell membrane, leading to non-specific ionic 
influx. The effect of LCAC 18:1 is greater than 16:0, suggesting the longer fatty acyl chain 
length and/or saturation status might modulate the extent of membrane disruption and thus 
ion flux. These findings also indicate that translatable LCAC concentrations that promote 
SOICR also do not induce a measurable increase in the cytosolic Zn2+ level. 
  




Figure 8.2. Long-chain acylcarnitines (LCACs) increase intracellular Ca2+ influx. RyR2 
expression was not induced in recombinant HEK293 cells prior to experimentation. Cells were 
loaded with fluo-4-AM and continuously superfused with 0 mM Ca2+ solution followed by 
introduction of 1 mM Ca2+ to stimulate Ca2+ influx. Experiments were concluded after application 
of Ca2+ ionophore, A23187 (10 µM, not shown for visual clarity), to induce a maximal cytosolic 
Ca2+ influx. Cells were treated with LCAC 16:0 (A), LCAC 18:1 (B), or equivalent volume 
vehicle controls (all 0.1-10 µM). C, peak Ca2+ fluorescence after introduction of 1 mM Ca2+ 
(normalised to maximal fluorescence induced by ionophore). D, Ca2+ influx rate, calculated as 
the change in Ca2+ fluorescence over time (dCa2+/dt). Data were analysed using two-way 
ANOVA with Tukey’s multiple comparisons. P values as indicated. Vehicle N = 10 coverslips 
for each concentration, N = 8 coverslips for each concentration of LCACs 16:0 and 18:1. Data 





Figure 8.3. Long-chain acylcarnitines (LCACs) increase intracellular Zn2+ influx. RyR2 
expression was not induced in recombinant HEK293 cells prior to experimentation. Cells were 
loaded with cytosolic Zn2+ indicator, fluoZin-3-AM, and continuously superfused with 0 mM 
Zn2+ solution followed by introduction of 1 mM Zn2+ to stimulate Zn2+ influx. Experiments were 
concluded after application of Zn2+ ionophore, pyrithione (10 µM, not shown for visual clarity), 
to induce a maximal cytosolic Zn2+ influx. Cells were treated with LCAC 16:0 (A), LCAC 18:1 
(B), or equivalent volume vehicle controls (all 0.1-10 µM). C, peak Zn2+ fluorescence after 
introduction of 1 mM Zn2+ (normalised to maximal fluorescence induced by ionophore). D, Zn2+ 
influx rate, calculated as the change in Zn2+ fluorescence over time (dZn2+/dt). Data were 
analysed using two-way ANOVA with Tukey’s multiple comparisons. P values as indicated. 
Vehicle N = 8 coverslips for each concentration, N = 6 coverslips for each concentration of 
LCACs 16:0 and 18:1. Data are mean ± SEM. 
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8.3.3 Effect of LCACs on luminal (intra-ER) Ca2+ handling 
If not measurably affecting cytosolic Ca2+ influx, our findings might suggest that 
LCACs could promote SOICR by altering the threshold of spontaneous ER Ca2+ release 
via RyR2. RyR2 expression is required for SOICR to occur in our HEK293 cell model 
(Aitken-Buck et al., 2021). Furthermore, we and others have shown that pharmacological 
modulation of RyR2 activity (Chakraborty et al., 2019), RyR2 modification (Waddell et 
al., 2018), and RyR2 mutations (Jiang et al., 2005) lower the threshold for RyR2-mediated 
SOICR. To assess RyR2 properties, we transfected HEK293 cells with the FRET-based 
luminal Ca2+ sensor, D1ER (Palmer et al., 2004), prior to inducing RyR2 expression, as 
used previously (Jones et al., 2008; Zhang et al., 2014). By incrementally increasing the 
superfusate Ca2+ concentration, SOICR can be induced in this model and the properties of 
the SOICR events analysed to assess RyR2 gating (Figure 8.4). LCACs 16:0 and 18:1 had 
no effect on luminal Ca2+ store size (Figure 8.4E). Both LCAC species did, however, 
significantly increase the frequency of SOICR events when applied at all concentrations 
(Figure 8.4F). Furthermore, this was linked to reductions in the thresholds for SOICR onset 
(Figure 8.4G) and termination (Figure 8.4H). Unlike the effect on cytosolic SOICR events 
(Figure 8.1), the effects of LCACs 16:0 and 18:1 on SOICR frequency and the SOICR 
thresholds were not different. Only the effect of LCAC 18:1 on SOICR release threshold 
showed concentration-dependency, as the 10 µM dose induced a significantly greater 
reduction than the 0.1 and 1.0 µM doses. These data confirm that RyR2-mediated Ca2+ 






Figure 8.4. Effect of long-chain acylcarnitines (LCACs) on luminal (intra-endoplasmic 
reticulum) Ca2+ handling in HEK293 cells expressing the cardiac ryanodine receptor (RyR2). 
Recombinant HEK293 cells were induced to stably express RyR2 16-20 hours prior to 
experiment.  
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Further analysis revealed that LCAC 16:0 and 18:1 at the excessive concentration 
(10 µM) reduce the latency of the onset of ER Ca2+ filling (upstroke latency) (Figure 8.5Aa 
& B). This indicates that the latency between extracellular Ca2+ introduction and filling of 
the ER is reduced, which indirectly links LCAC-induced Ca2+ influx to SOICR. There was 
no difference in latency reduction between the LCAC species. This is surprising since 
LCAC 18:1 induced a greater extent of Ca2+ influx when cytosolic Ca2+ was measured 
(Figure 8.2). Interestingly, this latency period was also reduced by the lower LCAC 16:0 
and 18:1 concentrations (Figure 8.5B), which were not previously linked to increased 
cytosolic Ca2+ influx measured by fluo-4. In addition to providing an indication of RyR2 
function, luminal Ca2+ imaging can be used to estimate the activity of the SR/ER Ca2+ 
uptake pump, SERCA2a. As done previously (Zhang et al., 2014), SERCA2a-mediated 
Ca2+ uptake was estimated from the one-phase association decay (Tau) of the final filling 
ER filling phase (see Figure 8.5Ab). LCAC 16:0 had no effect on Ca2+ uptake rate when 
superfused at any concentration (Figure 8.5C). Interestingly, however, 1 µM and 10 µM 
LCAC 18:1 significantly prolonged Ca2+ uptake (Figure 8.5C). This result would suggest 
that filling of the internal Ca2+ store is impaired. However, as shown in Figure 8.4E, the 
reduced Ca2+ uptake rate did not significantly affect the internal Ca2+ store size or the 






Figure 8.4. Continued. Cells were transfected with FRET-based luminal Ca2+ sensor, D1ER, 20 
hours prior to RyR2 expression induction. Cells were continuously superfused with solution 
containing 0-2 mM Ca2+ ± tetracaine (2 mM, RyR2 inhibitor) or caffeine (20 mM, depletes Ca2+ 
store). See methods for determination of each parameter. Representative traces shown for vehicle 
controls and 0.1-10 µM LCAC 18:1 in panels A to D, respectively. Traces from equivalent LCAC 
16:0 experiments have been omitted for visual clarity. Effect of LCACs 16:0 and 18:1 on store 
size, store overload-induced Ca2+ release (SOICR) frequency, SOICR release threshold, and 
SOICR termination threshold are shown in E-H, respectively. Data were analysed using two-
way ANOVA with Tukey’s multiple comparisons. P values as indicated. *P < 0.0001 vs. 0.1 µM 
LCAC 18:1, #P = 0.001 vs. 1.0 µM LCAC 18:1. Vehicle N = 5 coverslips per concentration, 
LCAC 16:0 N = 5 coverslips per concentration, LCAC 18:1 N = 9 per concentration. Data are 








Figure 8.5. Role of intracellular Ca2+ influx and sarcoplasmic reticulum (SR) Ca2+-ATPase 
(SERCA) activity in spontaneous SR Ca2+ release induced by long-chain acylcarnitines 
(LCACs). Recombinant HEK293 cells were induced to stably express RyR2 16-20 hours prior 
to experiment. Cells were transfected with FRET-based luminal Ca2+ sensor, D1ER, 20 hours 
prior to RyR2 expression induction. Cells were continuously superfused with solution containing 
0-2 mM Ca2+ ± tetracaine (2 mM, RyR2 inhibitor) or caffeine (20 mM, depletes Ca2+ store). 
Representative trace is shown in A. Aa indicates point of measurement for SR Ca2+ uptake 
latency (upstroke latency). Ab illustrates the analysis of the one-phase association curve fitting 
of the final pre-SOICR SR Ca2+ uptake rate. Effect of 0.1-10 µM LCAC 16:0, LCAC 18:1, or 
vehicle control on upstroke latency and tau (Ca2+ uptake rate) shown in B and C, respectively. 
Data were analysed using two-way ANOVA with Tukey’s multiple comparisons. P values as 
indicated. Vehicle N = 5 coverslips per concentration, LCAC 16:0 N = 5 coverslips per 
concentration, LCAC 18:1 N = 9 per concentration. Data are mean ± SEM. 




For this study we aimed to determine the effect of physiological and a range of 
pathological LCAC concentrations on RyR2-mediated Ca2+ release in our minimalistic cell 
model. Furthermore, we aimed to examine how cytosolic Ca2+ influx influences LCAC-
induced changes in RyR2-mediated Ca2+ release. As hypothesised, the pro-SOICR effect 
of excessively high exogenous LCAC 16:0 and 18:1 concentrations was accompanied by 
marked cytosolic Ca2+ overload, likely via membrane disrupting effects of the LCAC 
structure. We show that translatable LCAC 16:0 and 18:1 concentrations also promote 
SOICR. At these concentrations, the pro-SOICR effect is not accompanied by a measurable 
effect on cytosolic Ca2+ influx. However, our evidence from intra-luminal Ca2+ assessment 
indicates that the effect of physiological and pathological LCAC concentrations on SOICR 
is linked to enhanced Ca2+ influx from the extracellular environment. For the first time, this 
study shows that translatable LCAC concentrations promote SOICR and influence the 
threshold for RyR2-mediated Ca2+ release. Moreover, this study clarifies the role of LCAC 
membrane disrupting effects in driving spontaneous Ca2+ release. 
8.4.1 LCACs induce membrane disruption 
Part of the rationale for using physiological and pathological exogenous LCAC 
concentrations in this study was to dissect any effects on Ca2+ handling from LCAC-
induced membrane disruption. As amphipathic compounds, LCACs incorporate into cell 
membranes via their fatty acyl chains (Anwer et al., 2020), leading to changes in membrane 
fluidity and solubility (Requero et al., 1995; Anwer et al., 2020). In our previous study we 
found that excessively high concentrations (25 µM) of LCACs 16:0 and 18:1 markedly 
increased passive Ca2+ influx. For the current study using a lower yet still high 
concentration (10 µM) we recapitulated this finding by showing that LCAC treatment 
promotes cytosolic Ca2+ and Zn2+ influx. By also assessing Zn2+ influx, we have confirmed 
that Ca2+ influx induced by LCACs is due to non-specific changes in membrane structure, 
rather than a specific increase in Ca2+ permeability. Supporting this, we also found that 
LCAC 18:1 induced a greater extent of non-specific ion influx than LCAC 16:0, suggesting 
that the longer fatty acyl chain and greater membrane penetration of LCAC 18:1 exerts 
more membrane disruption (Anwer et al., 2020). This aligns with studies of SR and 




was dependent on fatty acyl chain length (De Villiers et al., 1986; Baydoun et al., 1988; 
El-Hayek et al., 1993; Yamada et al., 2000). 
The finding that translatable LCAC concentrations do not measurably increase 
passive cytosolic Ca2+ and Zn2+ influx could be interpreted that the lower doses do not 
induce discernible membrane disruption. However, we also found that all LCAC 
concentrations reduce the latency period from extracellular Ca2+ introduction to the onset 
of ER Ca2+ filling (Figure 8.5). Since this assesses the time taken for Ca2+ to enter the cell 
and initiate ER Ca2+ uptake, this finding suggests that translatable exogenous LCAC 
concentrations do increase the Ca2+ influx rate. The absence of measurable cytosolic Ca2+ 
influx induced by LCACs could be due to the extent of Ca2+ influx falling below the 
detection threshold of fluo-4. Based on this theory, it is therefore surprising that the 
reduction in ER filling onset was not dose-dependent nor was it influenced by LCAC fatty 
acyl chain length. To align with our hypothesis, we expected the excessive LCAC 
concentrations to reduce the latency period to a greater extent because the degree of 
membrane disruption and Ca2+ influx induced by these doses should sooner provide Ca2+ 
for ER uptake. As described below, the interpretation that low LCAC concentrations also 
promote Ca2+ influx fits well with the likely mechanism of RyR2 modulation. Therefore, 
for this study, we conclude from our data that all exogenous LCAC concentrations increase 
Ca2+ influx from the extracellular environment. However, at excessive concentrations this 
effect is augmented by detergent-like effects on the membrane. 
8.4.2 LCAC effects on RyR2-mediated Ca2+ release 
From our earlier study, we confirmed that RyR2 expression is required to mediate 
spontaneous Ca2+ release induced by LCAC 16:0 or 18:1 treatment (Aitken-Buck et al., 
2021). However, whether this was a product of RyR2 expression or via modulation of RyR2 
function could not be deduced. For the current study, we show that the SOICR propensity 
in RyR2-expressing HEK293 cells is increased by all concentrations of exogenous LCAC 
16:0 or LCAC 18:1. This aligns with findings of Roussel et al. who found that LCAC 16:0 
at a similar concentration (10 µM) promotes spontaneous SR Ca2+ sparks and waves in 
mouse cardiomyocytes (Roussel et al., 2015). Furthermore, our results recapitulate our 
previous findings in the HEK293 cell model and extend them to show that physiological 
and feasible pathological LCAC concentrations also induce SOICR (Aitken-Buck et al., 
2021).   
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We now show for the first time that the pro-SOICR effect of exogenous LCACs is 
associated with a reduction in the threshold for RyR2-mediated Ca2+ release. LCACs have 
been long known to promote release of Ca2+ from SR vesicles (El-Hayek et al., 1993; 
Yamada et al., 2000). However, the role of RyR2 in mediating this effect has been 
controversial. Some show that the electrophysiological derangements induced by LCACs 
are attenuated by prior low-dose ryanodine treatment and SR Ca2+ depletion (Sakata et al., 
1989; Meszaros & Pappano, 1990). Others, by contrast, show that LCAC-induced Ca2+ 
efflux from SR vesicles is not associated with increased RyR2 activity nor can it be 
prevented by RyR2 blockade (Yamada et al., 2000). This discrepancy in the literature could 
be attributed to differences in the concentrations of LCAC used, as those showing no role 
for RyR2 used concentrations significantly greater (50 µM) than the excessive levels used 
in our study (Yamada et al., 2000). Our data, therefore, provide evidence to confirm that 
LCACs 16:0 and 18:1 promote spontaneous Ca2+ release and that this occurs via a reduction 
in the RyR2 Ca2+ release threshold. 
How then can the cytosolic Ca2+ influx induced by LCACs be linked to a reduction 
in RyR2 Ca2+ release threshold and an increase in SOICR propensity? From our data, the 
interaction of these effects can be explained as a two-stage process based on mechanisms 
reported previously (Jones et al., 2017). (1) The initial increase in cytosolic Ca2+ 
concentration induced by LCACs (at all concentrations) causes an overload of the ER/SR 
Ca2+ store and leads to RyR2 opening and SOICR. (2) The conformational change allowing 
RyR2 to open then exposes the cytosolic and luminal Ca2+ binding sites on RyR2, thereby 
increasing the sensitivity of RyR2 to cytosolic and luminal Ca2+. As a result of the increased 
sensitivities of RyR2 to Ca2+ on both sides of the ER/SR membrane the threshold for 
spontaneous Ca2+ release is reduced and the propensity for SOICR increased. Furthermore, 
the increased cytosolic Ca2+ concentration induced by LCACs prolongs the time taken to 
deplete the Ca2+ levels local to RyR2 and thus reduces the SOICR termination threshold. 
Therefore, when the results of this study are interpreted in totality, the most likely 
mechanism underlying the pro-SOICR effect of LCAC treatment is not the result of a direct 
effect of LCACs on RyR2 per se. Instead, the increase in RyR2 Ca2+ sensitivity and reduced 
SOICR threshold promoted by LCACs result from an increased cytosolic Ca2+ influx and 
subsequent ER/SR Ca2+ overload that changes RyR2 conformation. 
Findings from previous research offers additional insight into the potential 
mechanism of how LCACs alter RyR2-mediated Ca2+ release. Roussel et al. found that 




modification of RyR2 and de-stabilisation of the RyR2 protein complex (Roussel et al., 
2015). Using our RyR2-expressing HEK293 cell model, we have previously characterised 
the effect of oxidative stress on RyR2 function (Waddell et al., 2016). Interestingly, like 
we have found for LCAC treatment, oxidative stress increases SOICR propensity by 
reducing the threshold for RyR2-mediated Ca2+ release without affecting the Ca2+ store size 
(Waddell et al., 2016). Our previous study would suggest that oxidative stress induced by 
LCACs promotes SOICR acutely. However, with prolonged exposure, the threshold for 
RyR2-mediated Ca2+ release reverses and becomes greater than the physiological threshold 
(Waddell et al., 2016). This biphasic effect on SR Ca2+ release could be extrapolated to 
explain why the effect of LCAC treatment on cardiac contractility is often positively 
inotropic acutely but transitions to become negative if exposure is prolonged (Sakata et al., 
1989; Hara et al., 1996). Overall, further research is required to elucidate whether oxidation 
(or any other form of post-translational modification) influences RyR2 gating and whether 
the modifications are dependent on extracellular Ca2+ influx. 
We have found that LCAC 18:1 exerts a greater pro-SOICR effect than LCAC 16:0 
at all exogenous concentrations. In line with the proposed mechanism described above, this 
would suggest that the longer fatty acyl chain of LCAC 18:1 permits greater cytosolic Ca2+ 
influx and thus a greater likelihood of ER/SR Ca2+ overload. Alternatively, this finding 
could suggest that the different LCAC species exert specific effects on RyR2 gating. Such 
LCAC-specific effects have been proposed previously. Ferro et al. found that LCAC 16:0 
and 18:1 both increase the current of the hERG K
+ channel in recombinant HEK293 cells; 
however, they do so by altering different channel properties (Ferro et al., 2012). Therefore, 
although the mechanisms remain undetermined, our evidence for LCAC-specific effects on 
cardiac excitation-contraction coupling processes adds to a growing body of evidence. 
Curiously, we also found that mid-to-high LCAC 18:1 concentrations (1.0-10 µM) 
prolonged ER Ca2+ uptake, while LCAC 16:0 had no such effect at any concentration. The 
slowed ER/SR Ca2+ uptake is supported by previous findings that LCAC 16:0 inhibits 
SERCA2a-mediated Ca2+ uptake in cardiac SR fractions (Dhalla et al., 1991; Yamada et 
al., 2000). In the context of the pro-SOICR effect of LCAC 18:1, it is however antithetical 
as it suggests that LCAC 18:1 prevents overloading of the Ca2+ store and spontaneous Ca2+ 
release. Since LCAC 18:1 was found to increase the SOICR frequency without affecting 
the Ca2+ store size, our data could indicate a relative potency of the LCAC 18:1 effect on 
RyR2 that negates the reduced Ca2+ uptake rate. However, this cannot be deduced from our 
 Effect of Translatable LCAC Concentrations on SOICR 
141 
 
current data and will require further exploration using specific measurements of SERCA2a 
activity. 
8.4.3 Limitations 
An objective of this investigation was to use extracellular LCAC concentrations 
that represent physiological and feasible pathological levels. A limitation of this study is 
that accuracy in estimating LCAC concentrations in solution is hindered by the 
hydrophobicity of the LCAC structure. As a result, typical estimates of working LCAC 
concentrations are overestimated as the fatty acyl chain of the LCACs promotes 
accumulation at the air-fluid phase (Busselen et al., 1988). Therefore, the concentrations 
used for this study are not aimed to be a direct translation of circulating levels measured in 
health and disease. Rather, the chosen working levels are estimates of significantly lower 
levels than that previously used for pre-clinical research. 
8.5 Conclusion 
To conclude, LCACs 16:0 and 18:1 promoted spontaneous Ca2+ release in our 
HEK293 cell model by alteration of RyR2 activity. Importantly, we show for the first time 
that physiological and feasible pathological LCAC concentrations alter Ca2+ handling 
directly via RyR2 functional modulation without a discernible disruption of the membrane. 
As per our previous investigation, the pro-SOICR effect of high extracellular LCAC 
concentrations was linked to marked membrane disruption and non-specific ion influx. Our 
study also indicates that subtle, yet significant, differences exist in the potency of the pro-





General Discussion of LCAC Findings 
The following discussion aims to build on those contained in the preceding 
published manuscripts with minimal repetition of discussion points. Firstly, the findings 
relating to aims three and four of my thesis will be summarised. Following this I will 
discuss the pro-arrhythmic and inotropic effects of LCAC 18:1 in human atrial 
myocardium. This will include some repetition from Chapter 6. The findings in the 
HEK293 cell model will then be discussed with initial focus on the postulated effects of 
LCACs on membrane perturbation and Ca2+ influx. Then there will be contextualisation of 
the effects of LCACs on RyR2-mediated Ca2+ release with the wider research field. Finally, 
the study limitations addressed and short-term and long-term follow up experiments will 
be suggested. 
9.1 Summary of findings 
Metabolomic profiling from large cohort studies has revealed that elevated 
circulating levels of the fat metabolites, LCACs, are associated with increased risk of CVD 
(Kalim et al., 2013; Cheng et al., 2015; Ruiz-Canela et al., 2017). Supporting these clinical 
associations is an extensive body of pre-clinical research. From this work, exogenous 
LCACs have been found to acutely alter myocardial contractility and promote pro-
arrhythmic electrical activity. Although extensive, the field has been limited by exclusive 
use of a single LCAC species, LCAC 16:0, and by an absence of study in human cardiac 
tissue (Aitken-Buck et al., 2020b). This thesis has addressed both limitations by 
investigating another common LCAC species, LCAC 18:1, and by utilising human atrial 
myocardium (Aim three). Additionally, this thesis has investigated the effects of LCACs 
on key cardiac Ca2+ handling processes in vitro (Aim four).  
Aim three was to determine the effect of LCAC 18:1 on the function of human 
atrial myocardium (Chapter 7). Based on the previous findings using LCAC 16:0, I 
hypothesised LCAC 18:1 will promote pro-arrhythmic spontaneous contractions. 
Similarly, based on the negative clinical associations of LCAC 18:1 on cardiac function, I 
hypothesised that LCAC 18:1 would induce a negative inotropic effect. Using atrial 
myocardium from non-AF and non-HF patients, I found that (1) LCAC 18:1 acutely and 
reversibly increases spontaneous contraction propensity when superfused at a high 
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concentration. Additionally, (2) LCAC 18:1 increased contraction force and contraction 
rate in a dose-dependent manner, without affecting myocardial relaxation. These findings 
show for the first time the acute effect of any LCAC species on human myocardial function 
and suggest that circulating LCACs could contribute to CVD pathogenesis in addition to 
providing diagnostic and prognostic utility. 
Aim four was to determine the effect of LCACs 16:0 and 18:1 on Ca2+ handling in 
vitro. Using a HEK293 cell model with inducible RyR2 expression, it was hypothesised 
that the pro-arrhythmic and inotropic effects of LCACs would be linked to aberrant in vitro 
Ca2+ handling. Excessive LCAC concentrations, including that used for Aim three, 
dramatically increased spontaneous Ca2+ release propensity while also inducing a marked 
increase in non-specific cytosolic ionic influx. This aberrant Ca2+ handling effect was 
confirmed to be via RyR2-mediated Ca2+ release driven by Ca2+ influx from the 
extracellular environment. At translatable concentrations, LCACs 16:0 and 18:1 promoted 
SOICR by reducing the threshold for RyR2-mediated Ca2+ release without a measurable 
change in cytosolic Ca2+ influx. These findings show for the first time that LCACs 16:0 
and 18:1 promote pro-arrhythmic spontaneous Ca2+ release in a recombinant cell model. I 
propose that these effects are intrinsically intertwined with cytosolic Ca2+ influx caused by 
the amphipathic structure of LCACs, even at translatable LCAC concentrations.  
Overall, these findings address important gaps in the pre-clinical understanding of 
LCAC effects in the heart. Although largely dormant for two decades, with the increased 
utility of metabolomics and discovery of LCAC associations with CVD, reprisal of pre-
clinical LCAC research has become necessary. These findings build on historical findings 
by extending the understanding to human heart tissue, to LCAC species not previously 
characterised, and to effects on Ca2+ handling protein function. This research provides 
rationale for further study of how translatable LCAC concentrations contribute to CVD 
pathogenesis. Furthermore, in supporting the clinical utility of circulating LCACs, it 
establishes LCACs as a potentially modifiable target in treating CVD. 
9.2 Circulating LCACs alter arrhythmia propensity and contractility 
9.2.1 Arrhythmia propensity 
A growing number of large cohort studies have linked plasma levels of broadly 
classified LCACs and specific LCAC 16:0 and 18:1 levels with incident AF risk (Harskamp 




plasma LCAC 18:1 levels are increased in persistent AF patients and that the LCAC 18:1 
level is predictive of persistent AF risk (Krause et al., 2018). This thesis sought to expand 
on these associations by determining whether the LCAC 18:1 directly affects cardiac 
function and contributes to AF pathogenesis. Another LCAC species, LCAC 16:0, is well-
known to induce electrophysiological derangements and arrhythmias in mammalian 
myocardial preparations (Sakata et al., 1989; Meszaros & Pappano, 1990; Wu & Corr, 
1994; Wu & Corr, 1995; Roussel et al., 2015). The results of Chapter 7 support these 
works by showing that 25 µM LCAC 18:1 promotes pro-arrhythmic contractions in human 
atrial myocardium. This resembles a previous finding that 30 µM LCAC 16:0 promotes 
DADs and aftercontractions at a similar time-point of maximal positive inotropy (30-45 
minutes) (Sakata et al., 1989). Sakata et al. found that arrhythmic activity of LCAC 16:0 
was triggered by reducing the stimulation cycle length and by delivering trains of stimuli 
(Sakata et al., 1989). For my study, arrhythmic activity induced by LCAC 18:1 was not 
triggered pharmacologically or by stimulatory modulation (Lebek et al., 2018; Lebek et al., 
2020). This could suggest a relative potency of the LCAC 18:1 arrhythmogenic effect 
relative to LCAC 16:0; however, further study is required to confirm this. 
It is noteworthy that lower LCAC 18:1 concentrations (1-10 µM) did not increase 
arrhythmia propensity, despite each inducing an increase in contractility. This absence of 
pro-arrhythmic effect contrasts with previous studies in isolated cardiomyocytes whereby 
1 µM LCAC 16:0 promoted DADs and aftercontractions (Meszaros & Pappano, 1990; 
Shen & Pappano, 1995). Similarly, the latency of the pro-arrhythmic effect of LCAC 18:1 
in trabeculae found in my study (45 minutes) is notably shorter than the latency found in 
isolated cardiomyocyte studies (5-10 minutes) (Meszaros & Pappano, 1990; Shen & 
Pappano, 1995). The reduced concentration- and time-dependency of the LCAC effect in 
isolated cardiomyocytes likely stems from the increased LCAC to lipid molar ratio. As 
discussed in later sections, this provides further evidence for membrane disruption 
mediating the effects of LCACs in cardiomyocytes. Importantly, there was no differences 
in mean trabeculae CSA between those treated with LCAC 18:1 at any superfusion 
concentration (Chapter 7). The dose-dependent pro-arrhythmic effect of LCAC 18:1 in 
human atrial myocardium found in my study, therefore, is not confounded by differences 
in LCAC vs. membrane molar ratio. 
Contemporary paradigms suggest that arrhythmias arise from ectopic myocardial 
contractions and/or the formation of conduction rotors (Heijman et al., 2014). Ectopic 
contractions typically arise from disturbances in ion handling and the development of 
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afterdepolarisations that force localised myocardial contraction independent of sinus node 
excitation (Heijman et al., 2014). My methodology of assessing spontaneous trabeculae 
contractions simulates ectopic myocardial activity. The results of my thesis, therefore, 
suggest that high concentrations of LCAC 18:1 might promote ectopic arrhythmias in vivo. 
The absence of spontaneous contraction induction by lower LCAC 18:1 doses does not, 
however, preclude an arrhythmogenic effect. My results showing a positive inotropic effect 
of low dose LCAC 18:1 and previous findings of action potential modulation by low dose 
LCAC 16:0 (Sakata et al., 1989) suggest that lower LCAC concentrations could underlie 
conduction velocity and refractory period changes that lead to rotor formation. Further 
study using in vivo or ex vivo optical mapping of the heart will determine whether LCACs 
alter electrical conduction propagation and facilitate rotor formation.  
9.2.2 Inotropic effect 
In addition to associations with AF risk, circulating LCACs are independently 
associated with indices of cardiac function and HF. Plasma LCAC 16:0 and 18:1 levels 
negatively correlate with NYHA class, patient cardiac performance, and with the severity 
of left ventricular hypertrophy (Lanfear et al., 2017; Elmariah et al., 2018). Cohort studies, 
as in AF patients, reveal that plasma levels of total LCACs and specific LCAC 16:0 and 
18:1 levels are increased in HF patients (Zordoky et al., 2015; Hunter et al., 2016; Ruiz et 
al., 2017). Moreover, circulating LCAC 16:0 and 18:1 levels can be used to differentiate 
between the stage of HF (Zordoky et al., 2015; Ahmad et al., 2016; Hunter et al., 2016), 
thereby highlighting the utility of LCACs in HF diagnosis.  
I found that LCAC 18:1 induces a dose-dependent positive inotropic effect in 
human atrial myocardium, suggesting a role for LCACs in mediating pathophysiological 
changes in contractility. Contextualisation of these findings with previous studies is 
included in Chapter 7 and thus will not be repeated in detail here. Briefly, my findings 
align with previous reports of LCAC 16:0-induced positive inotropy in mammalian 
multicellular (Nakaya & Tohse, 1986; Aomine et al., 1988; Sakata et al., 1989; Clarke et 
al., 1996) and single cardiomyocyte (Shen & Pappano, 1995) preparations. LCAC 18:1 
superfusion at 1-25 µM doses increased contraction force by ~7-31%, respectively. 
Although significant, it is notable that these changes are modest relative to 15-100% 
increases in contractility induced by 1-30 µM LCAC 16:0 treatment reported previously in 
papillary muscles (Clarke et al., 1996). This discrepancy could arise from the use of human 




content for each mm2 of CSA (Munro et al., 2018). Additionally, since intracellular Ca2+ 
influx drives the intracellular effects of LCACs, the relatively lower buffer Ca2+ 
concentrations used in my study (1.5 mM vs. 2.0 mM) could limit the capacity to increase 
contractility (Clarke et al., 1996). 
It should also be noted that the extent of positive inotropy found in my study is less 
than that induced by equivalent doses of LCAC 16:0 in isolated mammalian 
cardiomyocytes (Shen & Pappano, 1995). In these preparations, superfusion of 1 µM and 
3 µM LCAC 16:0 increases myocyte contractility by 47% and 100%, respectively (Shen & 
Pappano, 1995). As mentioned in the previous section, this effect is likely due to the greater 
LCAC to membrane molar ratio, thereby rendering a greater potency of the LCAC effect. 
This is further evidenced by the markedly reduced latency of inotropic change (10-20 min 
vs. 30-120 min) in single cell preparations (Shen & Pappano, 1995) vs. the multicellular 
preparation used for my study and by others (Aomine et al., 1988; Sakata et al., 1989; 
Clarke et al., 1996). 
Unlike the commonly reported pro-arrhythmic effect of LCAC 16:0, the direction 
and duration of inotropic modulation has been controversial, as I have recently reviewed in 
detail (Aitken-Buck et al., 2020b). Briefly, negative inotropy has been predominantly 
reported in studies of isolated rat hearts and has been linked to membrane disruption and 
possibly cardiomyocyte death (Busselen et al., 1988; Hara et al., 1996; Hara et al., 1997; 
Xiao et al., 1997; Arakawa et al., 1997; Arakawa & Hara, 1999; Maruyama et al., 2000). 
Since the coronary microcirculation is maintained in this technique, it is likely that LCAC 
delivery is enhanced relative to the substance diffusion that multicellular preparations rely 
on. Consequently, any detrimental effects of LCAC-induced membrane disruption manifest 
at a faster rate than in multicellular preparations, which could reduce contractility. This 
theory is supported by reports of a biphasic positive-to-negative effect of LCAC 16:0 on 
contractility in multicellular and isolated heart preparations (Hara et al., 1996; Xiao et al., 
1997; Sakata et al., 1989; Clarke et al., 1996). In these studies, the concentration- and time-
dependency of the biphasic effect has been found to be intertwined. Overall, this suggests 
that longer-term LCAC superfusion of multicellular preparations will result in a negative 
inotropic effect when the extracellular LCACs eventually diffuse throughout the entire 
muscle. This hypothesis would align with the clinical associations of circulating LCACs 
with HF since LCAC levels in this disease are chronically elevated (Zordoky et al., 2015; 
Hunter et al., 2016; Ruiz et al., 2017). 




In summary, I have found that exogenous LCAC 18:1 promotes arrhythmic 
contractions and a positive inotropic effect in human atrial myocardium. This pro-
arrhythmic effect aligns with commonly reported findings with LCAC 16:0 in other 
mammalian tissues, while the contractility effect aligns with previous studies utilising 
analogous methodology. Contextualisation with the literature suggests that LCACs 
increase contractility acutely but with chronic exposure, as occurs in vivo, the effect of 
LCACs on contractility could become detrimental. These findings improve the 
understanding of how LCACs contribute to the pathogenesis of arrhythmias and contractile 
dysfunction in AF and HF, respectively.  
9.3 LCACs alter Ca2+ handling in vitro 
Disruption in normal Ca2+ handling processes is fundamental to the development of 
arrhythmias and contractile dysfunction (Dobrev & Wehrens, 2017). In human 
cardiomyocytes, ~70% of Ca2+ available for each contraction is stored in the SR (Bassani 
et al., 1994), the release of which is gated by RyR2. RyR2 expression and activity is altered 
in AF and HF in a manner that enhances the rate of spontaneous Ca2+ leak, spontaneous 
contraction formation, and impaired contraction strength (Belevych et al., 2007; Voigt et 
al., 2012; Voigt et al., 2014). Since LCACs promoted arrhythmias and alter contractility in 
human atrial myocardium, the effect of LCACs on Ca2+ handling and RyR2 function was 
investigated. 
Post hoc analysis of LCAC effects on atrial myocardial contractility retrospectively 
strengthens the rationale to investigate the Ca2+ handling effects of LCACs. Alongside 
inducing spontaneous contractions during periods of no stimulation (paused periods), 
LCAC 18:1 also reduced the capacity for contraction PPP (Figure 9.1). This can be 
interpreted as LCAC 18:1 enhancing SR Ca2+ leak and/or slowing Ca2+ uptake during the 
pause period. If suggesting an enhanced SR Ca2+ leak rate, this would align with the 
increased spontaneous contraction propensity induced by LCAC 18:1. Similarly, it would 
align with the interpretation applied to a reduced PPP attributed to other pro-arrhythmic 
compounds (Lebek et al., 2018; Lebek et al., 2020). In contrast, an enhancement in SR 
Ca2+ leak is antithetical to the positive inotropy induced by LCAC 18:1 as it would suggest 
that LCAC 18:1 reduces SR Ca2+ available for contraction. It is possible that LCAC 18:1 




with the absence of LCAC 18:1 effect on myocardial relaxation (Chapter 7), which is 
predominantly dependent on SERCA2a-mediated Ca2+ uptake into the SR (Bers, 2002). 
Overall, it is unclear how to interpret this finding. However, because the PPP is tightly 
coupled to SR Ca2+ handling, this post hoc analysis further establishes the necessity to 
investigate LCAC effects on Ca2+ handling.  
 
Figure 9.1. Long-chain acylcarnitine (LCAC) 18:1 reduces the post-pause potentiation (PPP) 
capacity of human atrial myocardium. A, Example traces of the 30-second pause period with the 
potentiation of the post-pause contraction relative to the pre-pause contraction highlighted in red. 
Note these recordings are from the same trabecula (and thus same patient). B, Forty-five minute 
LCAC 18:1 treatment (25 µM) significantly reduces the PPP capacity relative to control 
(baseline). This effect is reversed with LCAC 18:1 wash out. C, Lower LCAC 18:1 
concentrations do not significantly reduce the PPP relative to respective control conditions. The 
25 µM LCAC 18:1 concentration reduces the PPP to a significantly greater extent than 1 µM 
LCAC 18:1. For B & C, differences between LCAC 18:1 treatment vs. respective control and 
wash out conditions determined by repeated measures one-way ANOVA with Tukey’s multiple 
comparisons. For C, LCAC 18:1 concentration differences determined by ordinary one-way 
ANOVA with Tukey’s multiple comparisons. N = 8 for each LCAC 18:1 concentration and 
condition. Data are means ± SEM. 
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I did this using a common HEK293 cell model with inducible RyR2 expression. 
LCAC effects on Ca2+ handling have been studied in isolated cardiomyocytes extensively 
(Clarke et al., 1996; Netticadan et al., 1999). In these models, LCACs have been proposed 
to affect a pleiotropy of Ca2+ handling proteins; however, in many cases the results are 
controversial (Aitken-Buck et al., 2020b). In part this is due to the inability to isolate the 
effects of LCACs on specific Ca2+ handling proteins without confounding influence of 
other proteins. Hence, the simplicity of my HEK293 cell model was advantageous as it 
allowed for isolated investigation LCAC effects on membrane disruption and inducible 
RyR2 function. We found that LCACs at a range of concentrations promote spontaneous 
Ca2+ release by reducing the threshold for RyR2 Ca2+ release. This finding prompts several 
discussion points about how LCACs might alter RyR2 activity. However, prior to doing 
that, it is pertinent to discuss how LCACs might increase Ca2+ influx as this is likely 
intertwined with the pro-arrhythmic effect of LCACs. 
9.3.1 How LCACs potentially increase cytosolic Ca2+ influx 
LCACs readily embed into phospholipid membranes via the hydrophobic charge 
carried along their fatty acyl chains (Requero et al., 1995; Anwer et al., 2020). As a result, 
when applied exogenously or endogenous levels are upregulated in ischaemia, LCACs tend 
to accumulate in cell membrane compartments (Knabb et al., 1986; Requero et al., 1995; 
Anwer et al., 2020). This has been modelled in artificial liposomes, which demonstrate that 
the extent of LCAC incorporation is correlated with the amount of phospholipid present 
and that the depth of membrane penetration is dependent on LCAC acyl chain length 
(Requero et al., 1995; Anwer et al., 2020). Functionally, LCAC membrane incorporation 
alters membrane fluidity, also in a chain length-dependent manner, and that excessive doses 
can promote membrane solubilisation (Requero et al., 1995). It is important to note that in 
extracellular solution the critical saturating and solubilising concentrations for LCAC 16:0 
are estimated at ~13 µM and ~66 µM, respectively (Requero et al., 1995). Thus, the LCAC 
concentrations used for this thesis overlap with the membrane saturation threshold, but not 
with the solubilisation threshold, suggesting that solubilisation and cell rupture do not 
underlie the effects of LCACs. 
Despite not inducing overt membrane solubilisation, my data suggests that Ca2+ 
overload induced by LCACs 16:0 and 18:1 is due to disruption of the cell membrane that 
facilitates intracellular ion influx. This has been postulated previously as to how LCACs 




Villiers et al., 1986; Baydoun et al., 1988; Yamada et al., 2000). I found that LCACs 
increase the extent and rate of Ca2+ influx from the extracellular environment. Furthermore, 
by analysing the influx of another divalent cation, Zn2+, I found that the effect on Ca2+ 
influx is non-specific. This suggests that LCAC disruption of the membrane does not yield 
an ionophore-like effect to permit Ca2+ influx. Additionally, it confirms that the primary 
Ca2+ influx channel, the LTCC, is not required to conduct the Ca2+ influx since HEK293 
cells do not natively express LTCCs (Berjukow et al., 1996). Further evidence for a 
membrane disrupting effect of LCACs comes from LCAC 18:1 promoting greater Ca2+ and 
Zn2+ influx than LCAC 16:0. This suggests that the longer fatty acyl chain length of LCAC 
18:1 penetrates the cell membrane to a greater depth, leading to greater phospholipid 
disorganisation and thus greater disruption to the membrane integrity. 
In Chapter 7, I concluded that it is this membrane disruption and subsequent Ca2+ 
influx induced by LCAC 18:1 (25 µM) that provides the ionic driving force for ER Ca2+ 
overload and SOICR. In doing so, the Ca2+ influx promoted by the LCACs is intrinsically 
intertwined with the increased spontaneous Ca2+ release propensity. This conclusion was 
re-enforced by the concurrency of the Ca2+ overload and pro-SOICR effects of the highest 
LCAC concentration used in Chapter 8 (10 µM). Furthermore, I found that increased Ca2+ 
influx induced by the greater membrane disruption of LCAC 18:1 also results in an 
enhanced SOICR propensity relative to LCAC 16:0. I also found that pro-SOICR effect of 
translatable LCAC concentrations (0.1 & 1.0 µM) was not accompanied by a measurable 
increase in Ca2+ influx rate. The following paragraphs will discuss this finding and whether 
it can be interpreted as an absence of membrane disrupting effect. This will involve 
discussion of the most probable interpretation, as well as alternative theories that are more 
speculative. 
The most probable reason that a measurable Ca2+ influx did not accompany the pro-
SOICR effect of translatable LCAC 16:0 and 18:1 concentrations is a methodological one. 
I employed the cytosolic Ca2+ indicator, fluo-4, to measure changes in cytosolic Ca2+ influx 
over time. This indicator was able to detect the changes in intracellular Ca2+ induced by 
higher LCAC concentrations. However, since the membrane disrupting effect is dose-
dependent, it is possible that the change in Ca2+ influx and thus cytosolic Ca2+ level induced 
by the translatable LCAC doses was below the detection threshold of fluo-4. Supporting 
this are measurements of intra-ER Ca2+ that revealed the latency between extracellular Ca2+ 
introduction and the onset of ER Ca2+ filling is reduced at all LCAC concentrations. 
Furthermore, an increase in Ca2+ influx would explain why LCAC 18:1 had a greater pro-
 General Discussion of LCAC Findings 
151 
 
SOICR effect than LCAC 16:0 as the longer acyl chain length would facilitate greater Ca2+ 
influx and thus a greater extent of SR Ca2+ overload. Arguing against this reasoning is that 
fluoZin-3, which has a greater Zn2+ sensitivity (Kd: ~15 nM) than fluo-4 has for Ca2+ (Kd: 
~335 nM), also did not detect a change in Zn2+ influx at translatable LCAC concentrations. 
This could be suggestive of other effects underlying LCAC-induced Ca2+ influx. Some 
speculative effects are described below. 
Firstly, Ca2+ could enter the cell via a Ca2+-handling protein that is not the LTCC 
(Wu & Corr, 1994; Wu & Corr, 1995). As proposed by Wu & Corr, LCAC 16:0, albeit at 
a relatively high exogenous concentration (10 µM), promotes the formation of a transient 
inward late Na+ current in guinea pig cardiomyocytes (Wu & Corr, 1994). The resultant 
increase in intracellular Na+ content then provides the ionic gradient for reverse mode 
Na+/Ca2+ exchange at the cell membrane that increases the cytosolic Ca2+ level (Wu & Corr, 
1995). This proposed mechanism is supported by findings in isolated rat hearts where 
blockade of this late Na+ current prevents mechanical dysfunction induced by LCAC 16:0 
(Wu et al., 2009). Therefore, it is possible that LCACs 16:0 and 18:1 at all concentrations 
indirectly promote Ca2+ influx by this pathway, while high doses also disrupt the membrane 
to allow passive transmembrane Ca2+ influx. 
Another explanation is that LCAC membrane incorporation alters the composition 
of LTCC lipid rafts. Within t-tubular membranes, LTCCs localise into lipid rafts called 
caveolae, which contain a heterogeneous mixture of membrane lipid types, cholesterol, and 
integral membrane proteins (Maguy et al., 2006). Alteration of the caveolae lipid 
composition is known known to modulate the structural organisation of LTCCs with RyR2 
proteins at cardiac dyads (Löhn et al., 2000). In turn, by altering the interfacing of LTCCs 
and RyR2, changes in LTCC caveolae composition has been proposed to alter the 
propensity for SR Ca2+ spark release (Löhn et al., 2000). As alluded to, HEK293 cells do 
not express LTCCs with homologous structure to those found in cardiomyocytes. They do, 
however, express a dihydropyridine-sensitive analogue (Berjukow et al., 1996), which 
could be functionally altered by LCAC incorporation at the lipid raft to drive RyR2-
mediated Ca2+ leak. At higher LCAC concentrations, the effect on specific lipid rafts would 
be overcome by generalised detergent-like membrane disruption. 
A final speculative explanation is that the polarity of the LCAC compound changes 
the electrostatic properties of the cell membrane and channel kinetics. The increased 
membrane mass associated with LCAC incorporation is related to the LCAC fatty acyl 




penetrated membrane leaflet (Anwer et al., 2020). It is postulated that the positive charge 
carried by the carnitine might compete for negatively charged groups on membrane lipids 
and thus alter the electrochemical gradient around the membrane that changes Ca2+ 
handling channel properties (Anwer et al., 2020).  
9.3.2 Summary 
In summary, my thesis provides clear evidence for LCACs 16:0 and 18:1 increasing 
passive Ca2+ influx via disruption of the cell membrane. Translational LCAC 
concentrations likely do increase Ca2+ influx also; however, methodological limitations 
prevented measurement of the change in cytosolic Ca2+ induced. This could be investigated 
using a fluorescent Ca2+ indicator with higher Ca2+ affinity, such as fluo-8-AM; although, 
similar sensitivity issues are likely to arise. Electrophysiological measurement of inward 
Ca2+ current could provide an alternative assessment of Ca2+ that captures the subtle change 
in influx rate. Overall, the results presented in this thesis strongly suggest that the Ca2+ 
influx effect of LCACs establishes the necessary driving force for ER/SR Ca2+ overload 
and SOICR.  
9.4 LCACs promote spontaneous Ca2+ release 
Supporting the pro-arrhythmic effect of LCACs in human atrial trabeculae, LCAC 
treatment also increased propensity for spontaneous Ca2+ release in HEK293 cells 
expressing RyR2. Underlying this was a reduction in the threshold for Ca2+ release from 
the ER. At high exogenous LCAC concentrations, the pro-SOICR effect was clearly linked 
to Ca2+ influx from the extracellular environment, presumably by detergent-like effects on 
the cell membrane (discussed above). However, at translatable LCAC concentrations, the 
pro-SOICR effect occurred independently of a measurable effect on intracellular Ca2+ 
influx. In the following sections, I will discuss how LCAC treatment leads to an alteration 
in RyR2-mediated Ca2+ leak. This will include a description of the most likely mechanism, 
as based on the current results. However, as for the previous section, alternative 
mechanisms will be proposed that are worthy of future investigation.  
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9.4.1 Previous studies and controversy of effect on RyR2 
Prior to discussing how LCACs might affect RyR2 function, I will revisit the 
previous proposals and controversies surrounding LCAC effects on RyR2. LCAC 
treatment is well-known to stimulate Ca2+ efflux from cardiac (Yamada et al., 2000) and 
skeletal muscle SR vesicles (El-Hayek et al., 1993; Dumonteil et al., 1994). Additionally, 
LCAC treatment of intact cardiomyocytes is known to reduce Ca2+ transient amplitudes 
and increase SR Ca2+ spark frequency (Roussel et al., 2015). Although not directly assessed 
in this thesis, my post hoc analysis reveals that the caffeine-induced Ca2+ release amplitude 
in RyR2-expressing HEK293 cells is reduced by LCAC treatment (Figure 9.2). Since 
caffeine depletes the internal Ca2+ store (Kong et al., 2008), this suggests that LCAC 
treatment promotes internal Ca2+ leak, thereby recapitulating the previous findings in Ca2+ 
loaded SR vesicles and in isolated cardiomyocytes. The promotion of SR Ca2+ efflux 
following LCAC treatment is not controversial; however, whether the Ca2+ efflux is 
mediated by RyR2 is. 
 
Figure 9.2. Long-chain acylcarnitine (LCAC) 18:1 reduces the caffeine-induced Ca2+ 
fluorescence in human embryonic kidney (HEK293) cells expressing the cardiac ryanodine 
receptor (RyR2). HEK293 cells expressing RyR2 were superfused with 20 mM caffeine in 0 mM 
[Ca2+]O KRH to induce maximal cytosolic Ca2+ fluorescence. Cells were treated with vehicle 
control (A) or 25 µM LCAC 18:1 (B). C, Cells exposed to 25 µM LCAC 18:1 had a significantly 
reduced caffeine-induced Ca2+ release fluorescence amplitude relative control cells in identical 
KRH solutions. Traces in A & B are overlays of replicate experiments with the derived mean 
trace superimposed in black. C, results are mean values ± SEM with difference between groups 






Yamada et al. found that LCAC treatment has no effect on [3H]ryanodine binding 
and that RyR2 inhibition does not prevent SR vesicle Ca2+ efflux induced by LCACs, 
suggesting no role for RyR2 in the spontaneous SR Ca2+ leak (Yamada et al., 2000). This 
study used excessively high LCAC concentrations (30-50 µM), the potency of which is 
augmented by the relatively high LCAC to SR vesicle ratio, which could promote passive 
Ca2+ release from the SR. Supporting this theory is that the extent of Ca2+ efflux from both 
cardiac and skeletal muscle SR vesicles is proportional to LCAC fatty acyl chain length 
and thus the SR membrane disruption (El-Hayek et al., 1993; Dumonteil et al., 1994; 
Yamada et al., 2000). Arguing against this theory is that skeletal muscle SR vesicle Ca2+ 
efflux induced by LCACs (at analogous concentrations) is associated with increase 
[3H]ryanodine binding and is attenuated by inhibition of RyR1 (El-Hayek et al., 1993; 
Dumonteil et al., 1994). Therefore, these studies in membrane vesicles provide 
controversial results about the role of RyR in mediating LCAC-induced effects on internal 
Ca2+ release. 
The best evidence supporting a role of RyR2 in mediating LCAC-induced SR Ca2+ 
release comes from Roussel et al. (Roussel et al., 2015). Here, treatment of mouse 
cardiomyocytes was found to acutely promote carbonylation and S-nitrosylation of RyR2, 
as well as a decrease in the FKBP12.6 to RyR2 ratio, suggesting that LCACs induce 
structural modification of RyR2 and the RyR2 macromolecular complex. Importantly, 
regulation of these LCAC-induced modifications was then linked to increased RyR2-
mediated spontaneous Ca2+ release and in vivo arrhythmias (Roussel et al., 2015). My 
results align with this finding of RyR2 dependency in mediating the effects of LCACs. In 
a recombinant HEK293 cell model, I found that RyR2 expression is not only necessary to 
facilitate the pro-SOICR effect of LCACs 16:0 and 18:1 but that the LCACs also modify 
threshold for RyR-mediated Ca2+ release. My findings build on those of Roussel et al. by 
showing that lower, more translatable LCAC concentrations also modify RyR2 activity and 
promote SOICR and that the extent of the effect is LCAC-specific.  
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9.4.2 What the luminal Ca2+ measurements tell us and proposed SOICR 
mechanism 
For this thesis, several properties of RyR2 function were analysed based on how 
Ca2+ is handled within the internal Ca2+ store (Zhang et al., 2015). Alongside increasing 
SOICR frequency, LCAC treatment also reduced the threshold for SOICR initiation, which 
indicates an increased sensitivity of RyR2 to cytosolic and/or luminal (intra-ER/SR) Ca2+ 
(Jones et al., 2017). An increase in either the RyR2 cytosolic or luminal Ca2+ sensitivity is 
known to reduce the threshold for SOICR and thus increase the propensity for spontaneous 
Ca2+ release (Jiang et al., 2005; Jones et al., 2008; Chen et al., 2014; Chakraborty et al., 
2019). Whether the reduced SOICR initiation threshold observed in my study occurs via 
an increase in the sensitivity of RyR2 to cytosolic and/or luminal Ca2+ cannot be deduced. 
However, mechanistic insight can be gained from models proposed previously (Jones et 
al., 2017). 
The mechanism underlying the changes in RyR2 Ca2+ sensitivity and pro-SOICR 
effects of LCACs are likely intertwined with the increased cytosolic Ca2+ influx (depicted 
in Figure 9.3). It is important to note that a singular increase in RyR2 Ca2+ sensitivity is 
not sufficient to induce SOICR – an overload in Ca2+ store level must also occur (Venetucci 
et al., 2007). With this in mind, the pro-SOICR effect of LCACs can initially be explained 
by the increased cytosolic Ca2+ influx increasing the store Ca2+ level closer towards the 
threshold for spontaneous RyR2-mediated Ca2+ release. This would suggest that the 
increased SOICR frequency induced by LCAC treatment is accompanied by an overall 
increase in Ca2+ store size; however, the store size did not change (Chapter 8). Therefore, 
after initially overloading store Ca2+ and promoting RyR2 opening, it is possible that the 
conformational change caused by RyR2 opening exposes the RyR2 cytosolic and luminal 
Ca2+ binding sites. The increased sensitivity of the cytosolic site to Ca2+ then reduces the 
cytosolic Ca2+ concentration required to open RyR2 and thus promotes SOICR. Similarly, 
by increasing luminal Ca2+ sensitivity, the level of the internal Ca2+ store required to initiate 
SOICR is reduced. Thus, this proposed mechanism is not the result of an effect on RyR2 
per se. Instead, it is intrinsically intertwined with the marked cytosolic Ca2+ influx induced 
by the LCACs. The change in RyR2 Ca2+ sensitivity occurs as a result of intrinsic changes 






Figure 9.3. Schematic depiction of likely mechanism of long-chain acylcarnitine (LCAC) effect 
on store overload-induced Ca2+ release (SOICR). As detailed in the main text, the proposed 
mechanism of the LCAC pro-SOICR effect occurs in two parts. In part I, the increased Ca2+ 
influx induced by LCACs increases the cytosolic Ca2+ concentration and thus the Ca2+ taken up 
into the sarcoplasmic reticulum (SR) by SERCA. This increases the SR Ca2+ load towards the 
threshold for RyR2-mediated Ca2+ release and leads to SOICR. Part II, as a consequence of the 
conformational change in RyR2, the cytosolic and luminal Ca2+ binding sites on RyR2 are 
exposed (depicted schematically on RyR2). This increases the sensitivity of RyR2 to Ca2+ 
activation, which in turn reduces the SR Ca2+ load required to trigger SOICR. 
The dependence of the LCAC-induced pro-SOICR effect on extracellular Ca2+ 
influx could explain how LCAC treatment also decreased the threshold for SOICR 
termination. Relative to RyR2 activation, the processes underlying RyR2 inactivation are 
poorly understood (Zhang et al., 2015). It is thought that the eventual decrease in dyadic 
Ca2+ caused by RyR2 opening and Ca2+ store depletion is sensed intrinsically by RyR2, 
leading to RyR2 closure (Laver, 2018). The constant termination threshold found with each 
CICR or SOICR event (~55-60% of Ca2+ store size) highlights the key role of the internal 
Ca2+ store depletion in dictating RyR2 closure. My finding that LCACs reduce the 
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threshold for SOICR termination is likely explained by the cytosolic Ca2+ overload induced 
by LCAC treatment prolonging the time required for the depletion of the Ca2+ level local 
to RyR2. Therefore, with feasible extrapolation from previous studies, my data suggests 
that the effect of LCACs on SOICR initiation and termination thresholds is a result of 
LCAC-induced Ca2+ influx and cytosolic Ca2+ overload. It should be noted, however, that 
there could also be a role for LCAC-induced dissociation of the accessory protein, 
FKBP12.6, from the RyR2 complex. The Jones lab group has previously found that 
expression of FKBP12.6 and its association with RyR2 increases the SOICR termination 
threshold (Zhang et al., 2016). Therefore, based on the previous finding that LCAC 16:0 
reduces the RyR2/FKBP12.6 binding ratio, it is possible that dissociation of this complex 
also contributes to the reduced termination threshold induced by LCAC treatment. 
It is re-emphasised that the above discussion is based on what is the most likely 
underlying LCAC effects on luminal Ca2+ handling and that the interpretation is limited by 
the descriptive nature of the results. Further investigation (see later) is required to determine 
if LCAC treatment modulates cytosolic and/or luminal RyR2 Ca2+ sensitivity and whether 
the termination threshold is the result of RyR2 or accessory protein modification. The 
following includes discussion of additional possible mechanisms; however, greater 
extrapolation from the data is required to support them. 
9.4.3 Potential role of oxidation 
RyR2 function is tightly regulated by post-translational modification. Whether this 
regulation is altered by LCACs cannot be deduced from my data. However, it has been 
proposed that LCAC 16:0 acutely promotes oxidative modification of RyR2 and that this 
contributes to pro-arrhythmic Ca2+ release induced by the LCAC (Roussel et al., 2015). 
Interestingly, the Jones lab has found that oxidative stress induced by H2O2 in RyR2-
expressing HEK293 cells increases SOICR frequency by reducing the threshold for SOICR 
(Waddell et al., 2016). These effects mirror those found with all LCAC concentrations, 
which, if extrapolated, suggest that oxidation of RyR2 is underlying the effects of RyR2. 
However, it should be noted that the pro-SOICR effect of oxidative stress was biphasic as 
it eventually reduced SOICR frequency if extended beyond 10 minutes (Waddell et al., 
2016). No such effect was observed with LCAC treatment. This could suggest that 
oxidation of RyR2 induced by LCACs varies from that induced by H2O2 or that other forms 




9.4.4 PKA- and CaMKII-mediated phosphorylation 
The role of RyR2 phosphorylation on RyR2 function and Ca2+ handling has been 
studied extensively. Phosphorylation of RyR2 serine residues 2030 (S2030) and 2814 
(S2814) by PKA and CaMKII, respectively, is increased in the myocardium of persistent 
AF and HF patients (Marx et al., 2000; Wehrens et al., 2006; Respress et al., 2012; Voigt 
et al., 2012; Fischer et al., 2013). Functionally, PKA-mediated S2030 phosphorylation has 
been found to increase RyR2 open probability and SOICR propensity in recombinant 
HEK293 cells (Xiao et al., 2007). Similarly, CaMKII phosphorylation at S2814 has been 
demonstrated thoroughly to promote spontaneous RyR2-mediated SR Ca2+ leak and 
arrhythmic contractions in human cardiomyocytes (Voigt et al., 2012). The overlap of the 
effects on RyR2 function and arrhythmia propensity shared with those found with LCAC 
treatment suggests that LCACs could modulate RyR2 phosphorylation. Currently, there is 
no evidence for LCACs regulating PKA or CaMKII activity in any cell type; therefore, 
theorising whether the LCAC effects on RyR2 depend on altered RyR2 S2030 and/or 
S2814 phosphorylation is speculative. Notably, since I found that LCACs increase 
intracellular Ca2+, it is more likely that the Ca2+-sensitive CaMKII rather than the cAMP-
sensitive PKA would be the affected kinase.  
9.4.5 PKC-dependent phosphorylation 
In reconstituted lipid bilayers, Carter et al. identified an endogenous regulator of 
RyR2 open probability that was resistant to PKA or CaMKII inhibition but sensitive to 
extracellular Ca2+ modulation and to classical inhibitors of protein kinase C (PKC) (Carter 
et al., 2011). These findings provide evidence that the Ca2+- and lipid-sensitive PKC could 
also serve as a regulator of RyR2 function. Whether PKC regulation of RyR2 is dependent 
on serine/threonine phosphorylation by the kinase is unknown (Carter et al., 2011). PKC 
presents a potential candidate for mediating the effects of LCACs on RyR2 function due to 
the sensitivity of the kinase to Ca2+ and to lipids and lipid derivatives (Churchill et al., 
2008). However, early work in cardiac membrane fractions suggests that LCAC 16:0 
significantly inhibits the activity of PKC and reduces phosphorylation of known PKC 
targets (RyR2 not determined) (Katoh et al., 1981). This in turn would suggest that the 
increased RyR2-mediated Ca2+ release induced by LCACs is not due to activation of 
endogenous PKC associated with RyR2. Although, it should be noted that this study used 
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an extreme LCAC concentration (70 µM), which would likely result in membrane fraction 
solubilisation.  
9.4.6 Other possible mechanisms 
Finally, as proposed above as a potential mechanism for enhanced transmembrane 
Ca2+ influx from the extracellular environment, it is possible that the amphipathic structure 
of LCACs also disrupts RyR2 structure. Ca2+ efflux from SR vesicles induced by high-dose 
LCAC treatment is known to be dependent on LCAC fatty acyl chain length (El-Hayek et 
al., 1993; Dumonteil et al., 1994; Yamada et al., 2000). This indicates that the LCACs can 
embed within the SR membrane and in some cases affect RyR-mediated Ca2+ release (El-
Hayek et al., 1993; Dumonteil et al., 1994). At lower concentrations, it possible that the 
effect of LCAC penetration of the SR membrane is not detergent-like but rather it alters the 
availability of charged residues of RyR2. For instance, the positive charge carried by the 
carnitine moiety of the LCAC compound, which does not embed in the membrane (Anwer 
et al., 2020), could interact with negatively charged residues within RyR2. This could 
promote allosteric changes that dissociate the RyR2-FKBP12.6 interaction (Roussel et al., 
2015) or that expose the cytosolic and luminal Ca2+ binding sites. This will require 
substantial further investigation to decipher; although, determining the effect of lipids on 
RyR2 (and other channels/transporters) biophysical properties is of interest to the wider 
research field. 
9.4.7 Summary 
In summary, I show that RyR2 expression is required to mediate pro-arrhythmic 
spontaneous SR Ca2+ leak in vitro. Our data suggests that this occurs via a reduction in the 
threshold for RyR2-mediated Ca2+ release. Whether this occurs due to direct modification 
of RyR2 cannot be deduced; however, it is likely that the effect on RyR2 function is 





9.5 Working model of LCAC effects in the heart 
A working model of how exogenous LCACs alter cellular Ca2+ handling to promote 
arrhythmias and inotropy is shown in Figure 9.4. For this model, the limitations of the 
HEK293 cell model (discussed below) have been ignored to allow extrapolation of the 
findings in the cell model to the observed effects in human myocardium. This mechanism 
applies the proposed effect of LCACs on Ca2+ influx and SOICR (detailed in Figure 9.3) 
to the positive inotropic and pro-arrhythmic effect of LCACs. Regarding positive inotropy 
(Figure 9.4A), the Ca2+ influx induced by LCACs increases the cytosolic Ca2+ 
concentration and, in turn, the SR Ca2+ concentration via SERCA2a-mediated Ca2+ uptake. 
During sinus rhythm (i.e., with rhythmic electrical pacing), this increased SR Ca2+ content 
results in an increased release of SR Ca2+ during systole, leading to greater Ca2+ binding at 
the myofilaments and thus a stronger contraction. As discussed above, the increased SR 
and cytosolic Ca2+ levels might also increase RyR2 Ca2+ sensitivity, which augments the 
amount of Ca2+ released for contraction.  
The Ca2+ influx effect of exogenous LCACs also drives the pro-arrhythmic effect 
of exogenous LCACs (Figure 9.4B). During periods of rest (i.e., no electrical pacing), the 
resultant increased SR Ca2+ concentration enhances the propensity for spontaneous RyR2-
mediated Ca2+ leak via SOICR, which is also augmented by the increase in RyR2 Ca2+ 
sensitivity. The increased SR Ca2+ leak increases the cytosolic Ca2+ level in diastole, 
thereby establishing the ionic substrate for Na+ entry via the sarcolemmal Na+/Ca2+ 
exchanger, the generation of DADs and spontaneous contractions. In the long-term, chronic 
cytosolic Ca2+ levels could lead to oxidative stress that de-stabilises RyR2-mediated Ca2+ 
release and a deterioration in myocardial contractility. Overall, this model suggests that 
exogenous LCACs could contribute to arrhythmogenesis and inotropic modulation, which 
might be responsible for the associations of LCACs with AF and HF, respectively. 
  




Figure 9.4. Working model of exogenous long-chain acylcarnitine (LCAC) effects on the heart.  
Cardiomyocyte model is extrapolated from observed effects of LCACs on Ca2+ influx and RyR2-
mediated Ca2+ release recombinant HEK293 cells (Chapters 7 & 8). In human atrial trabeculae, 
exogenous LCACs acutely increase contractility (positive inotropy) and spontaneous contraction 
propensity (arrhythmias) (Chapter 7). A (positive inotropy), exogenous LCACs increase Ca2+ 
influx from the extracellular environment, which increases the cytosolic Ca2+ concentration 
([Ca2+]O) and, in turn, the sarcoplasmic reticulum (SR) Ca2+ concentration ([Ca2+]SR) via SERCA-
mediated Ca2+ uptake. When stimulated at 1 Hz, the increased [Ca2+]SR results in an increased 
amount of Ca2+ released during systole, resulting in an increased cytosolic Ca2+ concentration 
during systole ([Ca2+]sys), greater Ca2+-myofilament interaction and thus increased contraction 
force. The increased [Ca2+]cyto and [Ca2+]SR also induces a conformational change in the cardiac 
ryanodine receptor (RyR2) that increases luminal (intra-SR) and cytosolic RyR2 Ca2+ 
sensitivities (depicted as * in figure), which augments the Ca2+ released during systole. The 
increased [Ca2+]cyto can also directly interact with the myofilaments to increase contractility. B 
(arrhythmias), during periods of rest (no stimulation), the increased [Ca2+]cyto and [Ca2+]SR 
induced by exogenous LCACs results in spontaneous RyR2-mediated Ca2+ leak (via store 
overload-induced Ca2+ release (SOICR)). As above, this changes RyR2 conformation, leading to 
increased RyR2 Ca2+ sensitivities (*) and an augmented SOICR effect. The increased SR Ca2+ 
leak increases the cytosolic Ca2+ concentration in diastole ([Ca2+]dia), which promotes 
sarcolemmal Na+/Ca2+ exchange (NCX), membrane depolarisation and delayed 






9.6 Linking EAT and LCACs in CVD 
This thesis investigated EAT deposition and circulating LCACs as independent 
factors in cardio-metabolic disease. However, a theoretical link can be drawn between the 
two factors. Much of the pre-clinical interest in EAT stems from the paracrine signalling 
postulated to occur between EAT and the myocardium (Yudkin et al., 2005). This includes 
our own work, whereby the cultured EAT secretome from cardiac surgery patients acutely 
increased the spontaneous contraction propensity and contractility of human atrial 
myocardium (Babakr et al., 2020). Other preliminary data from our group shows that EAT 
releases LCACs 16:0 and 18:1 as part of the secretome at levels similar to the plasma 
concentrations (Figure 5.5). Therefore, it is possible that the arrhythmogenic and inotropic 
effects of the EAT secretome can be attributed to the presence of LCACs. This theory 
would suggest that LCACs are important components of the EAT-myocardium paracrine 
signalling relationship that maintain contractile function in health (i.e., low levels of LCAC 
release) and drive arrhythmias in disease (i.e., excess LCAC release). However, it should 
be noted that the EAT secretome only induced cardiac effects if the fat was stimulated with 
the β3-adrenergic agonist, BRL37344, during the culture period. BRL37344 treatment 
nominally increased the concentration of LCACs 16:0 and 18:1 in the EAT secretome, but 
not to a statistically significant level. This counters the proposition of LCACs as a key 
component of the EAT-myocardium signalling relationship and suggests that another 
factor, or more likely a large combination of factors, underlies the cardiac effects of the 
EAT secretome. Despite this, the overlap of acute effects on the human atrial myocardium 
provides rationale for further examination of the role EAT-derived LCACs and how this 
contributes to CVD pathogenesis. 
9.7 Limitations 
My thesis was limited by several factors. Many of these are presented in the 
preceding published chapters. One of the overarching objectives of this thesis was to use 
translatable exogenous LCAC concentrations, which I specifically addressed in Chapter 
8. A limitation of this, however, is that true exogenous LCAC concentrations are difficult 
to achieve due to the tendency of amphipathic compounds like LCACs to accumulate at the 
air/water interphase of aqueous solutions (Busselen et al., 1988). Therefore, the 
manufactured concentrations used in this study are likely not accurate to those measured in 
the plasma. Importantly, comparisons of manufactured vs. true LCAC concentrations in 
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solution show that the true concentration is almost always an underestimation of the 
manufactured concentration (Busselen et al., 1988). This indicates that the concentrations 
used in this study are likely underestimates and thus the results, at low concentrations, are 
not confounded by unexpected detergent-like effects. 
A second overarching limitation is that HEK293 cells are not cardiomyocytes and, 
consequently, do not express several Ca2+ handling proteins that are known to influence 
SOICR. This includes LTCCs, which have been discussed above, and the negative regulator 
of SERCA2a-mediated Ca2+ uptake, PLB (Berjukow et al., 1996). Regulation of PLB 
phosphorylation in particular has been implicated as a key mediator of SR Ca2+ uptake in 
diastole and, in turn, the genesis of spontaneous Ca2+ leak and arrhythmias (Aschar-Sobbi 
et al., 2012). HEK293 cells do not natively express PLB; therefore, any of the effects 
observed on Ca2+ uptake and Ca2+ store overload have occurred without the influence of 
PLB on SERCA2a activity. The absence of these proteins in HEK293 cells formed part of 
the rationale for using such a cell model as it allowed for isolation of the specific LCAC 
effects on RyR2-mediated Ca2+ release and transmembrane Ca2+ influx. Despite this, the 
presence of any of these proteins could have theoretically altered the results. 
9.8 Future directions 
The following details future directions of research into LCAC effects in the heart, 
listed in descending order of priority and feasibility. To immediately build on the findings 
in this thesis, (1) it is important to determine the effect of LCACs on the cytosolic and 
luminal Ca2+ sensitivities of RyR2. This can be done using RyR2 channels reconstituted in 
artificial lipid bilayers whereby the ‘cytosolic’ and ‘luminal’ Ca2+ concentrations can be 
controlled (Jiang et al., 2004). Although partially addressed in this thesis, (2) further 
investigation of the interplay between LCAC-induced Ca2+ influx and RyR2-mediated Ca2+ 
release is required. This can be done by pre-treatment with a Ca2+ ionophore, such as 
A23187, which will allow for control of Ca2+ influx and the cytosolic Ca2+ concentration. 
By controlling the cytosolic Ca2+ content, any effect of LCACs on RyR2 gating can be 
directly assessed without confounding influence cytosolic Ca2+ overland and increased 
SR/ER Ca2+ filling. (3) In line with the limitations of this thesis, future research needs to 
utilise isolated atrial cardiomyocytes from human and/or animal models. This will allow 
for translation of my findings in recombinant HEK293 cells to a model with complete 
expression of cardiac proteins (e.g., PLB) and the excitability of atrial myocardium. (4) It 




proteins) and how this relates to acute and chronic effects of LCACs on arrhythmias and 
inotropy. Similar study is needed of other post-translational modifications, especially 
phosphorylation, which is well-established in arrhythmogenesis and inotropic modulation 
(Bers, 2002).  
(5) Regarding the functional effects of LCACs, future studies can use 
electrocardiographic assessment and optical mapping of isolated mammalian hearts to 
determine if LCAC exposure alters electrical conduction and arrhythmias. This will build 
on the pro-arrhythmic effect of LCACs identified in human atrial myocardium by using a 
different modality of arrhythmia with enhanced in vivo applicability. In addition, (6) 
isolated cardiomyocytes should be treated with clinically-relevant LCAC concentrations 
and LCAC species to determine the effect on Ca2+ spark and wave propensity, which is yet 
to be performed. (7) Besides the arrhythmogenic effect of exogenous LCACs, the effect of 
acute LCAC application on myocardial metabolism needs to be determined. This can be 
achieved using Oxygraph assessment of mitochondrial oxidative respiration in response to 
specific glycolytic and β-oxidative substrates. The dependence of metabolic modulation in 
the cardiovascular effects of LCACs is inconclusive (Sakata et al., 1989; Xiao et al., 1997). 
Therefore, since LCACs are critical metabolic intermediates, it is pertinent to clarify the 
direct effect of circulating LCACs on myocardial substrate utilisation and remodelling in 
disease. 
In the long-term, (8) it will be important to investigate the functional effect of 
chronic plasma LCAC upregulation in an animal model. Development of such a model via 
exogenous LCAC administration will be challenging because LCACs can be readily 
metabolised and thus removed from the circulation. Instead, models with native LCAC 
upregulation, such as obese and diabetic models, could be used; although, these will be 
significantly limited in translatability by the numerous confounding influences 
characteristic of the disease phenotype. A further possibility is to use an animal model of 
AF or HF whereby glycolytic substrate preference natively upregulates circulating LCAC 
levels. By using Etomoxir inhibition of CPTI during the AF induction process, the 
dependence of endogenous LCAC production in the long-term development of arrhythmias 
can be assessed. As discovered in clinical trials of CPTI inhibitors (Holubarsch et al., 
2007), reducing endogenous LCAC production and thus systemic fatty substrate utilisation 
has many off-target effects that significantly confound any positive cardiovascular effects 
of LCAC inhibition. Thus, development of an animal model for implication of long-term 
LCAC exposure presents many challenges.  
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Finally, (9) as the database of cardiovascular disease metabolomic profiles are 
expanded, the correlations between circulating LCACs with indices of cardiac function and 
arrhythmias should be investigated. The specificity and independence of LCAC 
associations with cardiac function will be enhanced by large sample sizes whereby factors 
influencing plasma LCAC levels, like obesity and diabetes status (Adams et al., 2009), can 
be adjusted for. Furthermore, with the evidence implicating LCACs in CVD diagnosis 
growing, the effect of incorporating LCACs into classical CVD risk models can be 
investigated.  
9.9 Conclusion 
Part two my thesis aimed to determine the direct effect of circulating LCAC 18:1, 
which is associated with AF and HF, on the function of human atrial myocardium. For the 
first time, I found that LCAC 18:1 acutely promotes arrhythmias and positive inotropy 
dose-dependently. This indicates that the clinical associations of LCACs with AF and HF 
risk can be extended to suggest that LCACs can directly contribute to the arrhythmogenesis 
and contractile alteration underlying the diseases. I also linked these effects in human heart 
tissue to marked dysfunction of Ca2+ handling in a cardiomyocyte cell model. Here, 
equivalent LCAC 16:0 and 18:1 concentrations acutely promoted pro-arrhythmic 
spontaneous Ca2+ release events. This effect was dependent on a reduction in the threshold 
for RyR2-mediated Ca2+ release from the ER/SR. Furthermore, all effects of LCACs on 
cytosolic Ca2+ overload and spontaneous Ca2+ release were intertwined with the 
amphipathic structure of LCACs and the disruption to cell membranes caused by LCAC 
fatty acyl chains.  
Overall, this largely descriptive research provides rationale for future investigations 
across pre-clinical, translational, and clinical research fields. Additionally, in supporting 
the established diagnostic and prognostic utility of circulating LCACs, it establishes 
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